Chr	Start	End	Ref	Alt	Func.refGene	Gene.refGene	GeneDetail.refGene	ExonicFunc.refGene	AAChange.refGene	pLi.refGene	pRec.refGene	pNull.refGene	Disease_description.refGene	P(HI).refGene	P(rec).refGene	RVIS.refGene	RVIS_percentile.refGene	GDI.refGene	GDI-Phred.refGene	SIFT_score	SIFT_converted_rankscore	SIFT_pred	Polyphen2_HDIV_score	Polyphen2_HDIV_rankscore	Polyphen2_HDIV_pred	Polyphen2_HVAR_score	Polyphen2_HVAR_rankscore	Polyphen2_HVAR_pred	LRT_score	LRT_converted_rankscore	LRT_pred	MutationTaster_score	MutationTaster_converted_rankscore	MutationTaster_pred	MutationAssessor_score	MutationAssessor_score_rankscore	MutationAssessor_pred	FATHMM_score	FATHMM_converted_rankscore	FATHMM_pred	PROVEAN_score	PROVEAN_converted_rankscore	PROVEAN_pred	VEST3_score	VEST3_rankscore	MetaSVM_score	MetaSVM_rankscore	MetaSVM_pred	MetaLR_score	MetaLR_rankscore	MetaLR_pred	M-CAP_score	M-CAP_rankscore	M-CAP_pred	CADD_raw	CADD_raw_rankscore	CADD_phred	DANN_score	DANN_rankscore	fathmm-MKL_coding_score	fathmm-MKL_coding_rankscore	fathmm-MKL_coding_pred	Eigen_coding_or_noncoding	Eigen-raw	Eigen-PC-raw	GenoCanyon_score	GenoCanyon_score_rankscore	integrated_fitCons_score	integrated_fitCons_score_rankscore	integrated_confidence_value	GERP++_RS	GERP++_RS_rankscore	phyloP100way_vertebrate	phyloP100way_vertebrate_rankscore	phyloP20way_mammalian	phyloP20way_mammalian_rankscore	phastCons100way_vertebrate	phastCons100way_vertebrate_rankscore	phastCons20way_mammalian	phastCons20way_mammalian_rankscore	SiPhy_29way_logOdds	SiPhy_29way_logOdds_rankscore	Interpro_domain	GTEx_V6_gene	GTEx_V6_tissue	Otherinfo
chr1	1225580	1225580	-	CC	intronic	SCNN1D	.	.	.	2.82E-15	0.004782576	0.995217424	.	0.70009	0.14008	1.771089818	96.77990092	880.06096	5.7775	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	66	381	chr1	1225580	chr1:1225580	T	TCC,TCCCGTGTCTCTGCTCCATTC	66	PASS	AN=2;DP=381	GT	0/1
chr1	1225580	1225580	-	CCCGTGTCTCTGCTCCATTC	intronic	SCNN1D	.	.	.	2.82E-15	0.004782576	0.995217424	.	0.70009	0.14008	1.771089818	96.77990092	880.06096	5.7775	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	66	381	chr1	1225580	chr1:1225580	T	TCC,TCCCGTGTCTCTGCTCCATTC	66	PASS	AN=2;DP=381	GT	0/1
chr1	1571829	1571829	A	G	exonic	CDK11B	.	synonymous SNV	CDK11B:NM_033487:exon16:c.T1164C:p.P388P,CDK11B:NM_033490:exon17:c.T1281C:p.P427P,CDK11B:NM_001291345:exon19:c.T1896C:p.P632P,CDK11B:NM_001787:exon19:c.T1965C:p.P655P,CDK11B:NM_033486:exon19:c.T1926C:p.P642P,CDK11B:NM_033489:exon20:c.T1824C:p.P608P	0.72829444	0.271588478	0.000117082	.	.	0.14135	.	.	147.53387	2.64628	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	48	chr1	1571829	chr1:1571829	A	G	52	PASS	AN=2;DP=48	GT	0/1
chr1	1843597	1843597	T	-	intergenic	GNB1;CALML6	dist=21041;dist=2669	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	44	chr1	1843596	chr1:1843596	CT	C	64	PASS	AN=2;DP=44	GT	0/1
chr1	6012757	6012757	C	A	intronic	NPHP4	.	.	.	1.29E-17	0.420064566	0.579935434	DISEASE: Note=Ciliary dysfunction leads to a broad spectrum of disorders, collectively termed ciliopathies. Overlapping clinical features include retinal degeneration, renal cystic disease, skeletal abnormalities, fibrosis of various organ, and a complex range of anatomical and functional defects of the central and peripheral nervous system. The ciliopathy range of diseases includes Meckel-Gruber syndrome, Bardet-Biedl syndrome, Joubert syndrome, nephronophtisis, Senior-Loken syndrome, and Jeune asphyxiating thoracic dystrophy among others. Single-locus allelism is insufficient to explain the variable penetrance and expressivity of such disorders, leading to the suggestion that variations across multiple sites of the ciliary proteome, including NPHP4, influence the clinical outcome (PubMed:21258341). {ECO:0000269|PubMed:21258341}.; DISEASE: Senior-Loken syndrome 4 (SLSN4) [MIM:606996]: A renal- retinal disorder characterized by progressive wasting of the filtering unit of the kidney (nephronophthisis), with or without medullary cystic renal disease, and progressive eye disease. Typically this disorder becomes apparent during the first year of life. {ECO:0000269|PubMed:12244321, ECO:0000269|PubMed:15776426}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.12343	0.16808	0.569383166	81.78815758	1128.55982	6.4092	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	193	chr1	6012757	chr1:6012757	C	A	.	PASS	AN=0;DP=193	GT	0/1
chr1	9714247	9714247	A	G	ncRNA_intronic	PIK3CD-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	24	chr1	9714247	chr1:9714247	A	G	62	PASS	AN=2;DP=24	GT	0/1
chr1	16094026	16094026	C	A	exonic	FBLIM1	.	nonsynonymous SNV	FBLIM1:NM_001024215:exon3:c.C406A:p.L136M,FBLIM1:NM_017556:exon4:c.C406A:p.L136M,FBLIM1:NM_001350151:exon5:c.C406A:p.L136M	0.00078906	0.928321057	0.070889883	.	0.30445	0.10649	0.510776592	80.23708422	197.45136	3.03792	0.134	0.912	T	0.999	0.764	D	0.998	0.875	D	0.008	0.309	N	1	0.810	D	1.955	0.530	M	0.22	0.608	T	-0.31	0.148	N	0.34	0.401	-0.385	0.725	T	0.358	0.721	T	0.031	0.535	D	3.855	0.520	23.4	0.996	0.733	0.848	0.436	D	c	0.383	0.283	1.000	0.436	0.672	0.522	0	3.81	0.429	0.878	0.276	0.765	0.311	0.998	0.411	0.950	0.426	11.030	0.468	.	.	.	0.5	.	55	chr1	16094026	chr1:16094026	C	A	.	PASS	AN=0;DP=55	GT	0/1
chr1	17662751	17662751	C	G	intronic	PADI4	.	.	.	1.30E-09	0.547876116	0.452123883	DISEASE: Rheumatoid arthritis (RA) [MIM:180300]: An inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. {ECO:0000269|PubMed:12833157}. Note=The gene represented in this entry may be involved in disease pathogenesis. The association to rheumatoid arthritis was initially thought to result from increased citrullination of target proteins (PubMed:12833157). However, variants that have been associated to rheumatoid arthritis (Ser-55, Ala-82 and Ala-112) do not affect the catalytic activity or the citrullination activity of PADI4, suggesting that these variants may affect the mRNA stability rather than the protein (PubMed:21245532). {ECO:0000269|PubMed:12833157, ECO:0000269|PubMed:21245532}.; 	0.08126	.	2.230515739	98.17173862	609.89444	4.99213	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	20	chr1	17662751	chr1:17662751	C	G	53	PASS	AN=2;DP=20	GT	0/1
chr1	24022437	24022437	A	G	intronic	RPL11	.	.	.	0.725843321	0.271290852	0.002865827	DISEASE: Diamond-Blackfan anemia 7 (DBA7) [MIM:612562]: A form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies. {ECO:0000269|PubMed:19061985, ECO:0000269|PubMed:19191325}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.91293	.	-0.053113545	49.38664779	5.48246	0.20413	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	25	chr1	24022437	chr1:24022437	A	G	52	PASS	AN=2;DP=25	GT	0/1
chr1	25717365	25717365	C	G	exonic	RHCE	.	nonsynonymous SNV	RHCE:NM_001330430:exon5:c.G676C:p.A226P,RHCE:NM_020485:exon5:c.G676C:p.A226P,RHCE:NM_138618:exon5:c.G676C:p.A226P	0.861454126	0.138457773	8.81E-05	.	0.18894	0.11913	1.686630123	96.38476056	2200.98585	8.63676	0.066	0.433	T	0.032	0.189	B	0.151	0.326	B	0.040	0.240	N	0.266	0.588	P	.	.	.	1.62	0.282	T	-3.12	0.657	D	0.392	0.483	-1.046	0.156	T	0.000	0.000	T	.	.	.	3.308	0.456	22.9	0.995	0.693	0.216	0.212	N	c	-0.427	-0.396	0.000	0.035	0.516	0.203	0	3.15	0.351	0.742	0.257	0.807	0.329	0.098	0.225	0.961	0.442	8.181	0.303	Ammonium transporter AmtB-like domain|Ammonium/urea transporter	ENSG00000261349.1|ENSG00000183726.6|ENSG00000188672.12|ENSG00000188672.12|ENSG00000261349.1|ENSG00000187010.14|ENSG00000224183.1|ENSG00000187010.14	Adipose_Subcutaneous|Artery_Aorta|Cells_Transformed_fibroblasts|Muscle_Skeletal|Skin_Sun_Exposed_Lower_leg|Testis|Thyroid|Whole_Blood	0.5	54	22	chr1	25717365	chr1:25717365	C	G	54	PASS	AN=2;DP=22	GT	0/1
chr1	26310394	26310394	A	G	intronic	PAFAH2	.	.	.	2.69E-07	0.497624678	0.502375053	.	0.13153	.	-0.402212257	26.7338995	141.07833	2.5923	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	15	chr1	26310394	chr1:26310394	A	G	44	PASS	AN=2;DP=15	GT	0/1
chr1	26487940	26487940	A	G	exonic	FAM110D	.	nonsynonymous SNV	FAM110D:NM_024869:exon2:c.A158G:p.H53R	0.550404227	0.396493199	0.053102574	.	0.42842	.	.	.	1309.4018	6.80877	0.531	0.070	T	0.677	0.394	P	0.326	0.402	B	0.070	0.216	U	0.894	0.278	P	1.32	0.331	L	1.08	0.394	T	-1.48	0.362	N	0.096	0.097	-0.947	0.416	T	0.000	0.000	T	.	.	.	1.147	0.205	11.47	0.706	0.091	0.229	0.217	N	c	-0.364	-0.329	1.000	0.747	0.658	0.486	0	4.42	0.526	0.582	0.234	1.005	0.623	0.041	0.208	0.790	0.333	13.078	0.583	.	ENSG00000236782.1|ENSG00000142684.7|ENSG00000142684.7|ENSG00000236782.1|ENSG00000197245.4|ENSG00000142684.7|ENSG00000236782.1|ENSG00000236782.1|ENSG00000197245.4|ENSG00000142684.7|ENSG00000236782.1|ENSG00000197245.4|ENSG00000142684.7|ENSG00000142684.7|ENSG00000236782.1|ENSG00000236782.1|ENSG00000142684.7|ENSG00000236782.1|ENSG00000142684.7|ENSG00000236782.1|ENSG00000142684.7|ENSG00000236782.1|ENSG00000142684.7|ENSG00000236782.1|ENSG00000236782.1|ENSG00000142684.7|ENSG00000142684.7|ENSG00000236782.1|ENSG00000197245.4|ENSG00000236782.1|ENSG00000142684.7|ENSG00000236782.1|ENSG00000142684.7|ENSG00000142684.7|ENSG00000236782.1|ENSG00000197245.4|ENSG00000142684.7|ENSG00000236782.1|ENSG00000236782.1|ENSG00000197245.4|ENSG00000142684.7|ENSG00000236782.1|ENSG00000197245.4|ENSG00000142684.7|ENSG00000236782.1|ENSG00000197245.4|ENSG00000142684.7|ENSG00000142684.7|ENSG00000236782.1|ENSG00000236782.1|ENSG00000236782.1|ENSG00000175087.5|ENSG00000142684.7|ENSG00000142684.7|ENSG00000236782.1|ENSG00000236782.1|ENSG00000142684.7|ENSG00000236782.1|ENSG00000197245.4|ENSG00000142684.7|ENSG00000236782.1|ENSG00000142684.7	Adipose_Subcutaneous|Adipose_Subcutaneous|Adipose_Visceral_Omentum|Adipose_Visceral_Omentum|Adipose_Visceral_Omentum|Adrenal_Gland|Adrenal_Gland|Artery_Aorta|Artery_Aorta|Artery_Aorta|Artery_Tibial|Artery_Tibial|Artery_Tibial|Brain_Caudate_basal_ganglia|Brain_Caudate_basal_ganglia|Brain_Cerebellar_Hemisphere|Brain_Cortex|Brain_Cortex|Brain_Frontal_Cortex_BA9|Brain_Frontal_Cortex_BA9|Brain_Nucleus_accumbens_basal_ganglia|Brain_Nucleus_accumbens_basal_ganglia|Brain_Putamen_basal_ganglia|Brain_Putamen_basal_ganglia|Cells_Transformed_fibroblasts|Cells_Transformed_fibroblasts|Colon_Sigmoid|Colon_Sigmoid|Esophagus_Gastroesophageal_Junction|Esophagus_Mucosa|Esophagus_Mucosa|Esophagus_Muscularis|Esophagus_Muscularis|Heart_Atrial_Appendage|Heart_Atrial_Appendage|Heart_Atrial_Appendage|Heart_Left_Ventricle|Heart_Left_Ventricle|Lung|Lung|Lung|Muscle_Skeletal|Muscle_Skeletal|Muscle_Skeletal|Nerve_Tibial|Nerve_Tibial|Nerve_Tibial|Pancreas|Pancreas|Pituitary|Skin_Sun_Exposed_Lower_leg|Skin_Sun_Exposed_Lower_leg|Skin_Sun_Exposed_Lower_leg|Stomach|Stomach|Testis|Testis|Thyroid|Thyroid|Thyroid|Whole_Blood|Whole_Blood	0.5	53	25	chr1	26487940	chr1:26487940	A	G	53	PASS	AN=2;DP=25	GT	0/1
chr1	28224050	28224050	G	A	intronic	RPA2	.	.	.	0.888461679	0.111293635	0.000244687	.	0.88914	0.39065	0.25917371	70.05779665	155.28434	2.72208	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	15	chr1	28224050	chr1:28224050	G	A	.	PASS	AN=0;DP=15	GT	0/1
chr1	31192650	31192650	T	G	ncRNA_intronic	MATN1-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	35	chr1	31192650	chr1:31192650	T	G	51	PASS	AN=2;DP=35	GT	0/1
chr1	35227362	35227362	C	G	exonic	GJB4	.	nonsynonymous SNV	GJB4:NM_153212:exon2:c.C507G:p.C169W	1.96E-06	0.077683308	0.922314728	DISEASE: Erythrokeratodermia variabilis (EKV) [MIM:133200]: A genodermatosis characterized by the appearance of two independent skin lesions: transient figurate erythematous patches and hyperkeratosis that is usually localized but occasionally occurs in its generalized form. Clinical presentation varies significantly within a family and from one family to another. Palmoplantar keratoderma is present in around 50% of cases. {ECO:0000269|PubMed:11017804}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.18667	0.11084	0.644875971	84.10002359	1814.33582	7.85361	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.843	D	1.000	0.588	D	3.88	0.961	H	-4.61	0.979	D	-10.41	0.990	D	0.349	0.410	0.148	0.850	D	0.670	0.886	D	.	.	.	5.321	0.720	25.8	0.994	0.643	0.892	0.492	D	c	0.647	0.523	1.000	0.451	0.554	0.283	0	2.84	0.321	2.774	0.471	0.068	0.175	1.000	0.715	0.156	0.207	4.611	0.117	Connexin, N-terminal|Connexin, conserved site|Gap junction protein, cysteine-rich domain	.	.	0.5	41	17	chr1	35227362	chr1:35227362	C	G	41	PASS	AN=2;DP=17	GT	0/1
chr1	40734058	40734058	A	G	intronic	ZMPSTE24	.	.	.	1.25E-07	0.572048078	0.427951797	DISEASE: Mandibuloacral dysplasia with type B lipodystrophy (MADB) [MIM:608612]: A disorder characterized by mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of the cranial suture, joint contractures, and generalized lipodystrophy with loss of subcutaneous fat from the extremities, face, neck and trunk. {ECO:0000269|PubMed:12913070, ECO:0000269|PubMed:17152860, ECO:0000269|PubMed:18435794, ECO:0000269|PubMed:20814950}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lethal tight skin contracture syndrome (LTSCS) [MIM:275210]: Rare disorder mainly characterized by intrauterine growth retardation, tight and rigid skin with erosions, prominent superficial vasculature and epidermal hyperkeratosis, facial features (small mouth, small pinched nose and micrognathia), sparse/absent eyelashes and eyebrows, mineralization defects of the skull, thin dysplastic clavicles, pulmonary hypoplasia, multiple joint contractures and an early neonatal lethal course. Liveborn children usually die within the first week of life. The overall prevalence of consanguineous cases suggested an autosomal recessive inheritance. {ECO:0000269|PubMed:15317753}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.14921	0.33283	-0.648365105	16.35999056	30.24713	0.96505	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	56	12	chr1	40734058	chr1:40734058	A	G	56	PASS	AN=2;DP=12	GT	0/1
chr1	44570083	44570083	C	G	intergenic	SLC6A9;KLF17	dist=72919;dist=14439	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	32	chr1	44570083	chr1:44570083	C	G	53	PASS	AN=2;DP=32	GT	0/1
chr1	44570092	44570092	A	C	intergenic	SLC6A9;KLF17	dist=72928;dist=14430	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	56	29	chr1	44570092	chr1:44570092	A	C	56	PASS	AN=2;DP=29	GT	0/1
chr1	47611598	47611598	T	C	exonic	CYP4A22	.	nonsynonymous SNV	CYP4A22:NM_001308102:exon8:c.T989C:p.L330P,CYP4A22:NM_001010969:exon10:c.T1283C:p.L428P	1.42E-08	0.583397923	0.416602062	.	0.28066	0.18241	3.202967632	99.35126209	9392.57383	20.982	1.0	0.010	T	0.001	0.067	B	0.004	0.093	B	0.000	0.843	N	0.002	0.441	P	-4.48	0.000	N	1.64	0.278	T	6.14	0.000	N	0.093	0.210	-0.934	0.435	T	0.000	0.000	T	.	.	.	-0.500	0.055	0.220	0.846	0.149	0.003	0.014	N	c	-1.616	-1.389	0.000	0.035	0.497	0.185	0	0.642	0.169	4.201	0.580	-0.213	0.100	1.000	0.715	0.015	0.124	5.799	0.175	.	ENSG00000162365.7|ENSG00000162365.7	Adipose_Subcutaneous|Nerve_Tibial	0.5	43	14	chr1	47611598	chr1:47611598	T	C	43	PASS	AN=2;DP=14	GT	0/1
chr1	70385153	70385153	C	T	ncRNA_exonic	PIN1P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	183	chr1	70385153	chr1:70385153	C	T	.	PASS	AN=0;DP=183	GT	0/1
chr1	78444691	78444691	T	C	UTR5	FUBP1	NM_003902:c.-3A>G;NM_001303433:c.-3A>G	.	.	0.999972831	2.72E-05	1.62E-12	.	0.60917	0.16996	-0.291981272	33.20358575	48.41037	1.35624	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	63	46	chr1	78444691	chr1:78444691	T	C	63	PASS	AN=2;DP=46	GT	0/1
chr1	89448623	89448623	A	G	exonic	RBMXL1	.	nonsynonymous SNV	RBMXL1:NM_019610:exon2:c.T887C:p.L296P,RBMXL1:NM_001162536:exon3:c.T887C:p.L296P	0.119596956	0.87492457	0.005478474	.	0.20063	.	0.72761005	86.08162302	80.60629	1.89749	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.000	0.843	N	1	0.810	D	-2.25	0.001	N	-0.57	0.713	T	5.66	0.000	N	0.031	0.012	-0.930	0.441	T	0.018	0.077	T	.	.	.	0.656	0.157	8.539	0.812	0.131	0.042	0.096	N	c	-1.211	-0.979	0.999	0.384	0.707	0.730	0	0.914	0.184	5.108	0.642	-0.395	0.063	1.000	0.715	0.400	0.254	6.535	0.214	.	.	.	0.5	54	16	chr1	89448623	chr1:89448623	A	G	54	PASS	AN=2;DP=16	GT	0/1
chr1	93646207	93646207	T	C	UTR5	TMED5	NM_016040:c.-408A>G;NM_001167830:c.-408A>G	.	.	0.002437131	0.775974615	0.221588254	.	0.24303	0.09726	0.082802743	60.09082331	5163.447	14.78411	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	48	chr1	93646207	chr1:93646207	T	C	64	PASS	AN=2;DP=48	GT	0/1
chr1	94474328	94474328	T	C	exonic	ABCA4	.	synonymous SNV	ABCA4:NM_000350:exon41:c.A5814G:p.L1938L	1.27E-28	0.894718807	0.105281193	DISEASE: Fundus flavimaculatus (FFM) [MIM:248200]: Autosomal recessive retinal disorder very similar to Stargardt disease. In contrast to Stargardt disease, FFM is characterized by later onset and slowly progressive course. {ECO:0000269|PubMed:11379881, ECO:0000269|PubMed:11385708, ECO:0000269|PubMed:9781034}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Macular degeneration, age-related, 2 (ARMD2) [MIM:153800]: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. {ECO:0000269|PubMed:19028736, ECO:0000269|PubMed:9295268}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Cone-rod dystrophy 3 (CORD3) [MIM:604116]: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa. {ECO:0000269|PubMed:10958761, ECO:0000269|PubMed:11385708, ECO:0000269|PubMed:11527935}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 19 (RP19) [MIM:601718]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP19 is characterized by choroidal atrophy. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.09923	0.38763	0.736662821	86.30573248	3827.03692	12.16874	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	12	chr1	94474328	chr1:94474328	T	C	43	PASS	AN=2;DP=12	GT	0/1
chr1	95332814	95332814	C	T	intronic	SLC44A3	.	.	.	1.82E-24	1.29E-05	0.999987063	.	0.10119	0.09355	-0.020150552	52.25288983	122.98894	2.41486	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	26	chr1	95332814	chr1:95332814	C	T	.	PASS	AN=0;DP=26	GT	0/1
chr1	111896013	111896013	C	T	downstream	PIFO	dist=374	.	.	7.55E-05	0.513249739	0.486674787	.	0.05344	.	0.3032669	72.009908	286.96298	3.62929	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	22	chr1	111896013	chr1:111896013	C	T	50	PASS	AN=2;DP=22	GT	0/1
chr1	145542815	145542815	A	-	UTR3	ITGA10	NM_001303041:c.*537delA;NM_001303040:c.*537delA;NM_003637:c.*537delA	.	.	8.55E-11	0.999944355	5.56E-05	.	0.53865	0.16452	1.274975588	93.67185657	1717.62595	7.64081	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	28	chr1	145542814	chr1:145542814	GA	G	42	PASS	AN=2;DP=28	GT	0/1
chr1	156248057	156248057	T	C	intronic	SMG5	.	.	.	0.998179753	0.001820247	1.55E-11	.	0.2395	0.1262	-1.015898037	8.144609578	170.50384	2.84858	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	45	chr1	156248057	chr1:156248057	T	C	51	PASS	AN=2;DP=45	GT	0/1
chr1	158368974	158368974	A	G	exonic	OR10T2	.	nonsynonymous SNV	OR10T2:NM_001004475:exon1:c.T283C:p.F95L	0.063110527	0.724960969	0.211928504	.	0.16058	.	2.065168262	97.79429111	5428.19223	15.19737	0.715	0.040	T	0.092	0.237	B	0.05	0.239	B	0.001	0.402	U	1	0.090	P	0.81	0.209	L	6.66	0.005	T	-1.04	0.273	N	0.205	0.251	-0.826	0.536	T	0.001	0.002	T	.	.	.	-0.983	0.033	0.017	0.403	0.028	0.128	0.173	N	c	-0.690	-0.677	0.997	0.348	0.487	0.133	0	4.56	0.555	0.920	0.281	1.006	0.624	0.009	0.180	0.466	0.265	13.035	0.581	GPCR, rhodopsin-like, 7TM	.	.	0.5	42	6	chr1	158368974	chr1:158368974	A	G	42	PASS	AN=2;DP=6	GT	1/0
chr1	160109408	160109408	-	C	intronic	ATP1A2	.	.	.	0.600219587	0.399780278	1.34E-07	DISEASE: Migraine, familial hemiplegic, 2 (FHM2) [MIM:602481]: A subtype of migraine with aura associated with hemiparesis in some families. Migraine is a disabling symptom complex of periodic headaches, usually temporal and unilateral. Headaches are often accompanied by irritability, nausea, vomiting and photophobia, preceded by constriction of the cranial arteries. Migraine with aura is characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred vision, hallucinations, vertigo, numbness and difficulty in concentrating and speaking. {ECO:0000269|PubMed:12539047, ECO:0000269|PubMed:12953268, ECO:0000269|PubMed:21352219, ECO:0000269|PubMed:23838748, ECO:0000269|PubMed:23918834}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Alternating hemiplegia of childhood 1 (AHC1) [MIM:104290]: A rare syndrome of episodic hemi- or quadriplegia lasting minutes to days. Most cases are accompanied by dystonic posturing, choreoathetoid movements, nystagmus, other ocular motor abnormalities, autonomic disturbances, and progressive cognitive impairment. It is typically distinguished from familial hemiplegic migraine by infantile onset and high prevalence of associated neurological deficits that become increasingly obvious with age. {ECO:0000269|PubMed:15174025}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.53654	0.22867	-1.374132436	4.429110639	48.50463	1.35867	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	66	chr1	160109408	chr1:160109408	A	AC	43	PASS	AN=2;DP=66	GT	0/1
chr1	167190252	167190252	C	-	intronic	POU2F1	.	.	.	0.913950638	0.086048322	1.04E-06	.	0.97789	0.41629	-0.334253673	30.70299599	100.87731	2.1746	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	57	77	chr1	167190251	chr1:167190251	GC	G	57	PASS	AN=2;DP=77	GT	0/1
chr1	167906503	167906503	A	G	intronic	DCAF6	.	.	.	0.996908923	0.003091077	1.14E-11	.	0.53934	0.13231	-0.242430445	36.22906346	1387.38336	6.97264	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	92	chr1	167906503	chr1:167906503	A	G	71	PASS	AN=2;DP=92	GT	0/1
chr1	179054692	179054692	T	G	intronic	TOR3A	.	.	.	2.47E-08	0.081099893	0.918900082	.	0.06192	0.09551	-0.490397599	22.50530786	76.75897	1.83877	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	78	52	chr1	179054692	chr1:179054692	T	G	78	PASS	AN=2;DP=52	GT	0/1
chr1	180404392	180404392	T	-	intronic	ACBD6	.	.	.	0.064959259	0.920160983	0.014879758	.	0.46704	0.10684	-0.427900189	25.14744043	16.07879	0.56883	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	18.63	67	chr1	180404391	chr1:180404391	AT	A	18.63	PASS	AN=0;DP=67	GT	0/1
chr1	207888640	207888640	-	T	intronic	CR1L	.	.	.	3.56E-15	0.020225564	0.979774436	.	0.06963	.	3.872389272	99.64614296	2178.56335	8.59961	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	25	chr1	207888640	chr1:207888640	C	CT	39	PASS	AN=2;DP=25	GT	0/1
chr1	215256701	215256701	A	-	UTR5	KCNK2	NM_001017425:c.-28del-	.	.	0.339842885	0.657147273	0.003009842	.	0.12841	.	-0.449946534	24.00330267	31.8264	1.00181	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	78	124	chr1	215256700	chr1:215256700	CA	C	78	PASS	AN=2;DP=124	GT	0/1
chr1	219575920	219575920	C	T	intergenic	LYPLAL1;LOC102723886	dist=189713;dist=32580	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	39	chr1	219575920	chr1:219575920	C	T	.	PASS	AN=0;DP=39	GT	0/1
chr1	219575961	219575961	C	T	intergenic	LYPLAL1;LOC102723886	dist=189754;dist=32539	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	41	chr1	219575961	chr1:219575961	C	T	.	PASS	AN=0;DP=41	GT	0/1
chr1	230800215	230800216	AA	-	intronic	COG2	.	.	.	0.000167565	0.999566074	0.000266361	.	0.14368	0.25108	-0.33061537	30.82094834	941.66479	5.94881	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	18	chr1	230800214	chr1:230800214	TAA	T	58	PASS	AN=2;DP=18	GT	0/1
chr1	231408091	231408091	A	G	exonic	GNPAT	.	nonsynonymous SNV	GNPAT:NM_001316350:exon10:c.A1373G:p.D458G,GNPAT:NM_014236:exon11:c.A1556G:p.D519G	0.291272733	0.708689868	3.74E-05	DISEASE: Rhizomelic chondrodysplasia punctata 2 (RCDP2) [MIM:222765]: A disease characterized by rhizomelic shortening of femur and humerus, vertebral disorders, cataract, cutaneous lesions and severe mental retardation. {ECO:0000269|PubMed:11152660, ECO:0000269|PubMed:21990100, ECO:0000269|PubMed:9536089}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.52109	0.26501	-0.200157416	39.11299835	1060.52275	6.249	0.109	0.292	T	0.075	0.227	B	0.034	0.212	B	0.037	0.244	N	0.998	0.224	P	2.16	0.606	M	-0.11	0.645	T	-2.45	0.535	N	0.168	0.280	-1.082	0.070	T	0.000	0.000	T	.	.	.	2.255	0.332	17.87	0.974	0.330	0.485	0.280	N	c	-0.612	-0.584	1.000	0.747	0.731	0.878	0	-0.263	0.123	1.924	0.395	1.194	0.916	0.806	0.296	0.794	0.334	9.158	0.360	.	ENSG00000116906.7|ENSG00000116906.7|ENSG00000116906.7	Artery_Tibial|Nerve_Tibial|Skin_Sun_Exposed_Lower_leg	0.5	41	14	chr1	231408091	chr1:231408091	A	G	41	PASS	AN=2;DP=14	GT	0/1
chr2	10560259	10560259	C	T	exonic	HPCAL1	.	stopgain	HPCAL1:NM_001258357:exon3:c.C376T:p.Q126X,HPCAL1:NM_001258358:exon3:c.C376T:p.Q126X,HPCAL1:NM_001258359:exon3:c.C376T:p.Q126X,HPCAL1:NM_002149:exon3:c.C376T:p.Q126X,HPCAL1:NM_134421:exon4:c.C376T:p.Q126X	0.779954229	0.212962413	0.007083358	.	0.2282	0.13477	-0.073340031	48.11866006	9.80626	0.35955	.	.	.	.	.	.	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.391	0.983	39	0.998	0.871	0.962	0.678	D	c	0.807	0.664	1.000	0.747	0.706	0.609	0	4.65	0.575	6.064	0.706	0.852	0.362	1.000	0.715	0.999	0.750	17.885	0.887	EF-hand domain|EF-hand domain pair	.	.	0.5	.	53	chr2	10560259	chr2:10560259	C	T	.	PASS	AN=0;DP=53	GT	0/1
chr2	10560278	10560278	C	T	intronic	HPCAL1	.	.	.	0.779954229	0.212962413	0.007083358	.	0.2282	0.13477	-0.073340031	48.11866006	9.80626	0.35955	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	46	chr2	10560278	chr2:10560278	C	T	.	PASS	AN=0;DP=46	GT	0/1
chr2	23698397	23698397	C	-	intronic	KLHL29	.	.	.	.	.	.	.	0.74488	.	-0.53631094	20.53550366	164.66985	2.80262	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	25	chr2	23698396	chr2:23698396	AC	A	58	PASS	AN=2;DP=25	GT	0/1
chr2	24413298	24413298	A	G	exonic	FAM228A	.	nonsynonymous SNV	FAM228A:NM_001040710:exon6:c.A419G:p.Y140C	0.00040974	0.638638547	0.360951713	.	.	.	0.193034296	66.82000472	.	.	0.828	0.162	T	0.0	0.026	B	0.0	0.013	B	0.018	0.277	N	1	0.090	P	-1.4	0.006	N	0.82	0.481	T	2.49	0.002	N	0.06	0.150	-0.979	0.352	T	0.000	0.000	T	.	.	.	-1.115	0.028	0.009	0.530	0.048	0.001	0.005	N	c	-1.417	-1.460	0.000	0.054	0.487	0.133	0	-1.3	0.087	-0.655	0.054	-1.526	0.010	0.000	0.063	0.000	0.016	4.287	0.102	.	ENSG00000186453.8|ENSG00000266118.1|ENSG00000186453.8|ENSG00000242628.1|ENSG00000219626.4|ENSG00000186453.8|ENSG00000266118.1|ENSG00000266118.1|ENSG00000266118.1|ENSG00000266118.1|ENSG00000266118.1|ENSG00000266118.1|ENSG00000186453.8|ENSG00000186453.8|ENSG00000186453.8|ENSG00000186453.8|ENSG00000242628.1|ENSG00000266118.1|ENSG00000219626.4|ENSG00000186453.8|ENSG00000223754.1|ENSG00000186453.8|ENSG00000266118.1|ENSG00000219626.4|ENSG00000186453.8|ENSG00000232642.1|ENSG00000242628.1|ENSG00000266118.1|ENSG00000186453.8|ENSG00000242628.1|ENSG00000198399.10|ENSG00000219626.4|ENSG00000115129.9	Adipose_Subcutaneous|Adipose_Subcutaneous|Adipose_Visceral_Omentum|Adipose_Visceral_Omentum|Adrenal_Gland|Artery_Aorta|Artery_Aorta|Artery_Tibial|Brain_Cerebellar_Hemisphere|Brain_Cerebellum|Brain_Cortex|Brain_Frontal_Cortex_BA9|Breast_Mammary_Tissue|Colon_Sigmoid|Esophagus_Gastroesophageal_Junction|Esophagus_Muscularis|Esophagus_Muscularis|Esophagus_Muscularis|Esophagus_Muscularis|Heart_Atrial_Appendage|Heart_Atrial_Appendage|Lung|Nerve_Tibial|Nerve_Tibial|Testis|Testis|Testis|Testis|Thyroid|Thyroid|Thyroid|Thyroid|Whole_Blood	0.5	41	14	chr2	24413298	chr2:24413298	A	G	41	PASS	AN=2;DP=14	GT	0/1
chr2	27597143	27597143	G	A	intronic	SNX17	.	.	.	0.686180301	0.313783013	3.67E-05	.	0.44161	0.1167	0.042348793	57.31304553	118.60339	2.3698	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	77	chr2	27597143	chr2:27597143	G	A	70	PASS	AN=2;DP=77	GT	0/1
chr2	27665361	27665361	C	G	intronic	KRTCAP3	.	.	.	0.044523534	0.850930012	0.104546453	.	0.21532	.	0.148941568	64.31941496	58.73938	1.55429	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	76	63	chr2	27665361	chr2:27665361	C	G	76	PASS	AN=2;DP=63	GT	0/1
chr2	47600581	47600581	-	T	intronic	EPCAM	.	.	.	7.50E-07	0.479893423	0.520105827	DISEASE: Diarrhea 5, with tufting enteropathy, congenital (DIAR5) [MIM:613217]: An intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum. {ECO:0000269|PubMed:18572020}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hereditary non-polyposis colorectal cancer 8 (HNPCC8) [MIM:613244]: An autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. {ECO:0000269|PubMed:19098912}. Note=The disease is caused by mutations affecting the gene represented in this entry. HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM.; 	0.61487	0.29457	0.373041938	75.29488087	2850.98345	10.10064	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	13	chr2	47600581	chr2:47600581	A	AT	39	PASS	AN=2;DP=13	GT	0/1
chr2	48807976	48807976	T	C	exonic	STON1;STON1-GTF2A1L	.	synonymous SNV	STON1-GTF2A1L:NM_001198594:exon1:c.T204C:p.D68D,STON1-GTF2A1L:NM_001198593:exon2:c.T204C:p.D68D,STON1:NM_006873:exon2:c.T204C:p.D68D,STON1-GTF2A1L:NM_172311:exon2:c.T204C:p.D68D,STON1:NM_001198595:exon3:c.T204C:p.D68D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	12	chr2	48807976	chr2:48807976	T	C	54	PASS	AN=2;DP=12	GT	0/1
chr2	64112707	64112707	T	-	intronic	UGP2	.	.	.	0.001020131	0.947456118	0.051523751	.	0.97124	0.39898	-0.979072682	8.752064166	24.54236	0.80685	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	45	chr2	64112706	chr2:64112706	CT	C	65	PASS	AN=2;DP=45	GT	0/1
chr2	79364374	79364374	C	G	ncRNA_exonic	REG1CP	.	.	.	.	.	.	.	.	0.21173	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	17	chr2	79364374	chr2:79364374	C	G	40	PASS	AN=2;DP=17	GT	0/1
chr2	89346026	89346026	G	-	intergenic	MIR4436A;NONE	dist=234058;dist=NONE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	42	chr2	89346025	chr2:89346025	AG	A	41	PASS	AN=2;DP=42	GT	0/1
chr2	90259965	90259965	T	C	intergenic	MIR4436A;LOC654342	dist=1147997;dist=1564744	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	27	chr2	90259965	chr2:90259965	T	C	55	PASS	AN=2;DP=27	GT	0/1
chr2	102315057	102315057	A	G	intronic	MAP4K4	.	.	.	0.999998979	1.02E-06	2.24E-17	.	0.51487	0.22596	-1.442099697	3.951403633	72.59332	1.77682	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	15	chr2	102315057	chr2:102315057	A	G	43	PASS	AN=2;DP=15	GT	0/1
chr2	111644331	111644331	A	G	intronic	ACOXL	.	.	.	6.28E-10	0.400098611	0.599901388	.	0.07205	0.07959	1.86668643	97.19863175	3441.02377	11.26674	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	56	chr2	111644331	chr2:111644331	A	G	71	PASS	AN=2;DP=56	GT	0/1
chr2	120980428	120980428	G	C	exonic	TMEM185B	.	nonsynonymous SNV	TMEM185B:NM_024121:exon1:c.C125G:p.A42G	0.493451137	0.430599693	0.07594917	.	.	.	.	.	50.82318	1.40476	0.175	0.224	T	0.102	0.243	B	0.137	0.317	B	.	.	.	0.000	0.588	P	1.79	0.469	L	1.8	0.253	T	-1.69	0.402	N	0.515	0.558	.	.	.	.	.	.	.	.	.	3.602	0.490	23.2	0.997	0.776	0.976	0.756	D	n	1.793	1.061	1.000	0.747	0.733	0.969	0	2.9	0.327	9.126	0.937	1.048	0.713	1.000	0.715	0.999	0.750	9.636	0.388	.	ENSG00000226479.3|ENSG00000115109.9|ENSG00000226479.3|ENSG00000226479.3|ENSG00000226479.3|ENSG00000226479.3|ENSG00000226479.3|ENSG00000226479.3|ENSG00000226479.3|ENSG00000144118.9|ENSG00000226479.3	Adipose_Subcutaneous|Adrenal_Gland|Artery_Aorta|Artery_Tibial|Cells_Transformed_fibroblasts|Esophagus_Muscularis|Heart_Atrial_Appendage|Heart_Left_Ventricle|Muscle_Skeletal|Testis|Testis	0.5	61	23	chr2	120980428	chr2:120980428	G	C	61	PASS	AN=2;DP=23	GT	0/1
chr2	160086692	160086692	A	G	exonic	TANC1	.	synonymous SNV	TANC1:NM_001350062:exon24:c.A4152G:p.T1384T,TANC1:NM_001350063:exon25:c.A4386G:p.T1462T,TANC1:NM_001350064:exon27:c.A4734G:p.T1578T,TANC1:NM_033394:exon27:c.A4755G:p.T1585T,TANC1:NM_001350065:exon28:c.A4734G:p.T1578T	0.140685896	0.859314101	2.36E-09	.	0.2207	0.09998	-1.262475058	5.266572305	1280.16491	6.73695	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	42	chr2	160086692	chr2:160086692	A	G	62	PASS	AN=2;DP=42	GT	0/1
chr2	162274729	162274729	C	A	exonic	TBR1	.	nonsynonymous SNV	TBR1:NM_006593:exon3:c.C865A:p.H289N	0.993588037	0.006410977	9.85E-07	.	0.93213	0.38022	-0.405853867	26.23260203	93.16795	2.07643	0.0	0.912	D	0.998	0.715	D	0.997	0.850	D	0.000	0.629	D	1	0.810	D	3.825	0.957	H	-3.22	0.934	D	-6.13	0.902	D	0.531	0.718	1.079	0.989	D	0.934	0.978	D	0.470	0.947	D	4.217	0.565	23.9	0.992	0.537	0.993	0.944	D	c	1.035	0.937	1.000	0.747	0.598	0.340	0	5.07	0.680	7.860	0.853	0.932	0.445	1.000	0.715	1.000	0.888	18.612	0.912	Transcription factor, T-box, conserved site|p53-like transcription factor, DNA-binding	.	.	0.5	.	26	chr2	162274729	chr2:162274729	C	A	.	PASS	AN=0;DP=26	GT	0/1
chr2	169984066	169984066	C	A	UTR3	LRP2	NM_004525:c.*1107G>T	.	.	1	1.49E-12	3.66E-46	.	0.64775	0.54233	3.324377969	99.4220335	2032.71856	8.29976	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	55	chr2	169984066	chr2:169984066	C	A	.	PASS	AN=0;DP=55	GT	0/1
chr2	179347386	179347386	C	T	ncRNA_intronic	MIR548N	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	33	chr2	179347386	chr2:179347386	C	T	58	PASS	AN=2;DP=33	GT	0/1
chr2	198362018	198362018	T	C	exonic	HSPD1	.	synonymous SNV	HSPD1:NM_002156:exon3:c.A273G:p.K91K,HSPD1:NM_199440:exon3:c.A273G:p.K91K	0.985208244	0.01479021	1.55E-06	DISEASE: Spastic paraplegia 13, autosomal dominant (SPG13) [MIM:605280]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. {ECO:0000269|PubMed:11898127}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Leukodystrophy, hypomyelinating, 4 (HLD4) [MIM:612233]: A severe autosomal recessive hypomyelinating leukodystrophy. Clinically characterized by infantile-onset rotary nystagmus, progressive spastic paraplegia, neurologic regression, motor impairment, profound mental retardation. Death usually occurs within the first two decades of life. {ECO:0000269|PubMed:18571143}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.9786	0.9809	-0.203796826	38.81811748	89.54005	2.03508	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	82	15	chr2	198362018	chr2:198362018	T	C	82	PASS	AN=2;DP=15	GT	1/0
chr2	206631554	206631554	T	-	intronic	NRP2	.	.	.	0.00171165	0.998241695	4.67E-05	.	0.30972	0.15109	-1.080231599	7.277659825	168.69076	2.83534	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	16	chr2	206631553	chr2:206631553	AT	A	39	PASS	AN=2;DP=16	GT	0/1
chr2	218706857	218706857	T	C	intronic	TNS1	.	.	.	0.924939889	0.075060111	5.03E-11	.	0.49253	0.15564	1.585596299	95.81269167	8076.56687	19.41076	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	28	chr2	218706857	chr2:218706857	T	C	55	PASS	AN=2;DP=28	GT	0/1
chr2	225781324	225781324	C	T	intronic	DOCK10	.	.	.	0.02919253	0.97080747	2.09E-12	.	0.22785	0.12287	-1.065786145	7.377919321	3131.37113	10.65498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	20	chr2	225781324	chr2:225781324	C	T	.	PASS	AN=0;DP=20	GT	0/1
chr2	234669144	234669144	G	A	exonic	UGT1A1	.	nonsynonymous SNV	UGT1A1:NM_000463:exon1:c.G211A:p.G71R	2.94E-09	0.085606144	0.914393853	DISEASE: Gilbert syndrome (GILBS) [MIM:143500]: Occurs as a consequence of reduced bilirubin transferase activity and is often detected in young adults with vague non-specific complaints. {ECO:0000269|PubMed:11013440, ECO:0000269|PubMed:12139570, ECO:0000269|PubMed:7715297, ECO:0000269|PubMed:9627603}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Transient familial neonatal hyperbilirubinemia (HBLRTFN) [MIM:237900]: A condition characterized by excessive concentration of bilirubin in the blood, which may lead to jaundice. Breast milk jaundice is a common problem in nursing infants. {ECO:0000269|PubMed:11061796}. Note=The disease may be caused by mutations affecting the gene represented in this entry. The defect has been ascribed to various breast milk substances, but the component or combination of components that is responsible remains unclear. Defects of UGT1A1 are an underlying cause of the prolonged unconjugated hyperbilirubinemia associated with breast milk. One or more components in the milk may trigger the jaundice in infants who have such mutations. Mutations are identical to those detected in patients with Gilbert syndrome, a risk factor of neonatal non-physiologic hyperbilirubinemia and a genetic factor in fasting hyperbilirubinemia.; DISEASE: Crigler-Najjar syndrome 1 (CN1) [MIM:218800]: Patients have severe hyperbilirubinemia and usually die of kernicterus (bilirubin accumulation in the basal ganglia and brainstem nuclei) within the first year of life. CN1 inheritance is autosomal recessive. {ECO:0000269|PubMed:11013440, ECO:0000269|PubMed:15712364, ECO:0000269|PubMed:1634050, ECO:0000269|PubMed:17229650, ECO:0000269|PubMed:19830808, ECO:0000269|PubMed:23992562, ECO:0000269|PubMed:7906695, ECO:0000269|PubMed:7989045, ECO:0000269|PubMed:7989595, ECO:0000269|PubMed:8226884}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Crigler-Najjar syndrome 2 (CN2) [MIM:606785]: Patients have less severe hyperbilirubinemia and usually survive into adulthood without neurologic damage. Phenobarbital, which induces the partially deficient glucuronyl transferase, can diminish the jaundice. CN2 inheritance is autosomal dominant. {ECO:0000269|PubMed:11013440, ECO:0000269|PubMed:11370628, ECO:0000269|PubMed:12402338, ECO:0000269|PubMed:15712364, ECO:0000269|PubMed:17229650, ECO:0000269|PubMed:19830808, ECO:0000269|PubMed:23099197, ECO:0000269|PubMed:23992562, ECO:0000269|PubMed:7989595, ECO:0000269|PubMed:8276413, ECO:0000269|PubMed:8280139, ECO:0000269|PubMed:8706880, ECO:0000269|PubMed:9621515, ECO:0000269|PubMed:9639672}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	.	0.58091	-0.556537043	19.72753008	185.91297	2.96084	0.04	0.421	D	0.127	0.581	B	0.183	0.497	B	.	.	.	0.599	0.309	P	1.39	0.351	L	0.09	0.615	T	-1.77	0.486	N	0.097	0.100	-1.081	0.071	T	0.001	0.002	T	.	.	.	4.055	0.545	23.7	0.997	0.801	0.339	0.247	N	c	-0.077	-0.054	1.000	0.500	0.487	0.133	0	5.14	0.699	3.900	0.558	1.048	0.713	0.572	0.273	0.951	0.427	7.612	0.271	.	.	.	0.5	40	6	chr2	234669144	chr2:234669144	G	A	40	PASS	AN=2;DP=6	GT	1/0
chr2	240900608	240900608	G	-	intronic	NDUFA10	.	.	.	0.00138794	0.964065844	0.034546216	.	0.0669	0.10997	0.060756528	58.52795471	1093.05276	6.32741	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	54	chr2	240900607	chr2:240900607	TG	T	54	PASS	AN=2;DP=54	GT	0/1
chr2	242612999	242613000	AT	-	UTR3	ATG4B	NM_013325:c.*1320_*1321delAT;NM_178326:c.*1379_*1380delAT	.	.	0.988495913	0.011499968	4.12E-06	.	.	0.10738	0.284856336	71.40835103	488.90283	4.55127	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	38	chr2	242612998	chr2:242612998	CAT	C	70	PASS	AN=2;DP=38	GT	0/1
chr3	7315446	7315446	T	G	intronic	GRM7	.	.	.	0.999169069	0.00083093	1.36E-09	.	0.68439	0.09371	-1.616692429	2.937013447	1262.73334	6.70044	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	20	chr3	7315446	chr3:7315446	T	G	71	PASS	AN=2;DP=20	GT	0/1
chr3	9489334	9489334	-	TTTC	intronic	SETD5	.	.	.	0.999999564	4.36E-07	2.82E-18	DISEASE: Mental retardation, autosomal dominant 23 (MRD23) [MIM:615761]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD23 patients manifest moderate to severe intellectual disability with additional variable features of brachycephaly, a low hairline, depressed nasal bridge, prominent high nasal root, tubular nose, upslanting palpebral fissures, long and smooth philtrum, micrognathia, thin upper lip, and crowded teeth. Behavioral problems, including obsessive-compulsive disorder, hand flapping with ritualized behavior, and autism, are prominent features. {ECO:0000269|PubMed:24680889}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.46735	0.10674	-0.791786324	12.59731069	500.45582	4.59199	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	16	chr3	9489334	chr3:9489334	A	ATTTC	50	PASS	AN=2;DP=16	GT	0/1
chr3	12861586	12861586	T	C	exonic	CAND2	.	synonymous SNV	CAND2:NM_012298:exon9:c.T2667C:p.G889G,CAND2:NM_001162499:exon11:c.T2946C:p.G982G	4.53E-09	0.806271649	0.193728346	.	0.25408	0.11518	1.526690916	95.49422033	6172.51432	16.42964	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	37	chr3	12861586	chr3:12861586	T	C	52	PASS	AN=2;DP=37	GT	0/1
chr3	13651011	13651011	A	G	splicing	FBLN2	NM_001998:exon4:c.1419-2A>G;NM_001004019:exon4:c.1419-2A>G;NM_001165035:exon4:c.1419-2A>G	.	.	0.629825153	0.370172306	2.54E-06	.	0.76637	0.22472	-1.091439713	6.988676575	754.76604	5.44846	.	.	.	.	.	.	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.312	0.457	22.9	0.984	0.407	0.949	0.625	D	c	0.869	0.656	0.998	0.361	0.078	0.016	0	4.79	0.608	5.907	0.694	1.135	0.883	1.000	0.715	0.690	0.307	12.761	0.566	.	.	.	0.5	.	36	chr3	13651011	chr3:13651011	A	G	.	PASS	AN=0;DP=36	GT	0/1
chr3	17747513	17747513	C	G	intronic	TBC1D5	.	.	.	6.52E-10	0.96022617	0.039773829	.	0.28341	0.1005	0.090079492	60.64519934	185.71366	2.95909	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	81	45	chr3	17747513	chr3:17747513	C	G	81	PASS	AN=2;DP=45	GT	0/1
chr3	23848923	23848923	-	T	intronic	UBE2E1	.	.	.	0.872957997	0.125383932	0.00165807	.	0.62873	0.11262	0.279402865	70.86577023	246.66235	3.38871	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	26	chr3	23848923	chr3:23848923	C	CT	39	PASS	AN=2;DP=26	GT	0/1
chr3	33887102	33887102	A	G	intronic	PDCD6IP	.	.	.	0.751958922	0.248040335	7.43E-07	.	0.26577	0.12495	-0.306750577	32.23047889	8447.59531	19.81694	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	12	chr3	33887102	chr3:33887102	A	G	62	PASS	AN=2;DP=12	GT	0/1
chr3	41266101	41266101	C	A	exonic	CTNNB1	.	nonsynonymous SNV	CTNNB1:NM_001098209:exon3:c.C98A:p.S33Y,CTNNB1:NM_001098210:exon3:c.C98A:p.S33Y,CTNNB1:NM_001904:exon3:c.C98A:p.S33Y,CTNNB1:NM_001330729:exon4:c.C77A:p.S26Y	0.99981275	0.00018725	3.61E-11	DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:9065402}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Note=Activating mutations in CTNNB1 have oncogenic activity resulting in tumor development. Somatic mutations are found in various tumor types, including colon cancers, ovarian and prostate carcinomas, hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant embryonal tumors mainly affecting young children in the first three years of life.; DISEASE: Pilomatrixoma (PTR) [MIM:132600]: Common benign skin tumor. {ECO:0000269|PubMed:10192393, ECO:0000269|PubMed:11703283}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. {ECO:0000269|PubMed:10666372}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:10391090}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving CTNNB1 is found in salivary gland pleiomorphic adenomas, the most common benign epithelial tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1.; DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle- shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. {ECO:0000269|PubMed:11464291}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Mental retardation, autosomal dominant 19 (MRD19) [MIM:615075]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD19 features include severe intellectual disability with absent or very limited speech, microcephaly, and spasticity which severely impaired the ability to walk. {ECO:0000269|PubMed:23033978, ECO:0000269|PubMed:25326669}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.99997	0.9963	-0.582225231	18.44184949	10.25364	0.37429	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.843	D	1	0.810	D	2.66	0.781	M	0.74	0.505	T	-5.89	0.887	D	0.239	0.784	-0.375	0.728	T	0.341	0.707	T	0.067	0.702	D	5.588	0.760	26.5	0.994	0.641	0.970	0.719	D	c	0.915	0.893	1.0	0.983	0.707	0.730	0	5.76	0.907	7.905	0.864	0.935	0.490	1.000	0.715	1.000	0.888	19.960	0.972	.	.	.	0.5	.	41	chr3	41266101	chr3:41266101	C	A	.	PASS	AN=0;DP=41	GT	0/1
chr3	42299737	42299737	G	A	intronic	CCK	.	.	.	0.023105402	0.768016901	0.208877697	.	0.075	0.19392	-0.031067188	51.03798066	31.7441	0.99985	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	9	chr3	42299737	chr3:42299737	G	A	50	PASS	AN=2;DP=9	GT	0/1
chr3	46482898	46482898	T	-	intronic	LTF	.	.	.	1.76E-13	0.332110461	0.667889539	.	.	0.31989	0.521707177	80.39631989	121.1482	2.39786	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	14	chr3	46482897	chr3:46482897	CT	C	44	PASS	AN=2;DP=14	GT	0/1
chr3	46620760	46620760	T	G	exonic	TDGF1	.	nonsynonymous SNV	TDGF1:NM_001174136:exon3:c.T79G:p.Y27D,TDGF1:NM_003212:exon3:c.T127G:p.Y43D	3.98E-06	0.212748142	0.787247875	.	.	0.56496	0.238945317	69.20853975	351.82952	3.97563	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.759	0.096	N	1.000	0.090	P	-1.845	0.003	N	0.24	0.597	T	3.84	0.001	N	0.024	0.021	-1.040	0.172	T	0.000	0.000	T	.	.	.	-0.616	0.049	0.114	0.634	0.070	0.001	0.005	N	c	-1.407	-1.300	1.000	0.500	0.628	0.401	0	3.31	0.369	0.679	0.248	0.123	0.211	0.003	0.159	0.002	0.062	7.482	0.264	.	.	.	0.5	52	16	chr3	46620760	chr3:46620760	T	G	52	PASS	AN=2;DP=16	GT	0/1
chr3	48681766	48681769	AGAG	-	intronic	CELSR3	.	.	.	0.999656221	0.000343779	1.51E-19	.	.	0.2449	-4.265082462	0.11205473	3038.6677	10.47295	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	12	chr3	48681765	chr3:48681765	CAGAG	C	42	PASS	AN=2;DP=12	GT	0/1
chr3	50407863	50407863	G	A	intronic	CACNA2D2	.	.	.	0.999693297	0.000306703	4.08E-14	.	0.48941	0.15443	-0.549263935	19.95163954	590.52071	4.92605	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	56	chr3	50407863	chr3:50407863	G	A	.	PASS	AN=0;DP=56	GT	0/1
chr3	50407875	50407875	G	A	intronic	CACNA2D2	.	.	.	0.999693297	0.000306703	4.08E-14	.	0.48941	0.15443	-0.549263935	19.95163954	590.52071	4.92605	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	67	99	chr3	50407875	chr3:50407875	G	A	67	PASS	AN=2;DP=99	GT	0/1
chr3	52290115	52290115	T	C	UTR3	WDR82	NM_025222:c.*1391A>G	.	.	0.923062144	0.076843893	9.40E-05	.	0.64619	0.12971	-0.031067188	51.03798066	1.24663	0.04374	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	19	chr3	52290115	chr3:52290115	T	C	.	PASS	AN=0;DP=19	GT	0/1
chr3	53226714	53226714	T	G	UTR3	PRKCD	NM_212539:c.*432T>G;NM_006254:c.*432T>G;NM_001316327:c.*432T>G	.	.	0.997593707	0.00240629	3.69E-09	DISEASE: Autoimmune lymphoproliferative syndrome 3 (ALPS3) [MIM:615559]: A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low. CVID9 patients have B-cell deficiency and severe autoimmunity. {ECO:0000269|PubMed:23319571}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.50726	0.64101	-1.041578376	7.773059684	38.38258	1.13875	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	64	chr3	53226714	chr3:53226714	T	G	72	PASS	AN=2;DP=64	GT	0/1
chr3	56763525	56763525	A	G	exonic	ARHGEF3	.	synonymous SNV	ARHGEF3:NM_001128616:exon10:c.T1372C:p.L458L,ARHGEF3:NM_019555:exon10:c.T1354C:p.L452L,ARHGEF3:NM_001289698:exon11:c.T1372C:p.L458L,ARHGEF3:NM_001128615:exon13:c.T1450C:p.L484L	0.991271358	0.008728557	8.58E-08	.	0.32682	0.12378	-0.290161348	33.33923095	2959.45549	10.30538	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	11	chr3	56763525	chr3:56763525	A	G	43	PASS	AN=2;DP=11	GT	0/1
chr3	57563121	57563121	A	-	intronic	ARF4;PDE12	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	14	chr3	57563120	chr3:57563120	GA	G	43	PASS	AN=2;DP=14	GT	0/1
chr3	75672730	75672730	T	C	intergenic	FAM86DP;MIR1324	dist=188464;dist=7184	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chr3	75672730	chr3:75672730	T	C	.	PASS	AN=0;DP=44	GT	0/1
chr3	78647220	78647220	G	A	UTR3	ROBO1	NM_001145845:c.*843C>T;NM_002941:c.*843C>T;NM_133631:c.*843C>T	.	.	3.04E-08	0.99999991	5.98E-08	.	0.94674	0.12413	-1.960545765	1.845954234	484.42539	4.53042	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	36	chr3	78647220	chr3:78647220	G	A	.	PASS	AN=0;DP=36	GT	0/1
chr3	87322555	87322555	A	T	exonic	POU1F1	.	nonsynonymous SNV	POU1F1:NM_000306:exon2:c.T156A:p.H52Q,POU1F1:NM_001122757:exon2:c.T234A:p.H78Q	0.618818419	0.379529678	0.001651904	DISEASE: Pituitary hormone deficiency, combined, 1 (CPHD1) [MIM:613038]: Combined pituitary hormone deficiency is defined as the impaired production of growth hormone and one or more of the other five anterior pituitary hormones. CPHD1 is characterized by pleiotropic deficiencies of growth hormone, prolactin and thyroid- stimulating hormone, while the production of adrenocorticotropic hormone, luteinizing hormone, and follicle-stimulating hormone are preserved. In infancy severe growth deficiency from birth as well as distinctive facial features with prominent forehead, marked midfacial hypoplasia with depressed nasal bridge, deep-set eyes, and a short nose with anteverted nostrils and hypoplastic pituitary gland by MRI examination can be seen. Some cases present with severe mental retardation along with short stature. {ECO:0000269|PubMed:11297581, ECO:0000269|PubMed:1472057, ECO:0000269|PubMed:1509262, ECO:0000269|PubMed:1509263, ECO:0000269|PubMed:15928241, ECO:0000269|PubMed:16968807, ECO:0000269|PubMed:7852536, ECO:0000269|PubMed:8768831, ECO:0000269|PubMed:9485179, ECO:0000269|PubMed:9626142}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.19992	0.28828	0.038710339	56.92380278	38.64856	1.14539	0.001	0.912	D	0.999	0.764	D	0.997	0.850	D	0.004	0.342	N	1.000	0.479	D	1.975	0.537	M	-0.19	0.659	T	-2.55	0.881	D	0.818	0.813	-0.480	0.694	T	0.340	0.706	T	0.034	0.553	D	3.849	0.519	23.4	0.989	0.485	0.742	0.360	D	c	0.087	0.012	0.000	0.046	0.428	0.059	0	-0.356	0.119	0.937	0.283	0.125	0.212	1.000	0.715	0.999	0.750	10.670	0.448	POU-specific domain	.	.	0.5	70	32	chr3	87322555	chr3:87322555	A	T	70	PASS	AN=2;DP=32	GT	1/0
chr3	118865127	118865129	GAA	-	exonic	C3orf30	.	nonframeshift deletion	C3orf30:NM_152539:exon1:c.91_93del:p.E32del	1.65E-06	0.415511995	0.584486357	.	0.04106	.	3.199316096	99.33946686	2760.18176	9.91164	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	14	chr3	118865126	chr3:118865126	GGAA	G	44	PASS	AN=2;DP=14	GT	0/1
chr3	133475722	133475722	C	T	exonic	TF	.	synonymous SNV	TF:NM_001063:exon7:c.C739T:p.L247L	0.002372266	0.996916882	0.000710852	DISEASE: Atransferrinemia (ATRAF) [MIM:209300]: A rare autosomal recessive disorder characterized by abnormal synthesis of transferrin leading to iron overload and microcytic hypochromic anemia. {ECO:0000269|PubMed:11110675, ECO:0000269|PubMed:15466165}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.62381	0.9477	-0.905656269	10.12031139	319.18799	3.79368	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	25	chr3	133475722	chr3:133475722	C	T	58	PASS	AN=2;DP=25	GT	0/1
chr3	139077605	139077605	G	A	exonic	COPB2	.	nonsynonymous SNV	COPB2:NM_004766:exon20:c.C2534T:p.S845L	0.999998457	1.54E-06	1.50E-15	.	0.51577	0.19561	-0.934977358	9.465675867	73.10436	1.78585	0.175	0.232	T	0.0	0.026	B	0.002	0.063	B	0.001	0.405	N	0.951	0.377	D	1.355	0.339	L	-0.02	0.629	T	-1.34	0.334	N	0.362	0.423	-0.884	0.495	T	0.168	0.508	T	0.018	0.400	T	3.544	0.483	23.1	0.985	0.412	0.941	0.598	D	c	-0.162	-0.001	1.000	0.747	0.719	0.830	0	4.53	0.548	2.611	0.458	1.048	0.713	1.000	0.715	0.991	0.552	9.916	0.404	.	.	.	0.5	.	25	chr3	139077605	chr3:139077605	G	A	.	PASS	AN=0;DP=25	GT	0/1
chr3	139257546	139257546	C	-	ncRNA_intronic	LOC100507291	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	68	chr3	139257545	chr3:139257545	GC	G	72	PASS	AN=2;DP=68	GT	0/1
chr3	180326488	180326488	G	C	splicing	TTC14	NM_001288582:exon11:c.1291-1G>C;NM_133462:exon11:c.1291-1G>C	.	.	4.42E-06	0.955823688	0.044171893	.	0.10216	0.1043	-0.020150552	52.25288983	125.31545	2.43621	.	.	.	.	.	.	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.409	0.590	24.1	0.995	0.675	0.998	0.995	D	c	1.224	1.087	1.000	0.747	0.295	0.044	0	5.64	0.864	8.519	0.903	1.048	0.713	1.000	0.715	1.000	0.888	19.701	0.960	.	.	.	0.5	60	33	chr3	180326488	chr3:180326488	G	C	60	PASS	AN=2;DP=33	GT	0/1
chr3	195965316	195965316	G	-	UTR3	PCYT1A	NM_001312673:c.*243delC;NM_005017:c.*243delC	.	.	0.098300076	0.90012567	0.001574255	DISEASE: Spondylometaphyseal dysplasia with cone-rod dystrophy (SMDCRD) [MIM:608940]: A disorder characterized by postnatal growth deficiency resulting in profound short stature, rhizomelia with bowing of the lower extremities, platyspondyly with anterior vertebral protrusions, progressive metaphyseal irregularity and cupping with shortened tubular bones, and early-onset progressive visual impairment associated with a pigmentary maculopathy and electroretinographic evidence of cone-rod dysfunction. {ECO:0000269|PubMed:24387990, ECO:0000269|PubMed:24387991}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.75481	.	-0.846787714	11.05803255	78.82184	1.87555	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	74	28	chr3	195965315	chr3:195965315	TG	T	74	PASS	AN=2;DP=28	GT	0/1
chr4	3318413	3318413	A	G	exonic	RGS12	.	synonymous SNV	RGS12:NM_002926:exon2:c.A516G:p.S172S,RGS12:NM_198229:exon2:c.A516G:p.S172S	0.000560374	0.999430106	9.52E-06	.	0.22901	.	-0.463176509	23.57867422	1192.69117	6.54837	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	13	chr4	3318413	chr4:3318413	A	G	51	PASS	AN=2;DP=13	GT	0/1
chr4	3941999	3941999	A	G	intergenic	ADRA2C;FAM86EP	dist=171746;dist=1488	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	78	78	chr4	3941999	chr4:3941999	A	G	78	PASS	AN=2;DP=78	GT	0/1
chr4	3942013	3942014	TG	-	intergenic	ADRA2C;FAM86EP	dist=171760;dist=1473	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	67	chr4	3942012	chr4:3942012	CTG	C	70	PASS	AN=2;DP=67	GT	0/1
chr4	3943067	3943067	C	G	downstream	FAM86EP	dist=420	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	90	65	chr4	3943067	chr4:3943067	C	G	90	PASS	AN=2;DP=65	GT	0/1
chr4	3954878	3954878	T	C	ncRNA_exonic	FAM86EP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	88	62	chr4	3954878	chr4:3954878	T	C	88	PASS	AN=2;DP=62	GT	0/1
chr4	4322770	4322770	T	C	exonic	ZBTB49	.	synonymous SNV	ZBTB49:NM_001330625:exon8:c.T2025C:p.G675G,ZBTB49:NM_145291:exon8:c.T2025C:p.G675G	0.009164155	0.98839363	0.002442215	.	0.13097	.	1.09310945	91.90846898	725.33362	5.34612	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	16	chr4	4322770	chr4:4322770	T	C	43	PASS	AN=2;DP=16	GT	0/1
chr4	9756888	9756888	C	T	intergenic	MIR548I2;DRD5	dist=198951;dist=26370	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	90	chr4	9756888	chr4:9756888	C	T	.	PASS	AN=0;DP=90	GT	0/1
chr4	38937317	38937317	T	-	intronic	FAM114A1	.	.	.	2.38E-08	0.457538177	0.542461799	.	0.11964	.	0.358272123	74.66383581	2541.88338	9.41853	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	19	chr4	38937316	chr4:38937316	CT	C	43	PASS	AN=2;DP=19	GT	0/1
chr4	49491310	49491310	T	C	intergenic	CWH43;NONE	dist=427215;dist=NONE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	138	chr4	49491310	chr4:49491310	T	C	62	PASS	AN=2;DP=138	GT	0/1
chr4	53732872	53732872	T	-	UTR3	RASL11B	NM_023940:c.*900delT	.	.	0.290784778	0.688380488	0.020834734	.	0.49003	0.10864	-0.095386216	46.48502005	63.84681	1.63863	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	16	chr4	53732871	chr4:53732871	CT	C	43	PASS	AN=2;DP=16	GT	0/1
chr4	68719737	68719737	C	T	intronic	TMPRSS11D	.	.	.	0.06251897	0.934180679	0.003300351	.	0.13173	0.51855	-0.736552314	13.93606983	32.5418	1.01329	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	13	chr4	68719737	chr4:68719737	C	T	.	PASS	AN=0;DP=13	GT	0/1
chr4	101947097	101947097	G	A	exonic	PPP3CA	.	synonymous SNV	PPP3CA:NM_001130692:exon12:c.C1335T:p.N445N,PPP3CA:NM_001130691:exon13:c.C1461T:p.N487N,PPP3CA:NM_000944:exon14:c.C1491T:p.N497N	0.998148789	0.001851202	9.61E-09	.	0.91458	0.30319	-0.427900189	25.14744043	6.37885	0.23918	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	58	chr4	101947097	chr4:101947097	G	A	.	PASS	AN=0;DP=58	GT	0/1
chr4	105393431	105393431	G	A	UTR3	CXXC4	NM_025212:c.*48C>T	.	.	.	.	.	.	0.53604	0.11809	-0.009020804	52.8544468	98.64157	2.14793	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	36	chr4	105393431	chr4:105393431	G	A	.	PASS	AN=0;DP=36	GT	0/1
chr4	113568168	113568168	G	A	ncRNA_intronic	LOC109864269	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr4	113568168	chr4:113568168	G	A	.	PASS	AN=0;DP=38	GT	0/1
chr4	129869594	129869594	T	A	intronic	SCLT1	.	.	.	5.17E-12	0.788518493	0.211481507	.	0.34487	0.09874	-0.064242613	48.844067	315.8929	3.77458	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	15	chr4	129869594	chr4:129869594	T	A	.	PASS	AN=0;DP=15	GT	0/1
chr4	151560820	151560820	A	T	intronic	LRBA	.	.	.	0.044229437	0.955770563	1.54E-17	DISEASE: Immunodeficiency, common variable, 8, with autoimmunity (CVID8) [MIM:614700]: An autosomal recessive immunologic disorder associated with defective B-cell differentiation and decreased or absent antibody production. Affected individuals have early- childhood onset of recurrent infections, particularly respiratory infections, and also develop variable autoimmune disorders, including idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and inflammatory bowel disease. {ECO:0000269|PubMed:22608502}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.31593	.	-2.513092117	0.925925926	4753.32179	13.94798	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	32	chr4	151560820	chr4:151560820	A	T	.	PASS	AN=0;DP=32	GT	0/1
chr4	151560835	151560835	A	-	intronic	LRBA	.	.	.	0.044229437	0.955770563	1.54E-17	DISEASE: Immunodeficiency, common variable, 8, with autoimmunity (CVID8) [MIM:614700]: An autosomal recessive immunologic disorder associated with defective B-cell differentiation and decreased or absent antibody production. Affected individuals have early- childhood onset of recurrent infections, particularly respiratory infections, and also develop variable autoimmune disorders, including idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and inflammatory bowel disease. {ECO:0000269|PubMed:22608502}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.31593	.	-2.513092117	0.925925926	4753.32179	13.94798	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	78	75	chr4	151560834	chr4:151560834	TA	T	78	PASS	AN=2;DP=75	GT	0/1
chr5	233734	233734	C	G	exonic	SDHA	.	synonymous SNV	SDHA:NM_001294332:exon7:c.C894G:p.S298S,SDHA:NM_001330758:exon8:c.C1038G:p.S346S,SDHA:NM_004168:exon8:c.C1038G:p.S346S	9.39E-06	0.996636308	0.003354304	DISEASE: Mitochondrial complex II deficiency (MT-C2D) [MIM:252011]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry. {ECO:0000269|PubMed:12794685}.; DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:10746566, ECO:0000269|PubMed:24781757, ECO:0000269|PubMed:7550341}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1GG (CMD1GG) [MIM:613642]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:20551992}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Paragangliomas 5 (PGL5) [MIM:614165]: A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion. Paragangliomas can develop at various body sites, including the head, neck, thorax and abdomen. Most commonly, they are located in the head and neck region, specifically at the carotid bifurcation, the jugular foramen, the vagal nerve, and in the middle ear. {ECO:0000269|PubMed:20484225}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.2964	.	-0.857930839	10.95187544	1260.39498	6.69421	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	38	chr5	233734	chr5:233734	C	G	53	PASS	AN=2;DP=38	GT	0/1
chr5	432898	432898	C	-	intronic	AHRR	.	.	.	6.76E-05	0.977269885	0.022662496	.	.	0.16352	1.004917985	90.78792168	1613.48158	7.43304	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	45	21	chr5	432897	chr5:432897	TC	T	45	PASS	AN=2;DP=21	GT	0/1
chr5	1632941	1632941	T	G	ncRNA_intronic	LOC728613	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	39	chr5	1632941	chr5:1632941	T	G	50	PASS	AN=2;DP=39	GT	0/1
chr5	5447607	5447607	A	G	exonic	ICE1	.	synonymous SNV	ICE1:NM_015325:exon8:c.A492G:p.E164E	.	.	.	.	.	.	-0.174712176	40.57560745	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	20	chr5	5447607	chr5:5447607	A	G	61	PASS	AN=2;DP=20	GT	0/1
chr5	34811137	34811137	T	G	exonic	RAI14	.	synonymous SNV	RAI14:NM_001145523:exon7:c.T447G:p.L149L,RAI14:NM_001145520:exon8:c.T471G:p.L157L,RAI14:NM_001145522:exon8:c.T471G:p.L157L,RAI14:NM_015577:exon8:c.T471G:p.L157L,RAI14:NM_001145521:exon9:c.T471G:p.L157L,RAI14:NM_001145525:exon10:c.T480G:p.L160L	0.487656416	0.512341946	1.64E-06	.	0.2442	0.11401	-0.216746887	37.69757018	3767.60269	12.00361	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	8	chr5	34811137	chr5:34811137	T	G	41	PASS	AN=2;DP=8	GT	0/1
chr5	40798325	40798325	G	A	upstream	PRKAA1	dist=28	.	.	0.035101034	0.96325073	0.001648236	.	0.90852	0.13068	-0.494039303	22.09247464	21.33891	0.72054	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	67	98	chr5	40798325	chr5:40798325	G	A	67	PASS	AN=2;DP=98	GT	0/1
chr5	56527030	56527030	G	A	exonic	GPBP1	.	nonsynonymous SNV	GPBP1:NM_001127236:exon4:c.G314A:p.R105H,GPBP1:NM_001127235:exon5:c.G314A:p.R105H,GPBP1:NM_001331037:exon5:c.G293A:p.R98H,GPBP1:NM_022913:exon5:c.G293A:p.R98H	0.975851112	0.024147841	1.05E-06	.	0.84318	0.11313	0.042348793	57.31304553	66.67652	1.68454	0.393	0.107	T	0.067	0.222	B	0.023	0.188	B	0.000	0.843	D	0.990	0.810	D	1.79	0.469	L	0.88	0.460	T	-1.64	0.422	N	0.322	0.388	-1.051	0.142	T	0.090	0.346	T	0.011	0.273	T	3.275	0.453	22.8	0.996	0.717	0.902	0.508	D	c	-0.134	0.035	1.000	0.473	0.722	0.854	0	4.9	0.635	2.869	0.479	0.108	0.203	1.000	0.715	0.999	0.750	9.911	0.404	.	.	.	0.5	.	28	chr5	56527030	chr5:56527030	G	A	.	PASS	AN=0;DP=28	GT	0/1
chr5	111065696	111065696	-	AAAG	ncRNA_intronic	STARD4-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	17	chr5	111065696	chr5:111065696	C	CAAAG	50	PASS	AN=2;DP=17	GT	0/1
chr5	111066697	111066697	T	C	exonic	NREP	.	nonsynonymous SNV	NREP:NM_001142483:exon3:c.A128G:p.E43G,NREP:NM_001142474:exon4:c.A230G:p.E77G,NREP:NM_001142475:exon4:c.A260G:p.E87G,NREP:NM_004772:exon4:c.A128G:p.E43G,NREP:NM_001142476:exon5:c.A128G:p.E43G,NREP:NM_001142477:exon5:c.A128G:p.E43G,NREP:NM_001142478:exon5:c.A128G:p.E43G,NREP:NM_001142479:exon5:c.A128G:p.E43G,NREP:NM_001142480:exon5:c.A128G:p.E43G,NREP:NM_001142481:exon5:c.A128G:p.E43G,NREP:NM_001142482:exon5:c.A128G:p.E43G	0.563643143	0.387749286	0.048607571	.	0.35283	.	0.72397987	85.91648974	72.00969	1.7668	0.145	0.348	T	0.012	0.151	B	0.016	0.166	B	0.093	0.203	N	1	0.192	P	.	.	.	0.6	0.537	T	-5.14	0.833	D	0.061	0.478	-1.064	0.109	T	0.000	0.000	T	.	.	.	-1.057	0.030	0.012	0.919	0.207	0.287	0.234	N	c	-0.900	-0.911	0.999	0.396	0.707	0.730	0	0.269	0.148	1.635	0.365	0.129	0.215	0.204	0.241	0.003	0.074	3.024	0.057	.	.	.	0.5	58	18	chr5	111066697	chr5:111066697	T	C	58	PASS	AN=2;DP=18	GT	0/1
chr5	131822133	131822133	T	C	intronic	IRF1	.	.	.	0.867788618	0.132133586	7.78E-05	DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. {ECO:0000269|PubMed:10395927, ECO:0000269|PubMed:9679752}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.72337	0.11079	-0.007201372	53.19061099	4.5089	0.16359	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	21	chr5	131822133	chr5:131822133	T	C	59	PASS	AN=2;DP=21	GT	0/1
chr5	134116962	134116962	T	A	intronic	DDX46	.	.	.	0.999997754	2.25E-06	3.09E-17	.	0.71667	0.11044	-1.111360919	6.717386176	12.79601	0.46528	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	27	chr5	134116962	chr5:134116962	T	A	.	PASS	AN=0;DP=27	GT	0/1
chr5	137451461	137451461	A	-	intronic	NME5	.	.	.	0.570640716	0.417771698	0.011587586	.	0.16576	.	0.3032669	72.009908	28.15255	0.90228	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	18	chr5	137451460	chr5:137451460	GA	G	42	PASS	AN=2;DP=18	GT	0/1
chr5	138718854	138718854	C	T	intronic	SLC23A1	.	.	.	0.024322306	0.972818626	0.002859068	.	0.15514	0.14852	0.266447942	70.5826846	399.62426	4.19635	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	33	chr5	138718854	chr5:138718854	C	T	.	PASS	AN=0;DP=33	GT	0/1
chr5	140182065	140182065	G	A	exonic	PCDHA3	.	nonsynonymous SNV	PCDHA3:NM_018906:exon1:c.G1283A:p.R428Q,PCDHA3:NM_031497:exon1:c.G1283A:p.R428Q	1.46E-13	0.013151602	0.986848398	.	0.09532	.	-0.676105878	15.40457655	903.22009	5.85119	0.183	0.217	T	0.242	0.323	B	0.069	0.374	B	0.030	0.253	U	1	0.090	N	1.37	0.343	L	0.65	0.527	T	-3.34	0.663	D	0.238	0.293	-1.046	0.154	T	0.069	0.284	T	0.017	0.392	T	3.203	0.444	22.7	0.990	0.503	0.048	0.104	N	c	-0.660	-0.632	0.408	0.202	0.615	0.372	0	2.92	0.329	-0.016	0.124	0.994	0.605	0.000	0.063	0.319	0.240	6.199	0.197	Cadherin|Cadherin-like	.	.	0.5	.	152	chr5	140182065	chr5:140182065	G	A	.	PASS	AN=0;DP=152	GT	0/1
chr5	140237387	140237387	T	G	exonic	PCDHA10	.	nonsynonymous SNV	PCDHA10:NM_018901:exon1:c.T1754G:p.V585G,PCDHA10:NM_031859:exon1:c.T1754G:p.V585G	4.18E-11	0.050751807	0.949248193	.	.	0.10821	1.611214866	95.93064402	3823.87742	12.16143	1.0	0.010	T	0.0	0.026	B	0.001	0.040	B	.	.	.	1.000	0.090	P	0.385	0.122	N	1.15	0.382	T	4.7	0.000	N	0.055	0.037	-0.971	0.371	T	0.000	0.000	T	.	.	.	-2.348	0.004	0.001	0.491	0.041	0.007	0.029	N	c	-1.390	-1.327	0.000	0.029	0.615	0.372	0	1.7	0.232	0.685	0.249	0.049	0.161	0.001	0.137	0.014	0.122	0.359	0.003	Cadherin|Cadherin-like	ENSG00000196963.2|ENSG00000204963.4|ENSG00000204967.6|ENSG00000196963.2|ENSG00000204967.6|ENSG00000196963.2|ENSG00000239389.3|ENSG00000204963.4|ENSG00000239389.3|ENSG00000204961.5|ENSG00000239389.3|ENSG00000204961.5|ENSG00000113119.8|ENSG00000239389.3|ENSG00000204961.5|ENSG00000250120.2|ENSG00000239389.3|ENSG00000204961.5|ENSG00000250120.2|ENSG00000239389.3|ENSG00000239389.3|ENSG00000213523.5|ENSG00000113141.11|ENSG00000120322.2|ENSG00000196963.2|ENSG00000196963.2|ENSG00000196963.2|ENSG00000204963.4|ENSG00000239389.3|ENSG00000239389.3|ENSG00000239389.3|ENSG00000176087.10	Adipose_Subcutaneous|Adipose_Subcutaneous|Artery_Aorta|Artery_Aorta|Artery_Tibial|Artery_Tibial|Brain_Anterior_cingulate_cortex_BA24|Brain_Anterior_cingulate_cortex_BA24|Brain_Caudate_basal_ganglia|Brain_Cerebellar_Hemisphere|Brain_Cerebellar_Hemisphere|Brain_Cerebellum|Brain_Cerebellum|Brain_Cerebellum|Brain_Cortex|Brain_Cortex|Brain_Cortex|Brain_Frontal_Cortex_BA9|Brain_Frontal_Cortex_BA9|Brain_Frontal_Cortex_BA9|Brain_Nucleus_accumbens_basal_ganglia|Cells_Transformed_fibroblasts|Colon_Transverse|Esophagus_Gastroesophageal_Junction|Heart_Atrial_Appendage|Lung|Nerve_Tibial|Nerve_Tibial|Nerve_Tibial|Pancreas|Thyroid|Whole_Blood	0.5	52	34	chr5	140237387	chr5:140237387	T	G	52	PASS	AN=2;DP=34	GT	0/1
chr5	140559679	140559679	C	G	exonic	PCDHB8	.	synonymous SNV	PCDHB8:NM_019120:exon1:c.C2064G:p.T688T	4.80E-08	0.117922549	0.882077403	.	0.03421	.	2.739661384	98.96201934	8920.76586	20.40904	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	77	chr5	140559679	chr5:140559679	C	G	61	PASS	AN=2;DP=77	GT	0/1
chr5	140590766	140590766	A	G	exonic	PCDHB12	.	nonsynonymous SNV	PCDHB12:NM_018932:exon1:c.A2287G:p.K763E	0.000155402	0.669826242	0.330018356	.	0.04439	.	2.476806522	98.62585515	2834.29925	10.05542	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	.	.	.	0.999	0.215	P	-3.455	0.000	N	2.72	0.120	T	3.46	0.001	N	0.028	0.021	-0.952	0.407	T	0.000	0.000	T	.	.	.	-0.381	0.063	0.429	0.487	0.040	0.026	0.071	N	c	-1.510	-1.264	0.487	0.208	0.534	0.214	0	3.13	0.349	5.514	0.665	-0.079	0.119	1.000	0.715	0.002	0.062	9.497	0.380	Cadherin, cytoplasmic C-terminal domain;Cadherin|Cadherin-like	ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000146001.4|ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000196963.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000120322.2|ENSG00000253159.1|ENSG00000120322.2|ENSG00000113212.4|ENSG00000120327.4|ENSG00000120322.2	Adipose_Subcutaneous|Adipose_Visceral_Omentum|Artery_Aorta|Artery_Coronary|Artery_Tibial|Brain_Cortex|Breast_Mammary_Tissue|Cells_Transformed_fibroblasts|Esophagus_Gastroesophageal_Junction|Esophagus_Muscularis|Esophagus_Muscularis|Heart_Atrial_Appendage|Heart_Left_Ventricle|Heart_Left_Ventricle|Lung|Nerve_Tibial|Pancreas|Pituitary|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Skin_Sun_Exposed_Lower_leg|Testis|Testis|Thyroid	0.5	55	22	chr5	140590766	chr5:140590766	A	G	55	PASS	AN=2;DP=22	GT	0/1
chr5	140615413	140615413	C	G	ncRNA_exonic	PCDHB18P	.	.	.	.	.	.	.	0.0684	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	56	chr5	140615413	chr5:140615413	C	G	71	PASS	AN=2;DP=56	GT	0/1
chr5	148386525	148386525	T	G	exonic	SH3TC2	.	synonymous SNV	SH3TC2:NM_024577:exon16:c.A3594C:p.P1198P	1.73E-12	0.792013075	0.207986925	DISEASE: Mononeuropathy of the median nerve mild (MNMN) [MIM:613353]: A disease characterized by median nerve mononeuropathy at the wrist. The clinical presentation ranges from a mild phenotype, consistent with carpal tunnel syndrome, to a severe median nerve mononeuropathy at the wrist associated with evidence of a more widespread axonal polyneuropathy. The latter phenotype is similar to that of patients with hereditary neuropathy with liability to pressure palsies. {ECO:0000269|PubMed:20220177}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.13415	0.13877	0.018271026	55.22528898	877.38282	5.76827	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	12	chr5	148386525	chr5:148386525	T	G	42	PASS	AN=2;DP=12	GT	0/1
chr5	148999881	148999881	-	C	intronic	ARHGEF37	.	.	.	1.08E-13	0.021156722	0.978843278	.	.	.	1.183126933	92.82849729	8667.38708	20.12571	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	14	chr5	148999881	chr5:148999881	G	GC	44	PASS	AN=2;DP=14	GT	0/1
chr5	149755744	149755744	G	C	exonic	TCOF1	.	nonsynonymous SNV	TCOF1:NM_000356:exon12:c.G1762C:p.A588P,TCOF1:NM_001135245:exon12:c.G1762C:p.A588P,TCOF1:NM_001008657:exon13:c.G1993C:p.A665P,TCOF1:NM_001135243:exon13:c.G1993C:p.A665P,TCOF1:NM_001135244:exon13:c.G1993C:p.A665P,TCOF1:NM_001195141:exon13:c.G1993C:p.A665P	0.765232863	0.234767111	2.59E-08	DISEASE: Treacher Collins syndrome 1 (TCS1) [MIM:154500]: A form of Treacher Collins syndrome, a disorder of craniofacial development. Treacher Collins syndrome is characterized by a combination of bilateral downward slanting of the palpebral fissures, colobomas of the lower eyelids with a paucity of eyelashes medial to the defect, hypoplasia of the facial bones, cleft palate, malformation of the external ears, atresia of the external auditory canals, and bilateral conductive hearing loss. {ECO:0000269|PubMed:9042910}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.11725	0.19531	0.466523353	78.69780609	3192.10978	10.76481	0.053	0.574	T	1.0	0.899	D	0.986	0.916	D	0.140	0.183	N	1.000	0.210	P	1.6	0.409	L	-0.52	0.707	T	-3.25	0.652	D	0.263	0.331	-0.797	0.553	T	0.033	0.140	T	.	.	.	2.841	0.402	21.6	0.993	0.601	0.462	0.275	N	c	-0.285	-0.468	0.999	0.380	0.707	0.730	0	1.85	0.243	0.260	0.181	0.017	0.142	0.595	0.275	0.003	0.074	3.913	0.086	Treacher Collins syndrome, treacle	.	.	0.5	43	10	chr5	149755744	chr5:149755744	G	C	43	PASS	AN=2;DP=10	GT	0/1
chr5	149763305	149763305	A	G	exonic	TCOF1	.	nonsynonymous SNV	TCOF1:NM_001008657:exon18:c.A2864G:p.Q955R	0.765232863	0.234767111	2.59E-08	DISEASE: Treacher Collins syndrome 1 (TCS1) [MIM:154500]: A form of Treacher Collins syndrome, a disorder of craniofacial development. Treacher Collins syndrome is characterized by a combination of bilateral downward slanting of the palpebral fissures, colobomas of the lower eyelids with a paucity of eyelashes medial to the defect, hypoplasia of the facial bones, cleft palate, malformation of the external ears, atresia of the external auditory canals, and bilateral conductive hearing loss. {ECO:0000269|PubMed:9042910}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.11725	0.19531	0.466523353	78.69780609	3192.10978	10.76481	0.023	0.481	D	0.0	0.026	B	0.0	0.013	B	.	.	.	1	0.090	P	.	.	.	-1.62	0.824	D	-0.03	0.075	N	0.189	0.231	-0.989	0.328	T	0.000	0.000	T	.	.	.	-0.207	0.075	1.063	0.465	0.037	0.010	0.038	N	c	-1.201	-1.438	0.869	0.254	0.563	0.310	0	-4.27	0.035	-0.935	0.040	-0.842	0.029	0.000	0.063	0.000	0.016	1.273	0.019	.	ENSG00000196743.4	Skin_Sun_Exposed_Lower_leg	0.5	65	40	chr5	149763305	chr5:149763305	A	G	65	PASS	AN=2;DP=40	GT	0/1
chr5	171763533	171763533	-	T	UTR3	SH3PXD2B	NM_001017995:c.*1839_*1840insA	.	.	0.018536793	0.981286619	0.000176588	DISEASE: Frank-Ter Haar syndrome (FTHS) [MIM:249420]: A syndrome characterized by brachycephaly, wide fontanels, prominent forehead, hypertelorism, prominent eyes, macrocornea with or without glaucoma, full cheeks, small chin, bowing of the long bones and flexion deformity of the fingers. {ECO:0000269|PubMed:20137777}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.26216	0.10532	-0.279250919	33.56923803	389.35486	4.15627	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	32	chr5	171763533	chr5:171763533	G	GT	50	PASS	AN=2;DP=32	GT	0/1
chr5	175957163	175957163	G	A	exonic	RNF44	.	synonymous SNV	RNF44:NM_014901:exon7:c.C846T:p.Y282Y	0.567929658	0.431553355	0.000516987	.	0.35919	.	-0.179930907	40.35739561	104.3157	2.20769	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	43	chr5	175957163	chr5:175957163	G	A	.	PASS	AN=0;DP=43	GT	0/1
chr5	177987759	177987759	A	-	intronic	COL23A1	.	.	.	9.57E-10	0.90264393	0.097356069	.	0.07258	0.08141	0.75875178	86.82472281	1444.11081	7.08807	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	38	chr5	177987758	chr5:177987758	GA	G	70	PASS	AN=2;DP=38	GT	0/1
chr5	178580562	178580562	G	A	exonic	ADAMTS2	.	nonsynonymous SNV	ADAMTS2:NM_014244:exon9:c.C1445T:p.P482L,ADAMTS2:NM_021599:exon9:c.C1445T:p.P482L	0.992213475	0.007786524	5.38E-10	DISEASE: Ehlers-Danlos syndrome 7C (EDS7C) [MIM:225410]: A connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. Marked by extremely fragile tissues, hyperextensible skin and easy bruising. Facial skin contains numerous folds, as in the cutis laxa syndrome. {ECO:0000269|PubMed:10417273}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.33346	0.31484	-1.800772772	2.217504128	5065.97781	14.58177	0.068	0.359	T	1.0	0.899	D	0.999	0.916	D	0.000	0.559	D	1	0.810	D	3.375	0.916	M	-0.34	0.685	T	-9.61	0.988	D	0.831	0.819	0.475	0.902	D	0.599	0.857	D	0.175	0.851	D	6.789	0.924	32	0.999	0.933	0.986	0.839	D	c	0.903	0.788	1.000	0.747	0.706	0.609	0	4.58	0.559	9.750	0.981	0.953	0.551	1.000	0.715	0.958	0.437	16.743	0.853	Metallopeptidase, catalytic domain	.	.	0.5	58	59	chr5	178580562	chr5:178580562	G	A	58	PASS	AN=2;DP=59	GT	0/1
chr6	2955802	2955802	T	C	exonic	SERPINB6	.	nonsynonymous SNV	SERPINB6:NM_001271822:exon3:c.A310G:p.M104V,SERPINB6:NM_001271823:exon3:c.A325G:p.M109V,SERPINB6:NM_001271824:exon3:c.A268G:p.M90V,SERPINB6:NM_001271825:exon3:c.A268G:p.M90V,SERPINB6:NM_001297699:exon3:c.A268G:p.M90V,SERPINB6:NM_001297700:exon3:c.A268G:p.M90V,SERPINB6:NM_004568:exon3:c.A268G:p.M90V,SERPINB6:NM_001195291:exon4:c.A280G:p.M94V	0.035668799	0.92837158	0.035959621	.	0.58499	.	-0.135838822	43.77211607	187.82392	2.97536	1.0	0.010	T	0.0	0.026	B	0.004	0.093	B	0.040	0.241	N	1	0.090	P	0.67	0.164	N	-1.79	0.838	D	0.35	0.038	N	0.063	0.320	-1.064	0.109	T	0.103	0.379	T	.	.	.	-0.718	0.044	0.066	0.393	0.027	0.237	0.220	N	c	-1.024	-0.932	0.999	0.380	0.707	0.730	0	3.8	0.427	2.232	0.424	1.061	0.807	0.033	0.204	0.018	0.130	9.206	0.363	Serpin domain	ENSG00000224846.1|ENSG00000124570.13|ENSG00000224846.1|ENSG00000124570.13|ENSG00000124588.15|ENSG00000224846.1|ENSG00000224846.1	Brain_Cerebellum|Nerve_Tibial|Pancreas|Skin_Sun_Exposed_Lower_leg|Thyroid|Thyroid|Whole_Blood	0.5	44	19	chr6	2955802	chr6:2955802	T	C	44	PASS	AN=2;DP=19	GT	0/1
chr6	4079928	4079928	C	G	intronic	C6orf201	.	.	.	0.092248285	0.766851936	0.14089978	.	0.10331	.	1.414757139	94.83958481	1518.5566	7.24416	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	96	156	chr6	4079928	chr6:4079928	C	G	96	PASS	AN=2;DP=156	GT	0/1
chr6	5000752	5000752	-	T	intronic	RPP40	.	.	.	0.002577208	0.932656444	0.064766348	.	0.09601	0.09999	0.52918614	80.81505072	902.88839	5.84863	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	28	chr6	5000752	chr6:5000752	A	AT	50	PASS	AN=2;DP=28	GT	0/1
chr6	26451888	26451888	T	C	intronic	BTN3A3	.	.	.	7.19E-10	0.246806885	0.753193114	.	0.11114	0.09582	-0.28470423	33.48667138	154.38227	2.71544	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	45	22	chr6	26451888	chr6:26451888	T	C	45	PASS	AN=2;DP=22	GT	0/1
chr6	27420281	27420281	G	C	exonic	ZNF184	.	nonsynonymous SNV	ZNF184:NM_001318891:exon6:c.C1057G:p.Q353E,ZNF184:NM_001318892:exon6:c.C1057G:p.Q353E,ZNF184:NM_001318893:exon6:c.C829G:p.Q277E,ZNF184:NM_001347832:exon6:c.C829G:p.Q277E,ZNF184:NM_007149:exon6:c.C1057G:p.Q353E	0.133748636	0.865332288	0.000919077	.	0.21513	0.10412	-0.023789244	52.09365416	46.59463	1.31817	0.048	0.400	D	0.602	0.375	P	0.444	0.441	B	0.000	0.449	D	0.851	0.352	D	0.38	0.122	N	2.25	0.178	T	-2.17	0.490	N	0.477	0.526	-1.072	0.089	T	0.025	0.105	T	0.003	0.078	T	4.779	0.641	24.7	0.992	0.534	0.038	0.090	N	c	0.198	0.310	1.000	0.500	0.563	0.310	0	5.12	0.693	2.441	0.443	0.820	0.335	0.987	0.361	1.000	0.888	16.106	0.809	Zinc finger C2H2-type/integrase DNA-binding domain|Zinc finger, C2H2|Zinc finger, C2H2-like	.	.	0.5	55	10	chr6	27420281	chr6:27420281	G	C	55	PASS	AN=2;DP=10	GT	0/1
chr6	40359453	40359453	G	A	UTR3	LRFN2	NM_020737:c.*229C>T	.	.	0.117460637	0.856182119	0.026357243	.	0.24906	0.11684	-1.240018202	5.461193678	778.81291	5.52227	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	29	chr6	40359453	chr6:40359453	G	A	.	PASS	AN=0;DP=29	GT	0/1
chr6	44418785	44418785	C	A	downstream	CDC5L	dist=624	.	.	0.999992549	7.45E-06	1.40E-14	DISEASE: Note=A chromosomal aberration involving CDC5L is found in multicystic renal dysplasia. Translocation t(6;19)(p21;q13.1) with USF2.; 	0.82165	0.15974	-0.799052816	12.45576787	81.93083	1.9192	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	32	chr6	44418785	chr6:44418785	C	A	.	PASS	AN=0;DP=32	GT	0/1
chr6	45517650	45517650	C	T	UTR3	RUNX2	NM_001024630:c.*2608C>T;NM_001015051:c.*2608C>T;NM_001278478:c.*2608C>T	.	.	0.995958899	0.004040782	3.19E-07	DISEASE: Cleidocranial dysplasia (CLCD) [MIM:119600]: Autosomal dominant skeletal disorder with high penetrance and variable expressivity. It is due to defective endochondral and intramembranous bone formation. Typical features include hypoplasia/aplasia of clavicles, patent fontanelles, wormian bones (additional cranial plates caused by abnormal ossification of the calvaria), supernumerary teeth, short stature, and other skeletal changes. In some cases defects in RUNX2 are exclusively associated with dental anomalies. {ECO:0000269|PubMed:10521292, ECO:0000269|PubMed:10545612, ECO:0000269|PubMed:10689183, ECO:0000269|PubMed:10980549, ECO:0000269|PubMed:11857736, ECO:0000269|PubMed:12081718, ECO:0000269|PubMed:12196916, ECO:0000269|PubMed:12424590, ECO:0000269|PubMed:16270353, ECO:0000269|PubMed:19744171, ECO:0000269|PubMed:20082269, ECO:0000269|PubMed:20648631, ECO:0000269|PubMed:9182765, ECO:0000269|PubMed:9207800}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly (MDMHB) [MIM:156510]: An autosomal dominant bone dysplasia characterized by metaphyseal flaring of long bones, enlargement of the medial halves of the clavicles, maxillary hypoplasia, variable brachydactyly, and dystrophic teeth. {ECO:0000269|PubMed:23290074}. Note=The disease is caused by mutations affecting the gene represented in this entry. Analysis for copy-number variations revealed that a 105 kb duplication within RUNX2 segregated with the MDMHB phenotype in a region with maximum linkage. Real-time PCR for copy-number variation in genomic DNA in eight samples, as well as sequence analysis of fibroblast cDNA from one subject with MDMHB confirmed that affected family members were heterozygous for the presence of an intragenic duplication encompassing exons 3 to 5 of RUNX2. These three exons code for the Q/A domain and the functionally essential DNA-binding Runt domain of RUNX2. The RUNX2 duplication found in individuals with MDMHB leads to a gain of function (PubMed:23290074). {ECO:0000269|PubMed:23290074}.; 	0.53349	0.8758	-0.446304853	24.33356924	87.92892	2.00467	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	27	chr6	45517650	chr6:45517650	C	T	.	PASS	AN=0;DP=27	GT	0/1
chr6	49412275	49412275	T	G	intronic	MUT	.	.	.	5.92E-18	0.006458009	0.993541991	DISEASE: Methylmalonic aciduria type mut (MMAM) [MIM:251000]: An often fatal disorder of organic acid metabolism. Common clinical features include lethargy, vomiting, failure to thrive, hypotonia, neurological deficit and early death. Two forms of the disease are distinguished by the presence (mut-) or absence (mut0) of residual enzyme activity. Mut0 patients have more severe neurological manifestations of the disease than do MUT- patients. MMAM is unresponsive to vitamin B12 therapy. {ECO:0000269|PubMed:10923046, ECO:0000269|PubMed:11350191, ECO:0000269|PubMed:1346616, ECO:0000269|PubMed:1351030, ECO:0000269|PubMed:15643616, ECO:0000269|PubMed:15781192, ECO:0000269|PubMed:16281286, ECO:0000269|PubMed:1670635, ECO:0000269|PubMed:1977311, ECO:0000269|PubMed:7909321, ECO:0000269|PubMed:7912889, ECO:0000269|PubMed:9285782, ECO:0000269|PubMed:9452100, ECO:0000269|PubMed:9554742}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.11346	0.69122	0.20030965	67.3566879	2774.75191	9.94221	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	11	chr6	49412275	chr6:49412275	T	G	42	PASS	AN=2;DP=11	GT	0/1
chr6	82910441	82910441	T	C	intronic	IBTK	.	.	.	0.901146102	0.098853897	5.05E-10	.	0.3651	0.08876	-0.659500046	16.07100731	1718.28989	7.64339	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	50	chr6	82910441	chr6:82910441	T	C	.	PASS	AN=0;DP=50	GT	0/1
chr6	86353381	86353381	C	T	upstream	SYNCRIP	dist=338	.	.	0.999378591	0.000621405	3.32E-09	.	0.9771	0.24974	-0.560178693	19.30879925	10.81382	0.39248	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	21	chr6	86353381	chr6:86353381	C	T	.	PASS	AN=0;DP=21	GT	0/1
chr6	89926966	89926966	T	C	exonic	GABRR1	.	nonsynonymous SNV	GABRR1:NM_001256703:exon1:c.A76G:p.M26V,GABRR1:NM_002042:exon1:c.A76G:p.M26V	2.12E-07	0.687205421	0.312794367	.	0.16436	0.12099	0.020302773	55.60863411	2268.00024	8.80716	1.0	0.037	T	0.0	0.026	B	0.0	0.013	B	0.074	0.213	N	1	0.588	P	0	0.065	N	1.89	0.237	T	0.21	0.102	N	0.008	0.003	-0.919	0.457	T	0.008	0.027	T	.	.	.	-1.057	0.030	0.012	0.929	0.219	0.125	0.171	N	c	-0.667	-0.448	0.512	0.210	0.497	0.185	0	2.91	0.328	0.192	0.168	-0.378	0.066	0.958	0.332	0.977	0.480	5.397	0.155	.	ENSG00000146276.7|ENSG00000146276.7|ENSG00000146276.7|ENSG00000146276.7|ENSG00000154548.8|ENSG00000146281.5|ENSG00000146276.7|ENSG00000146276.7|ENSG00000146276.7	Artery_Aorta|Artery_Coronary|Artery_Tibial|Esophagus_Mucosa|Esophagus_Mucosa|Esophagus_Mucosa|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg	0.5	42	13	chr6	89926966	chr6:89926966	T	C	42	PASS	AN=2;DP=13	GT	0/1
chr6	109616762	109616762	A	G	ncRNA_exonic	CCDC162P	.	.	.	.	.	.	.	0.08175	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	11	chr6	109616762	chr6:109616762	A	G	42	PASS	AN=2;DP=11	GT	0/1
chr6	126249914	126249914	T	G	exonic	NCOA7	.	nonsynonymous SNV	NCOA7:NM_001199622:exon6:c.T657G:p.D219E,NCOA7:NM_001199621:exon15:c.T2481G:p.D827E,NCOA7:NM_001122842:exon16:c.T2793G:p.D931E,NCOA7:NM_181782:exon16:c.T2826G:p.D942E,NCOA7:NM_001199619:exon17:c.T2826G:p.D942E,NCOA7:NM_001199620:exon18:c.T2826G:p.D942E	0.960907672	0.039092322	5.80E-09	.	0.10866	0.09333	-0.196519234	39.20736023	1154.66608	6.47379	1.0	0.010	T	0.0	0.026	B	0.0	0.040	B	0.000	0.843	N	1.000	0.090	P	-1.295	0.007	N	3.26	0.069	T	2.37	0.003	N	0.092	0.288	-0.967	0.378	T	0.010	0.035	T	.	.	.	0.059	0.099	3.180	0.712	0.092	0.283	0.233	N	c	-0.307	-0.145	1.000	0.462	0.707	0.730	0	4.1	0.470	1.701	0.372	0.136	0.221	1.000	0.715	0.998	0.697	6.278	0.201	TLDc domain	.	.	0.5	60	17	chr6	126249914	chr6:126249914	T	G	60	PASS	AN=2;DP=17	GT	0/1
chr6	129635730	129635730	T	C	intronic	LAMA2	.	.	.	1.18E-24	0.999999998	2.28E-09	DISEASE: Merosin-deficient congenital muscular dystrophy 1A (MDC1A) [MIM:607855]: Characterized by difficulty walking, hypotonia, proximal weakness, hyporeflexia, and white matter hypodensity on MRI. {ECO:0000269|PubMed:11591858, ECO:0000269|PubMed:12552556}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.30049	0.63589	0.497724973	79.64142486	3368.62227	11.11486	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	30	chr6	129635730	chr6:129635730	T	C	.	PASS	AN=0;DP=30	GT	0/1
chr6	138584685	138584685	T	G	exonic	ARFGEF3	.	nonsynonymous SNV	ARFGEF3:NM_020340:exon12:c.T2065G:p.S689A	.	.	.	.	.	0.12485	-2.2199121	1.338759141	.	.	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.000	0.002	N	1	0.090	P	-1.445	0.006	N	1.03	0.405	T	0.08	0.060	N	0.035	0.015	-0.999	0.301	T	0.017	0.071	T	.	.	.	-0.423	0.060	0.339	0.302	0.016	0.260	0.226	N	c	-0.775	-0.554	0.978	0.298	0.651	0.465	0	5.17	0.707	2.532	0.451	0.133	0.217	1.000	0.715	0.063	0.172	9.064	0.354	Sec7 domain	.	.	0.5	53	13	chr6	138584685	chr6:138584685	T	G	53	PASS	AN=2;DP=13	GT	0/1
chr6	145093075	145093075	C	T	exonic	UTRN	.	nonsynonymous SNV	UTRN:NM_007124:exon58:c.C8528T:p.P2843L	2.97E-09	0.999999997	2.24E-20	.	0.17851	0.56056	-1.550042262	3.255484784	1957.13132	8.14203	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.513	D	1	0.810	D	2.81	0.821	M	-5.81	0.994	D	-7.02	0.986	D	0.791	0.866	1.067	0.985	D	0.984	0.995	D	0.697	0.975	D	7.456	0.951	34	0.999	0.943	0.997	0.985	D	c	0.923	0.880	1.000	0.747	0.706	0.609	0	5.66	0.872	7.305	0.780	0.935	0.490	1.000	0.715	1.000	0.888	19.746	0.962	EF-hand domain pair|WW domain	.	.	0.5	.	78	chr6	145093075	chr6:145093075	C	T	.	PASS	AN=0;DP=78	GT	0/1
chr6	154520741	154520741	C	G	intronic	IPCEF1;OPRM1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	10	chr6	154520741	chr6:154520741	C	G	43	PASS	AN=2;DP=10	GT	0/1
chr6	158923296	158923296	G	A	exonic	TULP4	.	synonymous SNV	TULP4:NM_020245:exon13:c.G2601A:p.K867K	0.999936803	6.32E-05	5.19E-13	.	0.23566	.	-2.528819961	0.896437839	581.49333	4.88756	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	91	chr6	158923296	chr6:158923296	G	A	58	PASS	AN=2;DP=91	GT	0/1
chr6	159459132	159459132	A	T	intronic	TAGAP	.	.	.	0.927102798	0.07289384	3.36E-06	.	0.651	0.13404	0.935129812	89.86199575	148.37259	2.65445	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	19	chr6	159459132	chr6:159459132	A	T	.	PASS	AN=0;DP=19	GT	0/1
chr6	165713961	165713961	A	C	exonic	C6orf118	.	nonsynonymous SNV	C6orf118:NM_144980:exon3:c.T768G:p.I256M	1.46E-17	0.00041395	0.99958605	.	0.05882	.	0.935129812	89.86199575	1170.66372	6.50346	0.136	0.260	T	0.993	0.637	D	0.878	0.605	P	0.648	0.105	N	1	0.090	P	1.59	0.404	L	2.48	0.147	T	-1.07	0.279	N	0.082	0.075	-1.055	0.131	T	0.018	0.076	T	.	.	.	-2.709	0.002	0.001	0.781	0.117	0.004	0.021	N	c	-1.460	-1.770	0.999	0.392	0.487	0.133	0	-10.0	0.004	-1.978	0.016	-2.631	0.002	0.000	0.063	0.000	0.016	7.846	0.284	Translin-associated factor X-interacting protein 1, N-terminal	ENSG00000112539.10	Testis	0.5	43	12	chr6	165713961	chr6:165713961	A	C	43	PASS	AN=2;DP=12	GT	0/1
chr7	1516129	1516129	-	CCTCTCCCGGATGGGCCACCC	intronic	INTS1	.	.	.	0.224121375	0.775878625	1.91E-10	.	0.15585	.	-5.050633482	0.070771408	422.05224	4.29253	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	18	chr7	1516129	chr7:1516129	G	GCCTCTCCCGGATGGGCCACCC	44	PASS	AN=2;DP=18	GT	0/1
chr7	29186256	29186256	A	G	exonic	CHN2	.	synonymous SNV	CHN2:NM_001293069:exon1:c.A57G:p.P19P	0.025502324	0.97183321	0.002664466	.	0.26539	.	-0.380166007	27.88393489	1077.81846	6.29228	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	76	61	chr7	29186256	chr7:29186256	A	G	76	PASS	AN=2;DP=61	GT	0/1
chr7	34867239	34867239	A	G	ncRNA_intronic	NPSR1-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	42	chr7	34867239	chr7:34867239	A	G	.	PASS	AN=0;DP=42	GT	0/1
chr7	34874038	34874038	C	G	exonic	NPSR1	.	nonsynonymous SNV	NPSR1:NM_001300934:exon4:c.C525G:p.S175R,NPSR1:NM_001300933:exon6:c.C690G:p.S230R,NPSR1:NM_001300935:exon6:c.C723G:p.S241R,NPSR1:NM_207172:exon6:c.C723G:p.S241R,NPSR1:NM_207173:exon6:c.C723G:p.S241R	8.18E-07	0.736305525	0.263693657	.	0.23423	0.19297	1.335644081	94.24982307	5094.13552	14.62021	0.049	0.546	D	0.999	0.764	D	0.966	0.715	D	0.000	0.491	D	0.002	0.453	P	1.475	0.372	L	1.22	0.370	T	-2.73	0.580	D	0.381	0.441	-0.996	0.310	T	0.000	0.000	T	.	.	.	4.477	0.599	24.2	0.996	0.720	0.827	0.416	D	c	0.487	0.452	0.131	0.171	0.487	0.133	0	4.75	0.598	1.243	0.322	0.852	0.362	1.000	0.715	0.908	0.386	10.144	0.417	GPCR, rhodopsin-like, 7TM	.	.	0.5	57	17	chr7	34874038	chr7:34874038	C	G	57	PASS	AN=2;DP=17	GT	0/1
chr7	34979817	34979817	G	A	exonic	DPY19L1	.	synonymous SNV	DPY19L1:NM_015283:exon19:c.C1593T:p.S531S	0.142871737	0.857094823	3.34E-05	.	0.22929	.	-0.404032746	26.53338051	2009.33576	8.25199	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	28	chr7	34979817	chr7:34979817	G	A	.	PASS	AN=0;DP=28	GT	0/1
chr7	44054022	44054022	A	G	ncRNA_intronic	POLR2J4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	114	228	chr7	44054022	chr7:44054022	A	G	114	PASS	AN=2;DP=228	GT	0/1
chr7	44802408	44802408	G	A	intronic	ZMIZ2	.	.	.	0.999620382	0.000379618	4.09E-11	.	0.21655	0.09565	-0.08446956	47.15145081	1705.86311	7.61894	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	120	chr7	44802408	chr7:44802408	G	A	.	PASS	AN=0;DP=120	GT	0/1
chr7	55242466	55242480	GAATTAAGAGAAGCA	-	exonic	EGFR	.	nonframeshift deletion	EGFR:NM_001346941:exon13:c.1435_1449del:p.E479_A483del,EGFR:NM_001346897:exon18:c.2101_2115del:p.E701_A705del,EGFR:NM_001346899:exon18:c.2101_2115del:p.E701_A705del,EGFR:NM_001346898:exon19:c.2236_2250del:p.E746_A750del,EGFR:NM_001346900:exon19:c.2077_2091del:p.E693_A697del,EGFR:NM_005228:exon19:c.2236_2250del:p.E746_A750del	0.99866453	0.00133547	2.97E-13	DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:16672372}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Inflammatory skin and bowel disease, neonatal, 2 (NISBD2) [MIM:616069]: A disorder characterized by inflammatory features with neonatal onset, involving the skin, hair, and gut. The skin lesions involve perioral and perianal erythema, psoriasiform erythroderma, with flares of erythema, scaling, and widespread pustules. Gastrointestinal symptoms include malabsorptive diarrhea that is exacerbated by intercurrent gastrointestinal infections. The hair is short or broken, and the eyelashes and eyebrows are wiry and disorganized. {ECO:0000269|PubMed:24691054}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.99968	0.98895	-2.160861741	1.439018636	119.9504	2.38669	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	56	50	chr7	55242465	chr7:55242465	GGAATTAAGAGAAGCA	G	56	PASS	AN=2;DP=50	GT	0/1
chr7	73254463	73254463	G	-	intronic	METTL27	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	19	chr7	73254462	chr7:73254462	TG	T	59	PASS	AN=2;DP=19	GT	0/1
chr7	77265204	77265204	A	G	intronic	PTPN12	.	.	.	0.999459859	0.000540141	9.66E-11	.	0.37635	0.16791	-0.488577883	22.64685067	1762.97619	7.75318	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	36	chr7	77265204	chr7:77265204	A	G	51	PASS	AN=2;DP=36	GT	0/1
chr7	96637003	96637004	GG	-	exonic	DLX6	.	frameshift deletion	DLX6:NM_005222:exon2:c.490_491del:p.G164Efs*56	0.842830433	0.154279613	0.002889953	.	0.64931	0.18289	-0.163345027	41.24793583	1210.09882	6.58665	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	34	chr7	96637002	chr7:96637002	AGG	A	62	PASS	AN=2;DP=34	GT	0/1
chr7	97854222	97854222	C	-	intronic	TECPR1	.	.	.	2.43E-07	0.998926296	0.001073461	.	.	.	-2.24910054	1.29747582	1477.95454	7.16021	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	27	chr7	97854221	chr7:97854221	AC	A	43	PASS	AN=2;DP=27	GT	0/1
chr7	103202348	103202348	C	A	exonic	RELN	.	nonsynonymous SNV	RELN:NM_005045:exon35:c.G5263T:p.D1755Y,RELN:NM_173054:exon35:c.G5263T:p.D1755Y	1	2.44E-15	3.10E-43	DISEASE: Lissencephaly 2 (LIS2) [MIM:257320]: A classic type lissencephaly associated with ataxia, mental retardation, seizures and abnormalities of the cerebellum, hippocampus and brainstem. {ECO:0000269|PubMed:10973257}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epilepsy, familial temporal lobe, 7 (ETL7) [MIM:616436]: A focal form of epilepsy characterized by recurrent seizures that arise from foci within the temporal lobe. Seizures are usually accompanied by sensory symptoms, most often auditory in nature. {ECO:0000269|PubMed:26046367}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.25073	.	-2.151227095	1.462609106	2605.03558	9.54865	0.006	0.632	D	0.997	0.899	D	0.956	0.850	D	0.000	0.843	D	1.000	0.588	D	2.125	0.592	M	1.59	0.288	T	-2.88	0.605	D	0.844	0.831	-0.849	0.521	T	0.186	0.537	T	0.039	0.587	D	5.137	0.693	25.4	0.995	0.650	0.976	0.754	D	c	0.662	0.639	1.000	0.747	0.624	0.395	0	5.78	0.914	5.628	0.672	0.935	0.490	1.000	0.715	0.500	0.271	20.012	0.974	Sialidases	.	.	0.5	.	43	chr7	103202348	chr7:103202348	C	A	.	PASS	AN=0;DP=43	GT	0/1
chr7	130288638	130288638	G	A	intronic	COPG2	.	.	.	0.056037357	0.925314655	0.018647988	.	0.54002	.	.	.	27.4635	0.88482	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	62	chr7	130288638	chr7:130288638	G	A	.	PASS	AN=0;DP=62	GT	0/1
chr7	137588705	137588705	T	-	exonic	CREB3L2	.	frameshift deletion	CREB3L2:NM_001318246:exon7:c.785delA:p.V263Wfs*14,CREB3L2:NM_194071:exon7:c.974delA:p.V326Wfs*14	0.609225184	0.390408619	0.000366197	DISEASE: Note=A chromosomal aberration involving CREB3L2 is found in low grade fibromyxoid sarcoma (LGFMS). Translocation t(7;16)(q33;p11) with FUS.; 	0.27206	0.13635	-0.688817379	15.20405756	81.88749	1.91782	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	23	chr7	137588704	chr7:137588704	CT	C	44	PASS	AN=2;DP=23	GT	0/1
chr7	138453958	138453958	C	T	exonic	ATP6V0A4	.	synonymous SNV	ATP6V0A4:NM_130840:exon3:c.G156A:p.V52V,ATP6V0A4:NM_130841:exon3:c.G156A:p.V52V,ATP6V0A4:NM_020632:exon4:c.G156A:p.V52V	1.94E-12	0.945100202	0.054899798	.	0.23229	0.22304	-0.169017544	40.67586695	1425.59356	7.05075	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	110	chr7	138453958	chr7:138453958	C	T	.	PASS	AN=0;DP=110	GT	0/1
chr7	139754451	139754451	T	C	intronic	PARP12	.	.	.	7.93E-06	0.979732601	0.020259469	.	0.14634	0.10401	-0.661316159	16.02382637	1281.17409	6.7401	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	16	chr7	139754451	chr7:139754451	T	C	43	PASS	AN=2;DP=16	GT	0/1
chr7	151479545	151479545	C	T	intronic	PRKAG2	.	.	.	0.977557429	0.022442395	1.77E-07	DISEASE: Wolff-Parkinson-White syndrome (WPWS) [MIM:194200]: A supernormal conduction disorder characterized by the presence of one or several accessory atrioventricular connections, which can lead to episodes of sporadic tachycardia. {ECO:0000269|PubMed:11407343, ECO:0000269|PubMed:11748095}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, familial hypertrophic 6 (CMH6) [MIM:600858]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. CMH6 patients present Wolff-Parkinson-White ventricular preexcitation, enlarged myocytes without myofiber disarray, and glycogen- containing cytosolic vacuoles within cardiomyocytes. {ECO:0000269|PubMed:11371514, ECO:0000269|PubMed:11827995}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Glycogen storage disease of heart lethal congenital (GSDH) [MIM:261740]: Rare disease which leads to death within a few weeks to a few months after birth, through heart failure and respiratory compromise. {ECO:0000269|PubMed:15877279}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.75824	0.19412	-0.867014353	10.72776598	322.64102	3.81555	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	46	chr7	151479545	chr7:151479545	C	T	.	PASS	AN=0;DP=46	GT	0/1
chr7	151814378	151814378	T	C	exonic	GALNT11	.	nonsynonymous SNV	GALNT11:NM_001304514:exon8:c.T1127C:p.I376T,GALNT11:NM_022087:exon9:c.T1370C:p.I457T	0.004047419	0.995623523	0.000329058	DISEASE: Note=Defects in GALNT11 may be a cause of heterotaxy, a congenital heart disease resulting from abnormalities in left- right (LR) body patterning. {ECO:0000269|PubMed:21282601}.; 	0.13704	0.10054	-0.43902969	24.63434772	485.66524	4.53862	0.142	0.254	T	0.001	0.067	B	0.002	0.063	B	0.017	0.277	N	1	0.090	N	1.17	0.299	L	0.63	0.531	T	-0.95	0.253	N	0.13	0.149	-0.998	0.304	T	0.093	0.353	T	0.013	0.320	T	1.192	0.209	11.71	0.929	0.218	0.499	0.283	N	c	-0.636	-0.536	0.835	0.247	0.732	0.924	0	4.36	0.515	4.183	0.579	0.082	0.190	0.835	0.300	0.999	0.750	10.204	0.421	.	.	.	0.5	65	74	chr7	151814378	chr7:151814378	T	C	65	PASS	AN=2;DP=74	GT	0/1
chr8	8092006	8092006	A	G	ncRNA_exonic	FAM86B3P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	75	chr8	8092006	chr8:8092006	A	G	61	PASS	AN=2;DP=75	GT	0/1
chr8	9623897	9623897	C	T	exonic	TNKS	.	synonymous SNV	TNKS:NM_003747:exon25:c.C3702T:p.C1234C	0.777115954	0.222884041	4.52E-09	.	0.74052	0.15224	-2.45481381	1.008492569	80.76873	1.89852	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	32	chr8	9623897	chr8:9623897	C	T	.	PASS	AN=0;DP=32	GT	0/1
chr8	12236231	12236231	A	C	ncRNA_intronic	FAM66A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	88	31	chr8	12236231	chr8:12236231	A	C	88	PASS	AN=2;DP=31	GT	0/1
chr8	33230301	33230302	CC	-	exonic	FUT10	.	stopgain	FUT10:NM_032664:exon5:c.1233_1234del:p.W411fs*0	3.08E-07	0.526483136	0.473516557	.	0.06224	0.09649	0.446457185	77.97829677	3746.81614	11.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	63	16	chr8	33230300	chr8:33230300	TCC	T	63	PASS	AN=2;DP=16	GT	0/1
chr8	60032374	60032374	C	T	upstream	TOX	dist=607	.	.	0.892971025	0.106984331	4.46E-05	.	0.94527	0.20047	-0.622676946	17.30950696	265.75398	3.49664	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	82	chr8	60032374	chr8:60032374	C	T	.	PASS	AN=0;DP=82	GT	0/1
chr8	87755863	87755863	G	-	UTR5	CNGB3	NM_019098:c.-8delC	.	.	8.86E-11	0.884429906	0.115570094	DISEASE: Achromatopsia 3 (ACHM3) [MIM:262300]: An ocular stationary disorder due to the absence of functioning cone photoreceptors in the retina. It is characterized by total colorblindness, low visual acuity, photophobia and nystagmus. Achromatopsia type 3 patients manifest severe myopia. {ECO:0000269|PubMed:10888875, ECO:0000269|PubMed:10958649, ECO:0000269|PubMed:12357335, ECO:0000269|PubMed:14757870, ECO:0000269|PubMed:15657609, ECO:0000269|PubMed:15712225}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.08889	.	1.673699792	96.331682	696.97117	5.25879	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	17	chr8	87755862	chr8:87755862	TG	T	58	PASS	AN=2;DP=17	GT	0/1
chr8	101719034	101719114	CTAAAAAATAAGAACATTTTGTATTTTTATCTTGCTCTTTCAAATTGGTGATCAATTTTTAAAGGAAGGATTAAGACTCAC	-	splicing	PABPC1	.	.	.	0.999692443	0.000307557	1.21E-10	.	0.49883	0.4528	-0.383807564	27.41802312	3992.89486	12.49537	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	31	chr8	101719033	chr8:101719033	GCTAAAAAATAAGAACATTTTGTATTTTTATCTTGCTCTTTCAAATTGGTGATCAATTTTTAAAGGAAGGATTAAGACTCAC	G	70	PASS	AN=2;DP=31	GT	0/1
chr8	142222279	142222279	G	A	UTR3	SLC45A4	NM_001286648:c.*11C>T	.	.	0.00458961	0.988812046	0.006598344	.	0.25179	0.09355	-1.295313867	4.989384289	150.28485	2.67496	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	85	chr8	142222279	chr8:142222279	G	A	.	PASS	AN=0;DP=85	GT	0/1
chr9	118535	118535	T	C	upstream	FOXD4	dist=118	.	.	.	.	.	.	0.15599	.	0.885576705	89.14248644	2757.82566	9.90294	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	57	29	chr9	118535	chr9:118535	T	C	57	PASS	AN=2;DP=29	GT	0/1
chr9	21228040	21228040	C	G	exonic	IFNA17	.	nonsynonymous SNV	IFNA17:NM_021268:exon1:c.G133C:p.G45R	0.007025822	0.528540962	0.464433216	.	0.03731	0.5932	0.461228372	78.46190139	360.76195	4.02023	1.0	0.010	T	0.0	0.026	B	0.001	0.040	B	0.125	0.188	N	1	0.090	P	-2.335	0.001	N	4.11	0.029	T	5.54	0.000	N	0.031	0.012	-1.077	0.080	T	0.000	0.000	T	.	.	.	-2.750	0.002	0.001	0.417	0.030	0.010	0.038	N	c	-2.692	-2.643	0.001	0.081	0.487	0.133	0	-5.29	0.025	-0.247	0.088	-4.446	0.000	0.006	0.172	0.002	0.062	6.15	0.194	Four-helical cytokine, core|Four-helical cytokine-like, core	ENSG00000226393.1	Nerve_Tibial	0.5	73	21	chr9	21228040	chr9:21228040	C	G	73	PASS	AN=2;DP=21	GT	0/1
chr9	21994454	21994454	C	A	UTR5	CDKN2A	NM_058195:c.-124G>T	.	.	0.357648776	0.58984451	0.052506714	DISEASE: Note=The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients.; DISEASE: Melanoma, cutaneous malignant 2 (CMM2) [MIM:155601]: A malignant neoplasm of melanocytes, arising de novo or from a pre- existing benign nevus, which occurs most often in the skin but also may involve other sites. {ECO:0000269|PubMed:10651484, ECO:0000269|PubMed:10874641, ECO:0000269|PubMed:11506491, ECO:0000269|PubMed:12019208, ECO:0000269|PubMed:14646619, ECO:0000269|PubMed:19260062, ECO:0000269|PubMed:7987387, ECO:0000269|PubMed:8595405, ECO:0000269|PubMed:8653684, ECO:0000269|PubMed:8710906, ECO:0000269|PubMed:9328469, ECO:0000269|PubMed:9425228}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719]: An inherited cancer predisposition syndrome characterized by an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: Autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. {ECO:0000269|PubMed:10484981}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Melanoma-astrocytoma syndrome (MASTS) [MIM:155755]: Characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. {ECO:0000269|PubMed:11136714}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.03037	0.06846	0.725794416	85.98136353	20.60127	0.70067	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	24	chr9	21994454	chr9:21994454	C	A	.	PASS	AN=0;DP=24	GT	0/1
chr9	32986004	32986004	C	T	exonic	APTX	.	nonsynonymous SNV	APTX:NM_001195250:exon4:c.G388A:p.G130S,APTX:NM_001195254:exon4:c.G346A:p.G116S,APTX:NM_001195248:exon5:c.G550A:p.G184S,APTX:NM_001195249:exon5:c.G508A:p.G170S,APTX:NM_001195252:exon5:c.G334A:p.G112S,APTX:NM_175069:exon5:c.G550A:p.G184S,APTX:NM_001195251:exon6:c.G508A:p.G170S,APTX:NM_175073:exon6:c.G508A:p.G170S	7.73E-06	0.740449587	0.259542684	DISEASE: Ataxia-oculomotor apraxia syndrome (AOA) [MIM:208920]: An autosomal recessive syndrome characterized by early-onset cerebellar ataxia, oculomotor apraxia, early areflexia and late peripheral neuropathy. {ECO:0000269|PubMed:11586299, ECO:0000269|PubMed:11586300, ECO:0000269|PubMed:12196655, ECO:0000269|PubMed:12629250, ECO:0000269|PubMed:14506070, ECO:0000269|PubMed:15699391, ECO:0000269|PubMed:15852392}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.07205	0.29287	0.463046108	78.58575136	86.51936	1.98569	0.055	0.912	T	1.0	0.899	D	0.999	0.916	D	0.000	0.843	D	1	0.810	D	2.685	0.788	M	-1.92	0.916	D	-4.7	0.815	D	0.671	0.730	0.787	0.943	D	0.857	0.952	D	0.208	0.871	D	7.199	0.945	34	0.998	0.925	0.981	0.793	D	c	0.737	0.745	1.000	0.425	0.732	0.924	0	5.78	0.914	5.995	0.701	0.807	0.329	1.000	0.715	0.999	0.750	17.506	0.876	Forkhead-associated (FHA) domain;Forkhead-associated (FHA) domain|HIT-like domain;Forkhead-associated (FHA) domain|HIT-like domain|SMAD/FHA domain;Forkhead-associated (FHA) domain|SMAD/FHA domain	.	.	0.5	.	30	chr9	32986004	chr9:32986004	C	T	.	PASS	AN=0;DP=30	GT	0/1
chr9	34622389	34622389	A	C	exonic	ARID3C	.	nonsynonymous SNV	ARID3C:NM_001017363:exon5:c.T1003G:p.C335G	6.79E-07	0.269883999	0.730115322	.	0.32423	0.08104	0.52918614	80.81505072	546.80485	4.75348	0.416	0.099	T	0.0	0.026	B	0.0	0.013	B	0.079	0.210	N	1	0.090	P	-1.39	0.006	N	1.14	0.384	T	-0.16	0.095	N	0.024	0.007	-1.008	0.275	T	0.000	0.000	T	.	.	.	-0.996	0.032	0.016	0.709	0.092	0.001	0.006	N	c	-1.372	-1.249	0.980	0.300	0.549	0.223	0	0.293	0.149	-0.052	0.117	0.061	0.167	0.000	0.063	0.284	0.234	4.092	0.094	REKLES domain	ENSG00000230074.1|ENSG00000164967.5|ENSG00000230074.1|ENSG00000230074.1|ENSG00000164967.5|ENSG00000230074.1|ENSG00000230074.1|ENSG00000164967.5|ENSG00000205143.2|ENSG00000230074.1|ENSG00000230074.1|ENSG00000230074.1|ENSG00000122756.10|ENSG00000230074.1|ENSG00000164967.5|ENSG00000230074.1|ENSG00000164967.5|ENSG00000230074.1|ENSG00000230074.1|ENSG00000230074.1|ENSG00000230074.1|ENSG00000230074.1|ENSG00000147955.12|ENSG00000164967.5|ENSG00000230074.1|ENSG00000164967.5|ENSG00000230074.1|ENSG00000230074.1|ENSG00000230074.1	Adipose_Subcutaneous|Adipose_Subcutaneous|Adipose_Visceral_Omentum|Artery_Aorta|Artery_Aorta|Artery_Coronary|Artery_Tibial|Artery_Tibial|Brain_Cortex|Brain_Nucleus_accumbens_basal_ganglia|Breast_Mammary_Tissue|Cells_Transformed_fibroblasts|Colon_Transverse|Esophagus_Mucosa|Esophagus_Mucosa|Esophagus_Muscularis|Esophagus_Muscularis|Heart_Atrial_Appendage|Heart_Left_Ventricle|Lung|Muscle_Skeletal|Nerve_Tibial|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Skin_Sun_Exposed_Lower_leg|Testis|Thyroid|Whole_Blood	0.5	70	24	chr9	34622389	chr9:34622389	A	C	70	PASS	AN=2;DP=24	GT	0/1
chr9	35100569	35100569	A	G	intronic	STOML2	.	.	.	0.529200678	0.470656311	0.000143011	.	0.87655	0.14979	-0.471992905	23.03609342	30.66945	0.97588	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	9	chr9	35100569	chr9:35100569	A	G	41	PASS	AN=2;DP=9	GT	0/1
chr9	35812099	35812104	ACCGCG	-	exonic	SPAG8	.	frameshift deletion	SPAG8:NM_001039592:exon1:c.41_44del:p.S14Yfs*2,SPAG8:NM_172312:exon1:c.41_44del:p.S14Yfs*2	2.75E-07	0.740885869	0.259113856	.	0.11804	0.1054	0.867166666	88.81811748	3548.41665	11.49875	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	29	chr9	35812098	chr9:35812098	CACCGCG	C	42	PASS	AN=2;DP=29	GT	0/1
chr9	44120283	44120284	TT	-	intergenic	CNTNAP3P2;XLOC_007697	dist=196226;dist=61227	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	29	chr9	44120282	chr9:44120282	CTT	C	55	PASS	AN=2;DP=29	GT	0/1
chr9	66553447	66553447	G	C	ncRNA_exonic	LOC403323;LOC728673	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	56	40	chr9	66553447	chr9:66553447	G	C	56	PASS	AN=2;DP=40	GT	0/1
chr9	104170167	104170168	CA	-	intronic	ZNF189	.	.	.	0.004617885	0.964927865	0.03045425	.	0.74958	0.11322	0.154398214	64.73814579	98.59808	2.14648	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	20.21	18	chr9	104170166	chr9:104170166	TCA	T	20.21	PASS	AN=0;DP=18	GT	0/1
chr9	126783433	126783433	G	C	exonic	LHX2	.	synonymous SNV	LHX2:NM_004789:exon4:c.G783C:p.P261P	0.946789689	0.053028912	0.000181399	.	0.99245	0.23835	-0.117432389	44.89266336	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	17	chr9	126783433	chr9:126783433	G	C	53	PASS	AN=2;DP=17	GT	0/1
chr9	127032349	127032349	C	-	intronic	NEK6	.	.	.	0.644137661	0.35559309	0.000269249	.	0.12306	0.11384	-0.359940251	28.93371078	287.30993	3.63133	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	20	chr9	127032348	chr9:127032348	GC	G	44	PASS	AN=2;DP=20	GT	0/1
chr9	130536293	130536293	G	A	exonic	SH2D3C	.	nonsynonymous SNV	SH2D3C:NM_170600:exon2:c.C491T:p.P164L	0.000941187	0.996381628	0.002677185	.	0.33676	0.12268	-0.639268965	16.70794999	510.40629	4.62665	0.122	0.276	T	0.0	0.026	B	0.001	0.040	B	0.242	0.036	N	1	0.090	N	0	0.065	N	2.69	0.123	T	-0.16	0.095	N	0.156	0.186	-0.975	0.361	T	0.018	0.074	T	0.005	0.141	T	-0.032	0.091	2.287	0.763	0.110	0.010	0.037	N	c	-1.148	-1.168	1.000	0.747	0.707	0.730	0	-1.75	0.076	-2.349	0.012	-0.340	0.072	0.000	0.063	0.002	0.062	3.201	0.062	.	.	.	0.5	.	39	chr9	130536293	chr9:130536293	G	A	.	PASS	AN=0;DP=39	GT	0/1
chr9	133948049	133948049	A	G	exonic	LAMC3	.	nonsynonymous SNV	LAMC3:NM_006059:exon19:c.A3244G:p.S1082G	9.82E-11	0.9988887	0.001111299	DISEASE: Cortical malformations occipital (OCCM) [MIM:614115]: A disease in which affected individuals develop seizures, sometimes associated with transient visual changes. Brain MRI shows both pachygyria and polymicrogyria restricted to the lateral occipital lobes. {ECO:0000269|PubMed:21572413}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.15545	.	0.637377588	83.64000944	7208.01279	18.27431	0.515	0.074	T	0.0	0.026	B	0.001	0.040	B	0.512	0.118	N	1	0.090	P	-1.59	0.004	N	1.64	0.278	T	-0.08	0.082	N	0.011	0.001	-1.027	0.215	T	0.000	0.000	T	.	.	.	-0.178	0.078	1.221	0.639	0.071	0.004	0.020	N	c	-1.203	-1.153	1.000	0.747	0.706	0.609	0	2.24	0.271	0.511	0.223	-0.221	0.097	0.035	0.205	0.004	0.083	7.909	0.288	.	ENSG00000126878.8	Artery_Aorta	0.5	61	18	chr9	133948049	chr9:133948049	A	G	61	PASS	AN=2;DP=18	GT	0/1
chr9	136277480	136277480	A	G	exonic	REXO4	.	synonymous SNV	REXO4:NM_001279350:exon4:c.T438C:p.T146T,REXO4:NM_001279351:exon4:c.T570C:p.T190T,REXO4:NM_020385:exon4:c.T849C:p.T283T	9.99E-06	0.789928485	0.210061521	.	0.07311	0.09983	0.376678994	75.50719509	339.03688	3.90521	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	17	chr9	136277480	chr9:136277480	A	G	62	PASS	AN=2;DP=17	GT	0/1
chr9	136301993	136301993	C	A	exonic	ADAMTS13	.	synonymous SNV	ADAMTS13:NM_139025:exon12:c.C1353A:p.A451A,ADAMTS13:NM_139026:exon12:c.C1260A:p.A420A,ADAMTS13:NM_139027:exon12:c.C1353A:p.A451A	7.88E-11	0.998477308	0.001522692	DISEASE: Thrombotic thrombocytopenic purpura congenital (TTP) [MIM:274150]: A hematologic disease characterized by hemolytic anemia with fragmentation of erythrocytes, thrombocytopenia, diffuse and non-focal neurologic findings, decreased renal function and fever. recessive. {ECO:0000269|PubMed:11586351, ECO:0000269|PubMed:12181489, ECO:0000269|PubMed:12393505, ECO:0000269|PubMed:12614216, ECO:0000269|PubMed:12753286, ECO:0000269|PubMed:14512317, ECO:0000269|PubMed:14563640, ECO:0000269|PubMed:15009458, ECO:0000269|PubMed:15126318, ECO:0000269|PubMed:15327386, ECO:0000269|PubMed:16449289, ECO:0000269|PubMed:16453338, ECO:0000269|PubMed:16796708, ECO:0000269|PubMed:16807643, ECO:0000269|PubMed:17003922, ECO:0000269|PubMed:18443791, ECO:0000269|PubMed:19055667, ECO:0000269|PubMed:19116307, ECO:0000269|PubMed:22075512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.0682	0.12877	0.622690987	83.42179759	2255.36428	8.77522	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	130	chr9	136301993	chr9:136301993	C	A	.	PASS	AN=0;DP=130	GT	0/1
chr9	138377853	138377853	A	G	exonic	PPP1R26	.	synonymous SNV	PPP1R26:NM_014811:exon4:c.A1497G:p.V499V	0.985547303	0.014452401	2.96E-07	.	0.1034	0.10038	0.48857149	79.4821892	2978.84256	10.35088	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	12	chr9	138377853	chr9:138377853	A	G	42	PASS	AN=2;DP=12	GT	0/1
chr9	138676404	138676404	C	A	exonic	KCNT1	.	synonymous SNV	KCNT1:NM_001272003:exon25:c.C2832A:p.I944I,KCNT1:NM_020822:exon26:c.C2967A:p.I989I	0.005348738	0.994649439	1.82E-06	DISEASE: Epileptic encephalopathy, early infantile, 14 (EIEE14) [MIM:614959]: A rare epileptic encephalopathy of infancy that combines pharmacoresistant seizures with developmental delay. This severe neurologic disorder is characterized by onset in the first 6 months of life of refractory focal seizures and arrest of psychomotor development. Ictal EEG shows discharges that arise randomly from various areas of both hemispheres and migrate from one brain region to another. {ECO:0000269|PubMed:23086397}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epilepsy, nocturnal frontal lobe, 5 (ENFL5) [MIM:615005]: An autosomal dominant focal epilepsy syndrome characterized by childhood onset of clusters of motor seizures during sleep. Some patients may develop behavioral or psychiatric manifestations and/or intellectual disability. The phenotype is more severe than observed in other genetic forms of nocturnal frontal lobe epilepsy. {ECO:0000269|PubMed:23086396}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.10242	0.10521	-2.070835943	1.615947157	121.99362	2.40558	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	98	chr9	138676404	chr9:138676404	C	A	.	PASS	AN=0;DP=98	GT	0/1
chr10	20105997	20105999	GGC	-	UTR5	PLXDC2	NM_001282736:c.-12_-10del-;NM_032812:c.-12_-10del-	.	.	0.613047817	0.386937644	1.45E-05	.	0.46149	0.10853	0.531004228	80.87992451	87.18855	1.99411	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	31	chr10	20105996	chr10:20105996	TGGC	T	42	PASS	AN=2;DP=31	GT	0/1
chr10	27538942	27538942	T	C	ncRNA_exonic	LRRC37A6P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	26	chr10	27538942	chr10:27538942	T	C	53	PASS	AN=2;DP=26	GT	0/1
chr10	43694491	43694491	G	-	intronic	RASGEF1A	.	.	.	0.910096302	0.089875281	2.84E-05	.	0.28193	0.10809	0.084621747	60.31493277	52.5675	1.43524	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	37	chr10	43694490	chr10:43694490	CG	C	42	PASS	AN=2;DP=37	GT	0/1
chr10	50031213	50031213	T	-	intronic	WDFY4	.	.	.	.	.	.	.	.	0.09927	4.264461124	99.72281198	5281.75473	15.01039	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	24	chr10	50031212	chr10:50031212	CT	C	54	PASS	AN=2;DP=24	GT	0/1
chr10	51295198	51295198	A	C	ncRNA_intronic	PARGP1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	42	chr10	51295198	chr10:51295198	A	C	70	PASS	AN=2;DP=42	GT	0/1
chr10	71168729	71168729	G	-	exonic	TACR2	.	frameshift deletion	TACR2:NM_001057:exon3:c.690delC:p.G231Dfs*14	9.88E-07	0.182986486	0.817012526	.	0.13034	0.15131	2.087222794	97.84736966	2401.1648	9.09848	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	93	chr10	71168728	chr10:71168728	CG	C	69	PASS	AN=2;DP=93	GT	0/1
chr10	72521914	72521914	A	-	UTR3	ADAMTS14	NM_139155:c.*1305delA;NM_080722:c.*1305delA	.	.	2.33E-06	0.999989194	8.47E-06	.	0.21639	0.12333	-0.5513802	19.86907289	5123.0958	14.71781	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	10	chr10	72521913	chr10:72521913	GA	G	60	PASS	AN=2;DP=10	GT	1/0
chr10	73571690	73571690	G	C	UTR5	CDH23	NM_001171936:c.-359G>C;NM_001171935:c.-359G>C	.	.	0.050692959	0.949268623	3.84E-05	DISEASE: Usher syndrome 1D (USH1D) [MIM:601067]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:11138009, ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:15660226, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:18429043}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Usher syndrome 1D/F (USH1DF) [MIM:601067]: USH1DF patients are heterozygous for mutations in CDH23 and PCDH15, indicating a digenic inheritance pattern. {ECO:0000269|PubMed:15537665}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 12 (DFNB12) [MIM:601386]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:11090341, ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:12522556, ECO:0000269|PubMed:15829536, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:17850630, ECO:0000269|PubMed:22899989, ECO:0000269|PubMed:24767429}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.32126	0.20307	-1.837761842	2.05826846	23222.44281	31.45196	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	74	129	chr10	73571690	chr10:73571690	G	C	74	PASS	AN=2;DP=129	GT	0/1
chr10	75490355	75490358	AAGA	-	ncRNA_exonic	GLUD1P3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	62	chr10	75490354	chr10:75490354	GAAGA	G	54	PASS	AN=2;DP=62	GT	0/1
chr10	99219405	99219405	G	-	intronic	MMS19	.	.	.	0.831821999	0.16817795	5.05E-08	.	0.21908	.	-0.014692675	52.35314933	3051.13847	10.50027	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	12	chr10	99219404	chr10:99219404	TG	T	40	PASS	AN=2;DP=12	GT	0/1
chr10	99410790	99410790	T	C	exonic	PI4K2A	.	synonymous SNV	PI4K2A:NM_018425:exon2:c.T528C:p.P176P	0.980219633	0.019777207	3.16E-06	.	0.53922	.	0.549415813	81.38122199	145.91651	2.63201	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	24	chr10	99410790	chr10:99410790	T	C	55	PASS	AN=2;DP=24	GT	0/1
chr10	102770082	102770082	T	G	exonic	PDZD7	.	nonsynonymous SNV	PDZD7:NM_001195263:exon15:c.A2564C:p.N855T	0.722769808	0.27710588	0.000124312	DISEASE: Usher syndrome 2C (USH2C) [MIM:605472]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:20440071}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry. PDZD7 mutations have been found in combination with mutations in USH2A and GPR98 in patients affected by Usher syndrome, suggesting a role as contributor to digenic Usher syndrome or a modifier of retinal disease expression. {ECO:0000269|PubMed:20440071}.; 	0.24004	0.11039	-0.356299879	29.31115829	127.88087	2.46471	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.013	0.002	-1.030	0.206	T	0.000	0.000	T	.	.	.	1.131	0.203	11.38	0.677	0.082	0.008	0.032	N	c	-0.915	-0.946	0.999	0.379	0.035	0.002	2	1.35	0.210	0.131	0.156	-0.370	0.067	0.000	0.063	0.001	0.043	5.225	0.146	.	.	.	0.5	52	24	chr10	102770082	chr10:102770082	T	G	52	PASS	AN=2;DP=24	GT	0/1
chr10	113935379	113935379	T	C	exonic	GPAM	.	nonsynonymous SNV	GPAM:NM_001244949:exon6:c.A392G:p.E131G,GPAM:NM_020918:exon6:c.A392G:p.E131G	0.000580579	0.999410374	9.05E-06	.	0.22152	0.37514	-0.242430445	36.22906346	242.46149	3.3607	0.006	0.614	D	0.457	0.344	P	0.081	0.275	B	0.000	0.559	D	0.000	0.548	P	1.745	0.454	L	-0.52	0.707	T	-3.3	0.681	D	0.089	0.132	-0.903	0.477	T	0.000	0.000	T	.	.	.	4.433	0.593	24.2	0.998	0.901	0.984	0.825	D	c	0.178	0.277	1.000	0.500	0.563	0.310	0	5.11	0.691	7.113	0.766	1.061	0.807	1.000	0.715	0.996	0.625	13.501	0.607	.	.	.	0.5	58	15	chr10	113935379	chr10:113935379	T	C	58	PASS	AN=2;DP=15	GT	0/1
chr10	116608351	116608351	T	-	intronic	FAM160B1	.	.	.	0.999984985	1.50E-05	3.82E-13	.	0.15009	.	-0.754958418	13.57631517	80.29201	1.89406	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	11	chr10	116608350	chr10:116608350	CT	C	53	PASS	AN=2;DP=11	GT	0/1
chr10	124740238	124740238	C	T	intronic	PSTK	.	.	.	0.004110024	0.960308594	0.035581382	.	0.25378	0.0959	0.527368849	80.73248408	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	47	chr10	124740238	chr10:124740238	C	T	.	PASS	AN=0;DP=47	GT	0/1
chr10	134062542	134062542	C	T	intronic	STK32C	.	.	.	0.309709769	0.689507911	0.000782319	.	0.08231	0.1102	-0.356299879	29.31115829	1893.96573	8.00243	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	28	chr10	134062542	chr10:134062542	C	T	.	PASS	AN=0;DP=28	GT	0/1
chr10	134062572	134062572	C	T	intronic	STK32C	.	.	.	0.309709769	0.689507911	0.000782319	.	0.08231	0.1102	-0.356299879	29.31115829	1893.96573	8.00243	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	30	chr10	134062572	chr10:134062572	C	T	.	PASS	AN=0;DP=30	GT	0/1
chr11	771034	771034	A	G	exonic	GATD1	.	synonymous SNV	GATD1:NM_001318822:exon5:c.T357C:p.T119T,GATD1:NM_001318818:exon6:c.T465C:p.T155T,GATD1:NM_001318820:exon6:c.T507C:p.T169T,GATD1:NM_001318823:exon6:c.T465C:p.T155T,GATD1:NM_001318824:exon6:c.T507C:p.T169T,GATD1:NM_001318821:exon7:c.T615C:p.T205T,GATD1:NM_182612:exon7:c.T615C:p.T205T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	38	chr11	771034	chr11:771034	A	G	53	PASS	AN=2;DP=38	GT	0/1
chr11	1255933	1255933	G	A	intronic	MUC5B	.	.	.	0.999999706	2.94E-07	6.12E-25	DISEASE: Pulmonary fibrosis, idiopathic (IPF) [MIM:178500]: A lung disease characterized by shortness of breath, radiographically evident diffuse pulmonary infiltrates, and varying degrees of inflammation and fibrosis on biopsy. In some cases, the disorder can be rapidly progressive and characterized by sequential acute lung injury with subsequent scarring and end-stage lung disease. {ECO:0000269|PubMed:21506741, ECO:0000269|PubMed:21506748}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. A common polymorphism in the promoter of MUC5B is associated with familial interstitial pneumonia and idiopathic pulmonary fibrosis, suggesting that dysregulated MUC5B expression in the lung may be involved in the pathogenesis of pulmonary fibrosis (PubMed:21506741). {ECO:0000269|PubMed:21506741}.; 	0.07831	.	16.52445195	99.97640953	6531.39188	16.99148	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	62	chr11	1255933	chr11:1255933	G	A	.	PASS	AN=0;DP=62	GT	0/1
chr11	1457382	1457382	G	-	intronic	BRSK2	.	.	.	0.779570081	0.220416998	1.29E-05	.	0.16676	0.10676	-1.506435464	3.544468035	64.45039	1.64641	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	66	110	chr11	1457381	chr11:1457381	AG	A	66	PASS	AN=2;DP=110	GT	0/1
chr11	1462163	1462163	G	-	intronic	BRSK2	.	.	.	0.779570081	0.220416998	1.29E-05	.	0.16676	0.10676	-1.506435464	3.544468035	64.45039	1.64641	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	80	49	chr11	1462162	chr11:1462162	AG	A	80	PASS	AN=2;DP=49	GT	0/1
chr11	2356769	2356769	T	C	ncRNA_intronic	CD81-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	87	32	chr11	2356769	chr11:2356769	T	C	87	PASS	AN=2;DP=32	GT	0/1
chr11	9004402	9004402	C	T	UTR3	NRIP3	NM_020645:c.*690G>A	.	.	2.35E-05	0.501587461	0.498389076	.	0.10654	.	0.148941568	64.31941496	105.28116	2.22063	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	45	chr11	9004402	chr11:9004402	C	T	64	PASS	AN=2;DP=45	GT	0/1
chr11	11292700	11292700	G	C	exonic	GALNT18	.	synonymous SNV	GALNT18:NM_198516:exon11:c.C1815G:p.L605L	0.047685176	0.951285056	0.001029769	.	0.20546	0.09952	-0.775187015	13.05142722	69.4345	1.72927	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	35	chr11	11292700	chr11:11292700	G	C	55	PASS	AN=2;DP=35	GT	0/1
chr11	12225946	12225946	T	G	exonic	MICAL2	.	synonymous SNV	MICAL2:NM_001282666:exon2:c.T414G:p.R138R,MICAL2:NM_001282667:exon2:c.T414G:p.R138R,MICAL2:NM_001282664:exon3:c.T414G:p.R138R,MICAL2:NM_001282665:exon3:c.T414G:p.R138R,MICAL2:NM_001346292:exon3:c.T414G:p.R138R,MICAL2:NM_001346294:exon3:c.T414G:p.R138R,MICAL2:NM_001346298:exon3:c.T414G:p.R138R,MICAL2:NM_001282663:exon4:c.T414G:p.R138R,MICAL2:NM_001282668:exon4:c.T414G:p.R138R,MICAL2:NM_001346293:exon4:c.T414G:p.R138R,MICAL2:NM_001346295:exon4:c.T414G:p.R138R,MICAL2:NM_001346296:exon4:c.T414G:p.R138R,MICAL2:NM_001346297:exon4:c.T414G:p.R138R,MICAL2:NM_001346299:exon4:c.T414G:p.R138R,MICAL2:NM_014632:exon4:c.T414G:p.R138R	0.132223746	0.867775935	3.19E-07	.	0.35711	0.10318	0.549230812	81.22788393	597.9475	4.94889	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	17	chr11	12225946	chr11:12225946	T	G	43	PASS	AN=2;DP=17	GT	0/1
chr11	14535143	14535143	C	-	exonic	PSMA1	.	frameshift deletion	PSMA1:NM_002786:exon7:c.517delG:p.E173Rfs*11,PSMA1:NM_148976:exon8:c.535delG:p.E179Rfs*11	0.947988405	0.051976702	3.49E-05	.	0.94257	0.50622	-0.229483771	36.86010852	24.18661	0.7943	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	63	82	chr11	14535142	chr11:14535142	TC	T	63	PASS	AN=2;DP=82	GT	0/1
chr11	17593709	17593709	T	C	exonic	OTOG	.	nonsynonymous SNV	OTOG:NM_001277269:exon17:c.T2074C:p.S692P,OTOG:NM_001292063:exon18:c.T2038C:p.S680P	.	.	.	DISEASE: Deafness, autosomal recessive, 18B (DFNB18B) [MIM:614945]: A form of non-syndromic deafness characterized by a moderate hearing impairment, which can be associated with vestibular dysfunction, and a flat to shallow "U" or slightly downsloping shaped audiograms. {ECO:0000269|PubMed:23122587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.08265	.	.	.	14123.45118	25.75321	0.457	0.088	T	.	.	.	.	.	.	0.728	0.063	N	1	0.090	P	0.94	0.237	L	2.36	0.161	T	-0.48	0.154	N	0.072	0.075	-0.984	0.341	T	0.000	0.000	T	.	.	.	0.042	0.098	3.006	0.956	0.267	0.111	0.162	N	c	-0.955	-1.068	0.868	0.253	0.487	0.133	0	-4.21	0.035	0.125	0.155	-0.328	0.075	0.000	0.063	0.671	0.303	8.573	0.326	von Willebrand factor, type D domain	.	.	0.5	46	13	chr11	17593709	chr11:17593709	T	C	46	PASS	AN=2;DP=13	GT	0/1
chr11	45793154	45793154	A	C	ncRNA_exonic	DKFZp779M0652	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	45	15	chr11	45793154	chr11:45793154	A	C	45	PASS	AN=2;DP=15	GT	0/1
chr11	46539077	46539077	A	T	intronic	AMBRA1	.	.	.	0.999971641	2.84E-05	7.36E-14	.	0.36907	0.10363	-0.971800989	8.946685539	137.80881	2.55655	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	132	chr11	46539077	chr11:46539077	A	T	70	PASS	AN=2;DP=132	GT	0/1
chr11	47193367	47193367	T	G	intronic	ARFGAP2	.	.	.	0.562990971	0.436986931	2.21E-05	.	0.45415	0.12888	0.531004228	80.87992451	3477.91758	11.35381	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	27	chr11	47193367	chr11:47193367	T	G	54	PASS	AN=2;DP=27	GT	0/1
chr11	55587914	55587914	A	G	exonic	OR5D18	.	nonsynonymous SNV	OR5D18:NM_001001952:exon1:c.A809G:p.H270R	0.000954998	0.35843516	0.640609843	.	0.11145	.	0.485092724	79.37603208	428.76611	4.32426	0.69	0.043	T	0.004	0.112	B	0.021	0.181	B	0.022	0.268	N	1	0.090	P	-0.33	0.035	N	8.83	0.000	T	-1.14	0.293	N	0.068	0.068	-1.012	0.261	T	0.000	0.000	T	.	.	.	-1.272	0.023	0.005	0.289	0.015	0.118	0.167	N	c	-0.935	-0.850	0.000	0.012	0.487	0.133	0	2.44	0.287	0.706	0.252	0.018	0.143	0.000	0.063	0.496	0.270	5.983	0.185	GPCR, rhodopsin-like, 7TM	ENSG00000150244.8	Skin_Sun_Exposed_Lower_leg	0.5	54	15	chr11	55587914	chr11:55587914	A	G	54	PASS	AN=2;DP=15	GT	0/1
chr11	61539013	61539013	C	-	exonic	MYRF	.	frameshift deletion	MYRF:NM_001127392:exon6:c.782delC:p.S264Afs*7,MYRF:NM_013279:exon6:c.755delC:p.S255Afs*7	0.999847803	0.000152197	4.41E-12	.	0.22352	0.1057	-1.082044518	7.242274121	229.21291	3.27206	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	63	chr11	61539012	chr11:61539012	TC	T	44	PASS	AN=2;DP=63	GT	0/1
chr11	62381083	62381083	-	G	exonic	ROM1	.	frameshift insertion	ROM1:NM_000327:exon1:c.331dupG:p.L114Afs*17	0.00326883	0.826982383	0.169748787	.	0.4113	0.2303	-0.224023033	37.4321774	133.6058	2.51197	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	24	chr11	62381083	chr11:62381083	T	TG	60	PASS	AN=2;DP=24	GT	0/1
chr11	63706617	63706617	C	T	intronic	NAA40	.	.	.	0.005446684	0.970204184	0.024349133	.	0.15839	0.10522	-0.47017169	23.25430526	88.58642	2.01879	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	140	chr11	63706617	chr11:63706617	C	T	64	PASS	AN=2;DP=140	GT	0/1
chr11	63706627	63706627	C	T	intronic	NAA40	.	.	.	0.005446684	0.970204184	0.024349133	.	0.15839	0.10522	-0.47017169	23.25430526	88.58642	2.01879	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	121	chr11	63706627	chr11:63706627	C	T	64	PASS	AN=2;DP=121	GT	0/1
chr11	64715290	64715290	C	T	exonic	MAJIN	.	synonymous SNV	MAJIN:NM_001037225:exon7:c.G351A:p.G117G,MAJIN:NM_001318808:exon7:c.G33A:p.G11G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	88	chr11	64715290	chr11:64715290	C	T	50	PASS	AN=2;DP=88	GT	0/1
chr11	65266480	65266480	T	C	ncRNA_exonic	MALAT1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	90	175	chr11	65266480	chr11:65266480	T	C	90	PASS	AN=2;DP=175	GT	0/1
chr11	66049881	66049881	G	A	intronic	CNIH2	.	.	.	0.894540207	0.104434209	0.001025584	.	0.16073	0.11262	-0.119252484	44.53880632	2.28818	0.07752	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	139	chr11	66049881	chr11:66049881	G	A	.	PASS	AN=0;DP=139	GT	0/1
chr11	66631419	66631419	C	G	exonic	PC	.	synonymous SNV	PC:NM_022172:exon10:c.G1194C:p.R398R,PC:NM_000920:exon11:c.G1194C:p.R398R,PC:NM_001040716:exon12:c.G1194C:p.R398R	0.71643567	0.283564107	2.23E-07	DISEASE: Pyruvate carboxylase deficiency (PC deficiency) [MIM:266150]: Leads to lactic acidosis, mental retardation and death. It occurs in three forms: mild or type A, severe neonatal or type B, and a very mild lacticacidemia. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.19381	0.81784	-1.74358502	2.394432649	138.12153	2.55935	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	60	chr11	66631419	chr11:66631419	C	G	69	PASS	AN=2;DP=60	GT	0/1
chr11	69933920	69933920	C	T	exonic	ANO1	.	synonymous SNV	ANO1:NM_018043:exon2:c.C171T:p.D57D	0.99308464	0.006915359	4.02E-10	.	0.29465	0.12257	-1.521247944	3.44420854	826.58674	5.63458	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	37	chr11	69933920	chr11:69933920	C	T	.	PASS	AN=0;DP=37	GT	0/1
chr11	70348840	70348840	-	C	intronic	SHANK2	.	.	.	0.99992017	7.98E-05	2.24E-11	DISEASE: Autism 17 (AUTS17) [MIM:613436]: A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate mental retardation. {ECO:0000269|PubMed:20473310}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.35021	.	.	.	1233.68596	6.63651	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	45	37	chr11	70348840	chr11:70348840	G	GC	45	PASS	AN=2;DP=37	GT	0/1
chr11	111899202	111899202	C	G	intronic	DLAT	.	.	.	6.68E-06	0.974397294	0.02559603	DISEASE: Note=Primary biliary cirrhosis is a chronic, progressive cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies in patients' serum. It manifests with inflammatory obliteration of intra-hepatic bile duct, leading to liver cell damage and cirrhosis. Patients with primary biliary cirrhosis show autoantibodies against the E2 component of pyruvate dehydrogenase complex.; DISEASE: Pyruvate dehydrogenase E2 deficiency (PDHE2 deficiency) [MIM:245348]: Pyruvate dehydrogenase (PDH) deficiency is a major cause of primary lactic acidosis and neurological dysfunction in infancy and early childhood. In this form of PDH deficiency episodic dystonia is the major neurological manifestation, with other more common features of pyruvate dehydrogenase deficiency, such as hypotonia and ataxia, being less prominent. {ECO:0000269|PubMed:16049940}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.80314	0.42344	0.356452144	74.62845011	6667.69783	17.30223	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	38	chr11	111899202	chr11:111899202	C	G	59	PASS	AN=2;DP=38	GT	0/1
chr11	116640793	116640793	A	C	intronic	BUD13	.	.	.	0.002295428	0.994047189	0.003657382	.	0.20921	0.07302	0.778977686	87.21396556	1508.32155	7.21483	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	47	chr11	116640793	chr11:116640793	A	C	64	PASS	AN=2;DP=47	GT	0/1
chr11	117161295	117161295	G	T	exonic	BACE1	.	synonymous SNV	BACE1:NM_001207048:exon7:c.C873A:p.G291G,BACE1:NM_001207049:exon7:c.C798A:p.G266G,BACE1:NM_012104:exon8:c.C1173A:p.G391G,BACE1:NM_138971:exon8:c.C1041A:p.G347G,BACE1:NM_138972:exon8:c.C1098A:p.G366G,BACE1:NM_138973:exon8:c.C966A:p.G322G	0.944278809	0.055712783	8.41E-06	.	0.32571	0.32145	-0.758599262	13.32861524	36.43549	1.09195	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	20	chr11	117161295	chr11:117161295	G	T	50	PASS	AN=2;DP=20	GT	0/1
chr11	118240262	118240263	AC	-	intronic	UBE4A	.	.	.	0.937619432	0.062380564	3.79E-09	.	0.20567	0.099	-1.085675268	7.147912243	92.47287	2.06712	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	19.52	20	chr11	118240261	chr11:118240261	TAC	T	19.52	PASS	AN=0;DP=20	GT	0/1
chr11	124946649	124946649	G	A	intronic	SLC37A2	.	.	.	5.01E-10	0.581719585	0.418280414	.	0.10703	0.11611	0.04598748	57.47817882	1459.43023	7.12342	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	52	chr11	124946649	chr11:124946649	G	A	.	PASS	AN=0;DP=52	GT	0/1
chr11	132306153	132306153	T	C	intronic	OPCML	.	.	.	0.578155981	0.419519453	0.002324566	DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:12819783}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.58428	0.18409	-0.359940251	28.93371078	18.89153	0.65266	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	10	chr11	132306153	chr11:132306153	T	C	55	PASS	AN=2;DP=10	GT	0/1
chr11	133788992	133788992	T	C	intronic	IGSF9B	.	.	.	0.999873394	0.000126606	5.70E-13	.	0.1331	.	.	.	323.26411	3.81929	0.0	0.912	D	0.027	0.182	B	0.031	0.206	B	.	.	.	0.999	0.219	P	.	.	.	0.33	0.583	T	-0.46	0.150	N	0.217	0.399	-0.967	0.379	T	0.000	0.000	T	.	.	.	1.330	0.224	12.42	0.891	0.179	0.947	0.619	D	c	-0.450	-0.219	0.999	0.383	0.495	0.175	0	4.63	0.570	3.385	0.520	1.061	0.807	1.000	0.715	1.000	0.888	8.856	0.342	.	.	.	0.5	78	89	chr11	133788992	chr11:133788992	T	C	78	PASS	AN=2;DP=89	GT	0/1
chr12	2929867	2929867	T	C	intronic	ITFG2	.	.	.	1.39E-06	0.833434348	0.166564262	.	0.12392	0.08912	-0.824740496	11.67728238	49.68317	1.3815	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	87	chr12	2929867	chr12:2929867	T	C	72	PASS	AN=2;DP=87	GT	0/1
chr12	2996987	2996987	C	T	intronic	RHNO1	.	.	.	0.000558185	0.704918917	0.294522899	.	0.10242	.	.	.	34.24976	1.04792	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	41	chr12	2996987	chr12:2996987	C	T	.	PASS	AN=0;DP=41	GT	0/1
chr12	4410589	4410589	C	T	UTR3	CCND2	NM_001759:c.*1414C>T	.	.	0.949000818	0.050836062	0.000163119	DISEASE: Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 (MPPH3) [MIM:615938]: A syndrome characterized by megalencephaly, ventriculomegaly that may lead to hydrocephalus, and polymicrogyria; polydactyly may also be seen. There is considerable phenotypic similarity between this disorder and the megalencephaly-capillary malformation syndrome. {ECO:0000269|PubMed:24705253}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.93215	0.74954	-0.185391282	39.67916962	14.77663	0.53228	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	101	chr12	4410589	chr12:4410589	C	T	70	PASS	AN=2;DP=101	GT	0/1
chr12	6551754	6551755	CC	-	ncRNA_intronic	CD27-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	49	chr12	6551753	chr12:6551753	GCC	G	72	PASS	AN=2;DP=49	GT	0/1
chr12	7805236	7805236	C	G	exonic	APOBEC1	.	nonsynonymous SNV	APOBEC1:NM_005889:exon2:c.G105C:p.M35I,APOBEC1:NM_001644:exon3:c.G240C:p.M80I,APOBEC1:NM_001304566:exon4:c.G240C:p.M80I	0.000144862	0.654645151	0.345209988	.	0.12544	0.14891	1.126294249	92.16206653	82.9695	1.93477	0.569	0.062	T	0.0	0.026	B	0.0	0.013	B	0.804	0.068	N	1	0.090	P	-1.95	0.002	N	-0.03	0.631	T	-0.35	0.129	N	0.051	0.032	-0.972	0.369	T	0.000	0.000	T	.	.	.	-0.248	0.072	0.868	0.572	0.056	0.001	0.007	N	c	-1.290	-1.189	0.000	0.012	0.487	0.133	0	2.61	0.301	-0.182	0.096	-0.371	0.067	0.000	0.063	0.025	0.141	4.417	0.108	APOBEC-like, N-terminal|APOBEC/CMP deaminase, zinc-binding|Cytidine and deoxycytidylate deaminases, zinc-binding|Cytidine deaminase-like	.	.	0.5	43	5	chr12	7805236	chr12:7805236	C	G	43	PASS	AN=2;DP=5	GT	1/0
chr12	9590651	9590651	-	CTGAGTAAC	ncRNA_exonic	DDX12P	.	.	.	.	.	.	.	.	0.11668	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	57	chr12	9590651	chr12:9590651	A	ACTGAGTAAC	40	PASS	AN=2;DP=57	GT	0/1
chr12	10783729	10783729	A	G	exonic	STYK1	.	synonymous SNV	STYK1:NM_018423:exon5:c.T366C:p.S122S	1.54E-05	0.860451491	0.139533145	.	0.30034	0.11766	0.176444282	66.07100731	48.89567	1.36414	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	15	chr12	10783729	chr12:10783729	A	G	43	PASS	AN=2;DP=15	GT	0/1
chr12	40001487	40001487	C	T	exonic	ABCD2	.	nonsynonymous SNV	ABCD2:NM_005164:exon3:c.G1150A:p.E384K	2.97E-06	0.927390257	0.072606773	.	0.08475	0.19889	-0.091746757	46.91554612	167.46052	2.82724	0.009	0.574	D	0.079	0.230	B	0.12	0.306	B	0.000	0.523	D	1.000	0.588	D	2.065	0.569	M	-4.36	0.973	D	-2.96	0.617	D	0.652	0.666	0.689	0.930	D	0.860	0.953	D	0.340	0.920	D	5.539	0.753	26.3	0.998	0.916	0.984	0.818	D	c	0.170	0.328	1.000	0.747	0.651	0.465	0	5.24	0.728	7.505	0.804	0.935	0.490	1.000	0.715	0.995	0.604	18.842	0.921	.	.	.	0.5	.	34	chr12	40001487	chr12:40001487	C	T	.	PASS	AN=0;DP=34	GT	0/1
chr12	43945629	43945629	T	-	intronic	ADAMTS20	.	.	.	4.85E-26	0.78318392	0.21681608	.	0.14489	0.09297	-0.753453827	13.58221279	1152.89729	6.46984	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	70	chr12	43945628	chr12:43945628	CT	C	71	PASS	AN=2;DP=70	GT	0/1
chr12	52409427	52409500	CCCAGCGGGCCCCCAGGGGCATCAGGTGCTGGTCCTCCTCCCTCCTGGCCTCGACCCCTAAGGGCTTCGCCCCT	-	UTR3	GRASP	NM_181711:c.*444_*517delCCCAGCGGGCCCCCAGGGGCATCAGGTGCTGGTCCTCCTCCCTCCTGGCCTCGACCCCTAAGGGCTTCGCCCCT;NM_001271856:c.*444_*517delCCCAGCGGGCCCCCAGGGGCATCAGGTGCTGGTCCTCCTCCCTCCTGGCCTCGACCCCTAAGGGCTTCGCCCCT	.	.	0.930936502	0.068992108	7.14E-05	.	0.64717	0.15222	.	.	95.16207	2.10482	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	25	chr12	52409426	chr12:52409426	ACCCAGCGGGCCCCCAGGGGCATCAGGTGCTGGTCCTCCTCCCTCCTGGCCTCGACCCCTAAGGGCTTCGCCCCT	A	41	PASS	AN=2;DP=25	GT	0/1
chr12	56492265	56492266	CT	-	intronic	ERBB3	.	.	.	4.36E-06	0.9999955	1.41E-07	DISEASE: Lethal congenital contracture syndrome 2 (LCCS2) [MIM:607598]: A form of lethal congenital contracture syndrome, an autosomal recessive disorder characterized by degeneration of anterior horn neurons, extreme skeletal muscle atrophy, and congenital non-progressive joint contractures (arthrogryposis). The contractures can involve the upper or lower limbs and/or the vertebral column, leading to various degrees of flexion or extension limitations evident at birth. LCCS2 patients manifest craniofacial/ocular findings, lack of hydrops, multiple pterygia, and fractures, as well as a normal duration of pregnancy and a unique feature of a markedly distended urinary bladder (neurogenic bladder defect). The phenotype suggests a spinal cord neuropathic etiology. {ECO:0000269|PubMed:17701904}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.98417	0.53106	-0.655870776	16.12408587	704.71886	5.27522	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	57	chr12	56492264	chr12:56492264	CCT	C	65	PASS	AN=2;DP=57	GT	0/1
chr12	57593101	57593101	G	A	exonic	LRP1	.	synonymous SNV	LRP1:NM_002332:exon61:c.G9783A:p.T3261T	1	1.45E-26	2.05E-66	.	0.65439	0.76644	-7.278555259	0.017692852	526.27186	4.68307	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	44	chr12	57593101	chr12:57593101	G	A	65	PASS	AN=2;DP=44	GT	0/1
chr12	64812755	64812755	T	-	exonic	XPOT	.	frameshift deletion	XPOT:NM_007235:exon6:c.370delT:p.F126Lfs*5	0.997933923	0.002066077	2.11E-11	.	0.58008	0.3831	-0.688817379	15.20405756	39.60468	1.16741	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	32	chr12	64812754	chr12:64812754	GT	G	41	PASS	AN=2;DP=32	GT	0/1
chr12	70747575	70747575	-	A	intronic	CNOT2	.	.	.	0.999868597	0.000131403	7.53E-11	.	0.28744	0.14229	-0.117432389	44.89266336	17.74579	0.62027	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41.18	44	chr12	70747575	chr12:70747575	G	GA	41.18	PASS	AN=0;DP=44	GT	0/1
chr12	94575260	94575260	G	A	exonic	PLXNC1	.	synonymous SNV	PLXNC1:NM_005761:exon3:c.G1242A:p.E414E	0.99971484	0.00028516	3.41E-14	.	0.69608	0.10916	-0.325161626	30.92120783	2196.06093	8.62704	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr12	94575260	chr12:94575260	G	A	.	PASS	AN=0;DP=38	GT	0/1
chr12	95479478	95479478	G	C	intronic	FGD6	.	.	.	0.995227689	0.004772311	3.29E-11	.	0.18424	0.0913	-1.076610636	7.324840764	1000.15705	6.09179	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	73	28	chr12	95479478	chr12:95479478	G	C	73	PASS	AN=2;DP=28	GT	1/0
chr12	100480151	100480151	G	-	intronic	UHRF1BP1L	.	.	.	0.989377601	0.010622399	2.33E-10	.	0.73214	.	1.49913011	95.38216561	1032.40429	6.1729	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	23	chr12	100480150	chr12:100480150	AG	A	52	PASS	AN=2;DP=23	GT	0/1
chr12	104517076	104517076	G	A	exonic	NFYB	.	synonymous SNV	NFYB:NM_006166:exon5:c.C357T:p.L119L	0.003273758	0.827223732	0.169502511	.	0.82614	0.23984	0.101211609	60.95777306	6.01187	0.22629	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	18	chr12	104517076	chr12:104517076	G	A	.	PASS	AN=0;DP=18	GT	0/1
chr12	110290214	110290214	C	T	UTR3	GLTP	NM_016433:c.*146G>A	.	.	0.227088706	0.737737795	0.035173498	.	.	0.15588	-0.139478553	43.29440906	22.60764	0.75634	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	33	chr12	110290214	chr12:110290214	C	T	50	PASS	AN=2;DP=33	GT	0/1
chr12	110933783	110933864	GAGATATTTGAGAAGGGAAAGGGAAATACATCACCTCATCGAAGTCTCCTCTCACAATATGAACATCACCAGCCAGAGTCTT	-	exonic	VPS29	.	nonframeshift deletion	VPS29:NM_001282151:exon2:c.148_195del:p.T51_K66del,VPS29:NM_016226:exon2:c.148_195del:p.K50_E65del,VPS29:NM_057180:exon3:c.160_207del:p.K54_E69del,VPS29:NM_001282150:exon4:c.244_291del:p.K82_E97del	0.934744448	0.064952736	0.000302816	.	0.45412	0.10309	0.079165051	59.43029016	5.00308	0.18601	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	13.22	28	chr12	110933782	chr12:110933782	GGAGATATTTGAGAAGGGAAAGGGAAATACATCACCTCATCGAAGTCTCCTCTCACAATATGAACATCACCAGCCAGAGTCTT	G	13.22	PASS	AN=0;DP=28	GT	0/1
chr12	112516042	112516042	C	T	exonic	NAA25	.	nonsynonymous SNV	NAA25:NM_024953:exon7:c.G614A:p.R205H	0.999989964	1.00E-05	1.19E-15	.	0.37094	0.10762	-0.111973265	45.35857514	2728.20466	9.84256	0.135	0.262	T	1.0	0.899	D	0.925	0.643	D	0.000	0.843	D	1	0.810	D	2.08	0.576	M	1.12	0.387	T	-0.88	0.238	N	0.774	0.766	-0.846	0.523	T	0.197	0.552	T	0.022	0.454	T	4.431	0.593	24.2	0.999	0.986	0.991	0.907	D	c	0.686	0.714	1.000	0.747	0.707	0.730	0	5.52	0.821	7.330	0.783	0.892	0.403	1.000	0.715	0.998	0.697	19.431	0.947	Tetratricopeptide-like helical domain	.	.	0.5	.	109	chr12	112516042	chr12:112516042	C	T	.	PASS	AN=0;DP=109	GT	0/1
chr12	122614210	122614210	T	-	intronic	MLXIP	.	.	.	0.975747589	0.024251353	1.06E-06	.	0.16616	0.11073	.	.	1241.38763	6.65087	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	77	57	chr12	122614209	chr12:122614209	CT	C	77	PASS	AN=2;DP=57	GT	0/1
chr12	128899673	128899673	A	G	exonic	TMEM132C	.	nonsynonymous SNV	TMEM132C:NM_001136103:exon2:c.A482G:p.H161R	0.66707188	0.310682848	0.022245272	.	0.17363	.	.	.	3428.14645	11.24007	0.369	0.116	T	0.0	0.026	B	0.001	0.040	B	.	.	.	1	0.090	P	0.99	0.251	L	2.86	0.105	T	-1.34	0.334	N	0.015	0.002	-0.919	0.457	T	0.000	0.000	T	.	.	.	-2.555	0.003	0.001	0.396	0.027	0.076	0.134	N	c	-1.797	-1.890	0.121	0.169	0.554	0.246	0	-9.14	0.006	0.353	0.197	-0.145	0.109	0.000	0.063	0.002	0.062	8.807	0.339	Transmembrane protein TMEM132, N-terminal	.	.	0.5	59	38	chr12	128899673	chr12:128899673	A	G	59	PASS	AN=2;DP=38	GT	0/1
chr13	22275888	22275888	A	G	UTR3	FGF9	NM_002010:c.*314A>G	.	.	0.91071591	0.088614167	0.000669923	DISEASE: Multiple synostoses syndrome 3 (SYNS3) [MIM:612961]: A bone disease characterized by multiple progressive joint fusions that commonly involve proximal interphalangeal, tarsal-carpal, humeroradial and cervical spine joints. Additional features can include progressive conductive deafness and facial dysmorphism. {ECO:0000269|PubMed:19589401}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.90259	0.31502	0.169169615	65.33380514	24.43081	0.80364	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	26	chr13	22275888	chr13:22275888	A	G	42	PASS	AN=2;DP=26	GT	0/1
chr13	25517090	25517090	C	-	ncRNA_exonic	TPTE2P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	25	chr13	25517089	chr13:25517089	TC	T	54	PASS	AN=2;DP=25	GT	0/1
chr13	26343298	26343298	C	T	exonic	ATP8A2	.	synonymous SNV	ATP8A2:NM_001313741:exon26:c.C2379T:p.H793H,ATP8A2:NM_016529:exon26:c.C2499T:p.H833H	0.4180779	0.581922099	9.45E-10	DISEASE: Note=A chromosomal aberration disrupting ATP8A2 has been found in a patient with severe mental retardation and major hypotonia. Translocation t(10;13)(p12.1;q12.13) (PubMed:20683487). {ECO:0000269|PubMed:20683487}.; 	0.33216	0.22285	-1.104093597	6.894314697	112.54149	2.30702	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	30	chr13	26343298	chr13:26343298	C	T	.	PASS	AN=0;DP=30	GT	0/1
chr13	31821180	31821180	C	T	exonic	B3GLCT	.	synonymous SNV	B3GLCT:NM_194318:exon5:c.C291T:p.L97L	.	.	.	.	0.22185	0.13753	0.066214104	58.95848077	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	27	chr13	31821180	chr13:31821180	C	T	.	PASS	AN=0;DP=27	GT	0/1
chr13	36049080	36049080	T	G	UTR3	MAB21L1	NM_005584:c.*116A>C	.	.	0.367416502	0.620997062	0.011586436	.	0.79952	0.11262	-0.449946534	24.00330267	17.33297	0.60901	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	9	chr13	36049080	chr13:36049080	T	G	41	PASS	AN=2;DP=9	GT	0/1
chr13	41133191	41133191	T	C	intronic	FOXO1	.	.	.	0.966380394	0.033561804	5.78E-05	DISEASE: Rhabdomyosarcoma 2 (RMS2) [MIM:268220]: A form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchymal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas. Note=The gene represented in this entry may be involved in disease pathogenesis. Chromosomal aberrations involving FOXO1 are found in rhabdomyosarcoma. Translocation (2;13)(q35;q14) with PAX3 and translocation t(1;13)(p36;q14) with PAX7. The resulting protein is a transcriptional activator.; 	0.97621	0.82936	-0.468351206	23.42533616	329.3803	3.85852	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	53	chr13	41133191	chr13:41133191	T	C	62	PASS	AN=2;DP=53	GT	0/1
chr13	82264343	82264343	A	G	intergenic	LINC00564;NONE	dist=463225;dist=NONE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	24	chr13	82264343	chr13:82264343	A	G	42	PASS	AN=2;DP=24	GT	0/1
chr13	99098882	99098882	A	C	intronic	FARP1	.	.	.	0.045263074	0.954736546	3.80E-07	.	0.20246	0.11058	0.102819578	60.96956829	825.14469	5.63133	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	15	chr13	99098882	chr13:99098882	A	C	65	PASS	AN=2;DP=15	GT	0/1
chr13	111973303	111973303	G	A	intronic	TEX29	.	.	.	0.001451668	0.671141973	0.32740636	.	0.02058	.	-0.139478553	43.29440906	19.3167	0.66507	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	61	chr13	111973303	chr13:111973303	G	A	.	PASS	AN=0;DP=61	GT	0/1
chr14	19806717	19806717	A	C	intergenic	DUXAP10;LINC01296	dist=113801;dist=73492	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	53	chr14	19806717	chr14:19806717	A	C	69	PASS	AN=2;DP=53	GT	0/1
chr14	20228354	20228354	A	G	intergenic	OR4Q3;OR4M1	dist=11826;dist=20128	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	46	chr14	20228354	chr14:20228354	A	G	51	PASS	AN=2;DP=46	GT	0/1
chr14	22314985	22314985	T	C	intergenic	OR4E1;LINC02332	dist=175753;dist=710220	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	57	20	chr14	22314985	chr14:22314985	T	C	57	PASS	AN=2;DP=20	GT	0/1
chr14	22315060	22315060	T	G	intergenic	OR4E1;LINC02332	dist=175828;dist=710145	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	34	chr14	22315060	chr14:22315060	T	G	62	PASS	AN=2;DP=34	GT	1/0
chr14	23312863	23312863	C	G	intronic	MMP14	.	.	.	0.987123657	0.01287612	2.23E-07	DISEASE: Winchester syndrome (WNCHRS) [MIM:277950]: A disease characterized by severe osteolysis in the hands and feet, generalized osteoporosis, bone thinning, and absence of subcutaneous nodules. Various additional features include coarse face, corneal opacities, gum hypertrophy, and EKG changes. {ECO:0000269|PubMed:22922033}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.54891	0.55746	0.04598748	57.47817882	1317.7477	6.82691	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	25	chr14	23312863	chr14:23312863	C	G	54	PASS	AN=2;DP=25	GT	0/1
chr14	39746198	39746198	G	T	exonic	MIA2	.	stopgain	MIA2:NM_001247988:exon2:c.G37T:p.E13X,MIA2:NM_001247989:exon2:c.G124T:p.E42X,MIA2:NM_005930:exon2:c.G124T:p.E42X,MIA2:NM_203354:exon2:c.G88T:p.E30X,MIA2:NM_203355:exon2:c.G124T:p.E42X,MIA2:NM_203356:exon2:c.G37T:p.E13X,MIA2:NM_001329214:exon7:c.G1948T:p.E650X	0.00020882	0.908098694	0.091692485	.	0.18559	0.10293	1.133561642	92.28591649	1216.13549	6.59678	.	.	.	.	.	.	.	.	.	0.057	0.225	N	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.945	0.979	38	0.998	0.855	0.947	0.617	D	c	1.071	0.904	1.000	0.747	0.651	0.465	0	5.01	0.663	5.575	0.669	1.048	0.713	1.000	0.715	0.996	0.625	17.248	0.869	.	.	.	0.5	.	37	chr14	39746198	chr14:39746198	G	T	.	PASS	AN=0;DP=37	GT	0/1
chr14	64669478	64669478	T	-	intronic	SYNE2	.	.	.	1.85E-11	1	3.59E-33	DISEASE: Emery-Dreifuss muscular dystrophy 5, autosomal dominant (EDMD5) [MIM:612999]: A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects. {ECO:0000269|PubMed:17761684}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.21106	.	3.839142661	99.63434772	10907.00643	22.66019	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	43	chr14	64669477	chr14:64669477	GT	G	51	PASS	AN=2;DP=43	GT	0/1
chr14	74404756	74404756	T	C	exonic	FAM161B	.	nonsynonymous SNV	FAM161B:NM_152445:exon6:c.A1649G:p.K550R	9.86E-11	0.27905519	0.72094481	.	0.09509	0.08229	0.536463361	81.06864827	3600.98595	11.61635	0.241	0.176	T	0.767	0.418	P	0.279	0.385	B	0.016	0.281	N	0.144	0.353	P	0.995	0.252	L	1.88	0.239	T	-0.27	0.114	N	0.053	0.146	-0.906	0.474	T	0.000	0.000	T	.	.	.	1.201	0.210	11.75	0.993	0.593	0.806	0.399	D	c	0.059	0.127	0.940	0.274	0.563	0.310	0	4.31	0.505	0.772	0.261	0.964	0.580	0.998	0.411	1.000	0.888	9.615	0.387	.	ENSG00000140043.7|ENSG00000119723.11|ENSG00000140043.7|ENSG00000119723.11|ENSG00000140043.7|ENSG00000119723.11|ENSG00000119723.11|ENSG00000156050.4|ENSG00000119725.13|ENSG00000140043.7|ENSG00000119725.13|ENSG00000140043.7|ENSG00000119725.13|ENSG00000119723.11|ENSG00000140043.7|ENSG00000140043.7|ENSG00000119725.13|ENSG00000140043.7|ENSG00000119723.11|ENSG00000258586.1|ENSG00000119725.13|ENSG00000119723.11|ENSG00000119725.13|ENSG00000140043.7|ENSG00000140043.7|ENSG00000119723.11|ENSG00000258891.1|ENSG00000119723.11|ENSG00000140043.7|ENSG00000119725.13	Adipose_Visceral_Omentum|Artery_Aorta|Artery_Aorta|Artery_Tibial|Artery_Tibial|Brain_Cerebellum|Breast_Mammary_Tissue|Cells_EBV-transformed_lymphocytes|Colon_Sigmoid|Colon_Transverse|Colon_Transverse|Esophagus_Mucosa|Esophagus_Mucosa|Esophagus_Muscularis|Heart_Left_Ventricle|Lung|Lung|Muscle_Skeletal|Nerve_Tibial|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Skin_Sun_Exposed_Lower_leg|Small_Intestine_Terminal_Ileum|Stomach|Testis|Testis|Thyroid|Thyroid|Thyroid	0.5	56	25	chr14	74404756	chr14:74404756	T	C	56	PASS	AN=2;DP=25	GT	0/1
chr14	77491136	77491136	C	-	UTR3	IRF2BPL	NM_024496:c.*609delG	.	.	0.968935346	0.031017133	4.75E-05	.	0.69645	0.11157	.	.	62.7394	1.62021	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	57	88	chr14	77491135	chr14:77491135	TC	T	57	PASS	AN=2;DP=88	GT	0/1
chr14	105269393	105269393	G	A	UTR3	ZBTB42	NM_001137601:c.*590G>A	.	.	.	.	.	.	.	.	0.768075923	86.8895966	146.30778	2.63567	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	181	chr14	105269393	chr14:105269393	G	A	70	PASS	AN=2;DP=181	GT	0/1
chr14	105411260	105411260	A	G	exonic	AHNAK2	.	nonsynonymous SNV	AHNAK2:NM_001350929:exon7:c.T10228C:p.S3410P,AHNAK2:NM_138420:exon7:c.T10528C:p.S3510P	.	.	.	.	0.0478	.	27.59634509	99.99410238	24654.11397	32.49932	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	.	.	.	1	0.090	N	-2.03	0.002	N	6.68	0.005	T	4.92	0.000	N	0.026	0.008	-0.939	0.428	T	0.000	0.000	T	.	.	.	-1.455	0.018	0.003	0.105	0.001	0.000	0.003	N	c	-1.915	-1.755	0.000	0.071	0.707	0.730	0	1.14	0.197	0.438	0.211	-1.940	0.005	0.006	0.172	0.000	0.016	3.781	0.081	.	.	.	0.5	76	157	chr14	105411260	chr14:105411260	A	G	76	PASS	AN=2;DP=157	GT	0/1
chr14	105416936	105416936	T	C	exonic	AHNAK2	.	nonsynonymous SNV	AHNAK2:NM_001350929:exon7:c.A4552G:p.K1518E,AHNAK2:NM_138420:exon7:c.A4852G:p.K1618E	.	.	.	.	0.0478	.	27.59634509	99.99410238	24654.11397	32.49932	0.926	0.023	T	0.0	0.026	B	0.0	0.013	B	.	.	.	1	0.294	N	-1.4	0.006	N	5.64	0.008	T	0.63	0.024	N	0.061	0.045	-0.963	0.386	T	0.001	0.004	T	.	.	.	-0.927	0.035	0.023	0.172	0.005	0.001	0.005	N	c	-1.420	-1.302	0.006	0.110	0.672	0.522	0	4.15	0.478	0.001	0.128	-0.077	0.119	0.002	0.151	0.001	0.043	8.565	0.325	.	.	.	0.5	66	86	chr14	105416936	chr14:105416936	T	C	66	PASS	AN=2;DP=86	GT	0/1
chr14	106091504	106091504	A	G	intergenic	MIR8071-2;MIR8071-2	dist=3987;dist=15001	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	88	30	chr14	106091504	chr14:106091504	A	G	88	PASS	AN=2;DP=30	GT	0/1
chr14	107078567	107078567	T	C	intergenic	LINC00221;MIR7641-2	dist=127038;dist=14149	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	84	33	chr14	107078567	chr14:107078567	T	C	84	PASS	AN=2;DP=33	GT	0/1
chr15	20362835	20362835	G	C	intergenic	NONE;CHEK2P2	dist=NONE;dist=125162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	76	74	chr15	20362835	chr15:20362835	G	C	76	PASS	AN=2;DP=74	GT	0/1
chr15	20457244	20457244	G	C	intergenic	NONE;CHEK2P2	dist=NONE;dist=30753	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	75	38	chr15	20457244	chr15:20457244	G	C	75	PASS	AN=2;DP=38	GT	0/1
chr15	20495286	20495286	A	C	ncRNA_intronic	CHEK2P2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	39	chr15	20495286	chr15:20495286	A	C	71	PASS	AN=2;DP=39	GT	0/1
chr15	22960868	22960868	G	C	exonic	CYFIP1	.	synonymous SNV	CYFIP1:NM_001033028:exon3:c.G768C:p.L256L,CYFIP1:NM_001324125:exon15:c.G1695C:p.L565L,CYFIP1:NM_001324124:exon17:c.G1971C:p.L657L,CYFIP1:NM_001324126:exon17:c.G1959C:p.L653L,CYFIP1:NM_001324119:exon18:c.G2163C:p.L721L,CYFIP1:NM_001324120:exon18:c.G2061C:p.L687L,CYFIP1:NM_001324123:exon18:c.G2061C:p.L687L,CYFIP1:NM_014608:exon18:c.G2061C:p.L687L,CYFIP1:NM_001287810:exon19:c.G2061C:p.L687L,CYFIP1:NM_001324122:exon19:c.G381C:p.L127L	0.994933032	0.005066968	1.56E-12	.	0.18853	0.14087	-1.295313867	4.989384289	2808.37817	9.99956	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	15	chr15	22960868	chr15:22960868	G	C	64	PASS	AN=2;DP=15	GT	0/1
chr15	23200294	23200294	T	C	ncRNA_exonic	WHAMMP3	.	.	.	.	.	.	.	.	0.09497	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	20	chr15	23200294	chr15:23200294	T	C	44	PASS	AN=2;DP=20	GT	0/1
chr15	23892037	23892037	C	T	exonic	MAGEL2	.	nonsynonymous SNV	MAGEL2:NM_019066:exon1:c.G853A:p.G285R	0.922411269	0.077492727	9.60E-05	.	.	.	.	.	653.05336	5.12739	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.166	0.200	.	.	.	.	.	.	.	.	.	3.130	0.436	22.6	0.894	0.182	0.021	0.062	N	n	1.027	1.211	1.000	0.404	0.162	0.030	1	2.18	0.267	0.361	0.199	0.790	0.321	0.005	0.169	0.963	0.446	8.335	0.312	.	.	.	0.5	.	67	chr15	23892037	chr15:23892037	C	T	.	PASS	AN=0;DP=67	GT	0/1
chr15	40066796	40066796	G	A	intronic	FSIP1	.	.	.	4.51E-07	0.609400584	0.390598965	.	0.09176	0.07645	1.556142814	95.65935362	3550.99356	11.51445	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	23	chr15	40066796	chr15:40066796	G	A	.	PASS	AN=0;DP=23	GT	0/1
chr15	42736369	42736369	G	A	intronic	ZNF106	.	.	.	0.219458519	0.780541481	4.04E-11	.	0.28817	0.10531	-0.448371699	24.00920028	657.40284	5.14043	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	232	chr15	42736369	chr15:42736369	G	A	70	PASS	AN=2;DP=232	GT	0/1
chr15	45364707	45364707	G	-	intronic	SORD	.	.	.	0.004347946	0.962638319	0.033013735	.	0.48997	0.60308	0.863528995	88.74144845	2436.461	9.17126	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	18	chr15	45364706	chr15:45364706	TG	T	42	PASS	AN=2;DP=18	GT	0/1
chr15	63638658	63638658	G	A	intronic	CA12	.	.	.	9.91E-09	0.168655225	0.831344765	.	0.21265	0.1284	-0.622676946	17.30950696	40.85482	1.19656	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	29	chr15	63638658	chr15:63638658	G	A	.	PASS	AN=0;DP=29	GT	0/1
chr15	64983838	64983838	T	-	intronic	OAZ2	.	.	.	0.866153028	0.131948234	0.001898738	.	0.70388	.	.	.	17.63191	0.61771	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	13.25	34	chr15	64983837	chr15:64983837	AT	A	13.25	PASS	AN=0;DP=34	GT	0/1
chr15	65208025	65208025	G	A	exonic	ANKDD1A	.	nonsynonymous SNV	ANKDD1A:NM_182703:exon2:c.G64A:p.A22T	1.16E-15	0.005458509	0.994541491	.	0.10053	0.09163	-0.24061166	36.28214201	2935.68232	10.27688	.	.	.	1.0	0.899	D	0.999	0.916	D	.	.	.	1.000	0.501	D	3.245	0.900	M	.	.	.	.	.	.	0.517	0.559	0.233	0.865	D	0.650	0.878	D	0.017	0.382	T	5.257	0.710	25.7	0.999	0.970	0.782	0.383	D	c	0.393	0.221	1.000	0.747	0.554	0.283	0	2.88	0.325	4.419	0.593	0.100	0.199	1.000	0.715	0.746	0.321	7.207	0.249	Ankyrin repeat-containing domain	.	.	0.5	.	29	chr15	65208025	chr15:65208025	G	A	.	PASS	AN=0;DP=29	GT	0/1
chr15	65674776	65674776	C	T	UTR3	IGDCC4	NM_020962:c.*1571G>A	.	.	0.014885498	0.985104501	1.00E-05	.	.	0.12313	0.85606445	88.52323661	4828.87634	14.09369	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	42	chr15	65674776	chr15:65674776	C	T	.	PASS	AN=0;DP=42	GT	0/1
chr15	67892147	67892147	G	A	intronic	MAP2K5	.	.	.	0.475918461	0.524072679	8.86E-06	.	0.38366	0.21895	-0.692458599	14.96815287	37.4829	1.11572	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	31	chr15	67892147	chr15:67892147	G	A	.	PASS	AN=0;DP=31	GT	0/1
chr15	69018137	69018137	C	T	intronic	CORO2B	.	.	.	0.779053737	0.220882015	6.42E-05	.	0.50461	0.11034	-0.380166007	27.88393489	54.48241	1.47592	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	15	chr15	69018137	chr15:69018137	C	T	50	PASS	AN=2;DP=15	GT	0/1
chr15	78207469	78207469	C	G	ncRNA_exonic	LOC645752	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	18	chr15	78207469	chr15:78207469	C	G	61	PASS	AN=2;DP=18	GT	0/1
chr15	78207729	78207729	G	C	ncRNA_intronic	LOC645752	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	73	100	chr15	78207729	chr15:78207729	G	C	73	PASS	AN=2;DP=100	GT	0/1
chr15	78214375	78214375	T	C	ncRNA_exonic	LOC645752	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	76	59	chr15	78214375	chr15:78214375	T	C	76	PASS	AN=2;DP=59	GT	0/1
chr15	78310281	78310282	TG	-	exonic	TBC1D2B	.	stopgain	TBC1D2B:NM_015079:exon7:c.1488_1489del:p.Y496fs*0,TBC1D2B:NM_144572:exon7:c.1488_1489del:p.Y496fs*0	6.51E-05	0.99487708	0.00505782	.	0.17736	0.11001	0.068033485	59.0351498	1987.47287	8.21355	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	22	chr15	78310280	chr15:78310280	TTG	T	39	PASS	AN=2;DP=22	GT	0/1
chr15	78632830	78632830	C	G	exonic	CRABP1	.	synonymous SNV	CRABP1:NM_004378:exon1:c.C60G:p.L20L	0.125504894	0.780082092	0.094413014	.	0.5128	0.35026	-0.163345027	41.24793583	9.97302	0.36559	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	49	chr15	78632830	chr15:78632830	C	G	55	PASS	AN=2;DP=49	GT	0/1
chr15	80452172	80452172	G	C	exonic	FAH	.	synonymous SNV	FAH:NM_000137:exon3:c.G267C:p.L89L	2.81E-11	0.142874356	0.857125644	.	0.1414	0.24341	-0.909290275	10.03184713	149.7435	2.66839	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	20	chr15	80452172	chr15:80452172	G	C	52	PASS	AN=2;DP=20	GT	0/1
chr15	84527569	84527569	C	T	exonic	ADAMTSL3	.	nonsynonymous SNV	ADAMTSL3:NM_001301110:exon8:c.C779T:p.T260I,ADAMTSL3:NM_207517:exon8:c.C779T:p.T260I	9.55E-09	0.999999675	3.15E-07	.	0.29754	0.10931	0.334233824	73.62585515	5035.60394	14.49965	0.107	0.295	T	0.589	0.764	P	0.413	0.832	B	0.884	0.072	N	0.989	0.409	D	1.23	0.308	L	-0.15	0.659	T	-1.63	0.418	N	0.55	0.690	-0.712	0.599	T	0.356	0.719	T	0.036	0.571	D	3.940	0.530	23.5	0.998	0.876	0.836	0.424	D	c	0.106	0.111	0.993	0.329	0.554	0.246	0	3.64	0.407	4.101	0.573	0.807	0.329	0.998	0.411	0.995	0.604	10.341	0.429	.	.	.	0.5	.	28	chr15	84527569	chr15:84527569	C	T	.	PASS	AN=0;DP=28	GT	0/1
chr15	84946642	84946642	C	G	intergenic	GOLGA6L4;LOC103171574	dist=32522;dist=30575	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	105	111	chr15	84946642	chr15:84946642	C	G	105	PASS	AN=2;DP=111	GT	0/1
chr15	90774448	90774451	AGAG	-	intronic	CIB1	.	.	.	0.016102965	0.883934356	0.099962679	.	0.1621	0.27055	-0.295622497	32.61972163	38.05583	1.13067	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	40	chr15	90774447	chr15:90774447	TAGAG	T	40	PASS	AN=2;DP=40	GT	0/1
chr15	99023968	99023968	T	G	exonic	FAM169B	.	synonymous SNV	FAM169B:NM_182562:exon4:c.A45C:p.L15L	0.001356899	0.656623918	0.342019183	.	.	.	0.749657564	86.56522765	50.63929	1.40077	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	10	chr15	99023968	chr15:99023968	T	G	43	PASS	AN=2;DP=10	GT	0/1
chr16	456416	456416	T	G	intronic	DECR2	.	.	.	3.47E-09	0.04976336	0.950236636	.	0.30516	0.13063	-0.244249595	36.17008728	109.53122	2.27353	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	86	91	chr16	456416	chr16:456416	T	G	86	PASS	AN=2;DP=91	GT	0/1
chr16	1260333	1260333	G	A	intronic	CACNA1H	.	.	.	0.755916976	0.244083023	1.19E-09	DISEASE: Epilepsy, idiopathic generalized 6 (EIG6) [MIM:611942]: A disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain. {ECO:0000269|PubMed:15048902}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Epilepsy, childhood absence 6 (ECA6) [MIM:611942]: A subtype of idiopathic generalized epilepsy characterized by an onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3-Hz spike waves on EEG. Tonic-clonic seizures often develop in adolescence. Absence seizures may either remit or persist into adulthood. {ECO:0000269|PubMed:12891677}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.1215	0.15825	-2.059460781	1.627742392	3476.91536	11.35078	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr16	1260333	chr16:1260333	G	A	.	PASS	AN=0;DP=38	GT	0/1
chr16	1395408	1395408	G	A	intronic	BAIAP3	.	.	.	2.21E-19	0.088488031	0.911511969	.	0.29593	0.09988	-2.150176731	1.468506723	719.07294	5.32413	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	32	chr16	1395408	chr16:1395408	G	A	.	PASS	AN=0;DP=32	GT	0/1
chr16	1741779	1741783	GGGGT	-	intronic	JPT2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	35	chr16	1741778	chr16:1741778	GGGGGT	G	42	PASS	AN=2;DP=35	GT	0/1
chr16	2223956	2223956	G	A	exonic	TRAF7	.	synonymous SNV	TRAF7:NM_032271:exon13:c.G1170A:p.G390G	0.460647228	0.539342814	9.96E-06	.	0.16599	0.14085	-1.50825116	3.503184713	28.55417	0.91487	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	64	chr16	2223956	chr16:2223956	G	A	.	PASS	AN=0;DP=64	GT	0/1
chr16	10935149	10935149	T	C	intergenic	TVP23A;CIITA	dist=22498;dist=35906	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	63	28	chr16	10935149	chr16:10935149	T	C	63	PASS	AN=2;DP=28	GT	0/1
chr16	11022763	11022763	T	-	UTR3	DEXI	NM_014015:c.*803delA	.	.	0.453687572	0.450603985	0.095708443	.	.	.	0.079165051	59.43029016	3.59417	0.13074	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	21.49	30	chr16	11022762	chr16:11022762	AT	A	21.49	PASS	AN=0;DP=30	GT	0/1
chr16	11367195	11367195	G	C	exonic	PRM3	.	nonsynonymous SNV	PRM3:NM_021247:exon1:c.C258G:p.H86Q	.	.	.	.	0.18725	0.10186	.	.	12.87986	0.46948	0.659	0.047	T	.	.	.	.	.	.	0.371	0.135	N	1	0.090	P	.	.	.	1.04	0.402	T	1.71	0.006	N	0.01	0.001	-1.064	0.107	T	0.000	0.000	T	.	.	.	-2.539	0.003	0.001	0.417	0.030	0.005	0.024	N	c	-1.945	-2.168	1.000	0.747	0.497	0.185	0	-9.63	0.005	-3.218	0.006	-3.178	0.001	0.000	0.063	0.000	0.016	0.748	0.009	.	ENSG00000175643.7|ENSG00000175643.7|ENSG00000175643.7|ENSG00000175643.7|ENSG00000175643.7|ENSG00000175643.7|ENSG00000175643.7|ENSG00000175643.7	Adipose_Visceral_Omentum|Artery_Tibial|Brain_Putamen_basal_ganglia|Muscle_Skeletal|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Thyroid	0.5	54	34	chr16	11367195	chr16:11367195	G	C	54	PASS	AN=2;DP=34	GT	0/1
chr16	11544509	11544509	C	G	intergenic	RMI2;LOC101927131	dist=98889;dist=14607	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.001	0.416	N	0.999	0.218	P	1.755	0.458	L	3.82	0.038	T	.	.	.	0.074	0.064	-1.058	0.123	T	0.001	0.004	T	.	.	.	3.068	0.429	22.4	0.961	0.281	0.104	0.157	N	c	-0.481	-0.567	0.781	0.238	0.661	0.498	0	1.72	0.234	0.947	0.285	-0.032	0.126	0.008	0.178	0.030	0.147	9.731	0.393	.	.	.	0.5	43	20	chr16	11544509	chr16:11544509	C	G	43	PASS	AN=2;DP=20	GT	0/1
chr16	23646821	23646821	T	C	exonic	PALB2	.	nonsynonymous SNV	PALB2:NM_024675:exon4:c.A1046G:p.N349S	1.33E-10	0.770851369	0.229148631	DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. {ECO:0000269|PubMed:17287723, ECO:0000269|PubMed:22241545}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Breast cancer susceptibility is strongly associated with PALB2 truncating mutations. Conversely, rare missense mutations do not strongly influence breast cancer risk (PubMed:22241545). {ECO:0000269|PubMed:22241545}.; DISEASE: Fanconi anemia complementation group N (FANCN) [MIM:610832]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. {ECO:0000269|PubMed:17200672}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Pancreatic cancer 3 (PNCA3) [MIM:613348]: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue. {ECO:0000269|PubMed:19264984}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.16352	0.27931	0.321464691	72.85326728	296.6407	3.67511	0.084	0.329	T	0.084	0.233	B	0.037	0.218	B	0.199	0.166	N	1	0.090	N	1.15	0.294	L	2.22	0.182	T	-1.98	0.457	N	0.123	0.138	-1.027	0.215	T	0.042	0.181	T	0.011	0.290	T	-0.146	0.080	1.411	0.904	0.191	0.093	0.149	N	c	-0.822	-0.834	0.124	0.169	0.563	0.310	0	2.31	0.277	1.108	0.305	0.039	0.154	0.204	0.241	0.982	0.498	7.409	0.260	.	.	.	0.5	42	39	chr16	23646821	chr16:23646821	T	C	42	PASS	AN=2;DP=39	GT	0/1
chr16	28734579	28734581	GAG	-	exonic	EIF3C;EIF3CL	.	nonframeshift deletion	EIF3C:NM_001267574:exon8:c.871_873del:p.E294del,EIF3C:NM_001037808:exon9:c.871_873del:p.E294del,EIF3CL:NM_001099661:exon9:c.871_873del:p.E294del,EIF3C:NM_001199142:exon9:c.871_873del:p.E294del,EIF3C:NM_001286478:exon9:c.841_843del:p.E284del,EIF3CL:NM_001317856:exon9:c.871_873del:p.E294del,EIF3CL:NM_001317857:exon9:c.871_873del:p.E295del,EIF3C:NM_003752:exon9:c.871_873del:p.E294del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	56	72	chr16	28734578	chr16:28734578	TGAG	T	56	PASS	AN=2;DP=72	GT	0/1
chr16	28846506	28846506	A	G	exonic	ATXN2L	.	nonsynonymous SNV	ATXN2L:NM_001308230:exon19:c.A2579G:p.Y860C,ATXN2L:NM_007245:exon19:c.A2561G:p.Y854C,ATXN2L:NM_017492:exon19:c.A2561G:p.Y854C,ATXN2L:NM_145714:exon19:c.A2561G:p.Y854C,ATXN2L:NM_148414:exon19:c.A2561G:p.Y854C,ATXN2L:NM_148415:exon19:c.A2561G:p.Y854C,ATXN2L:NM_148416:exon19:c.A2561G:p.Y854C	0.999950396	4.96E-05	5.82E-14	.	0.45112	0.12083	-1.725143594	2.447511205	101.85413	2.1834	0.0	0.912	D	1.0	0.899	D	0.997	0.850	D	0.001	0.420	D	1.000	0.588	D	2.05	0.567	M	0.72	0.520	T	-3.04	0.761	D	0.558	0.838	-0.745	0.582	T	0.224	0.588	T	0.029	0.520	D	5.946	0.816	27.6	0.997	0.820	0.991	0.917	D	c	0.610	0.606	1.000	0.747	0.672	0.522	0	5.03	0.669	7.181	0.770	1.199	0.960	1.000	0.715	1.000	0.888	13.881	0.630	Ataxin 2, SM domain	.	.	0.5	92	114	chr16	28846506	chr16:28846506	A	G	92	PASS	AN=2;DP=114	GT	0/1
chr16	30992180	30992180	G	A	intronic	SETD1A	.	.	.	0.999996231	3.77E-06	5.40E-16	.	0.31946	.	-2.934884757	0.560273649	360.97151	4.02191	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	30	chr16	30992180	chr16:30992180	G	A	.	PASS	AN=0;DP=30	GT	0/1
chr16	46661227	46661227	C	G	intergenic	SHCBP1;VPS35	dist=5913;dist=30664	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	25	chr16	46661227	chr16:46661227	C	G	55	PASS	AN=2;DP=25	GT	0/1
chr16	56673143	56673143	A	G	intronic	MT1A	.	.	.	0.007776186	0.549963564	0.44226025	.	0.10097	.	0.567831482	81.78225997	3587.00557	11.59065	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	7	chr16	56673143	chr16:56673143	A	G	41	PASS	AN=2;DP=7	GT	0/1
chr16	58021306	58021306	C	G	exonic	TEPP	.	synonymous SNV	TEPP:NM_199046:exon8:c.C873G:p.V291V,TEPP:NM_199456:exon8:c.C792G:p.V264V	6.80E-05	0.729947501	0.269984542	.	.	.	-0.069700724	48.54328851	39.64027	1.16858	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	23	chr16	58021306	chr16:58021306	C	G	55	PASS	AN=2;DP=23	GT	0/1
chr16	58550456	58550456	T	G	exonic	SETD6	.	nonsynonymous SNV	SETD6:NM_001160305:exon4:c.T551G:p.I184S,SETD6:NM_024860:exon5:c.T479G:p.I160S	1.02E-09	0.088411248	0.911588751	.	0.3769	.	0.132352165	63.48785091	65.5989	1.6682	0.002	0.721	D	1.0	0.899	D	1.0	0.971	D	0.000	0.629	D	1.000	0.810	D	2.045	0.562	M	-1.46	0.810	T	-3.11	0.636	D	0.905	0.902	0.275	0.872	D	0.624	0.868	D	0.255	0.893	D	5.503	0.747	26.2	0.994	0.634	0.981	0.791	D	c	0.575	0.540	1.000	0.747	0.722	0.854	0	5.37	0.769	5.949	0.698	1.011	0.635	1.000	0.715	0.921	0.396	14.217	0.652	SET domain	.	.	0.5	69	73	chr16	58550456	chr16:58550456	T	G	69	PASS	AN=2;DP=73	GT	0/1
chr16	60392816	60392816	G	-	exonic	LOC729159	.	frameshift deletion	LOC729159:NM_001282301:exon1:c.791delC:p.P264Qfs*13	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	86	98	chr16	60392815	chr16:60392815	TG	T	86	PASS	AN=2;DP=98	GT	0/1
chr16	66947383	66947383	C	G	intronic	CDH16	.	.	.	6.80E-13	0.212349983	0.787650017	.	0.09081	0.12844	-0.946125119	9.377211607	998.46283	6.08909	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	27	chr16	66947383	chr16:66947383	C	G	60	PASS	AN=2;DP=27	GT	0/1
chr16	67670520	67670520	A	G	intronic	CTCF	.	.	.	0.997924958	0.002075029	1.27E-08	DISEASE: Mental retardation, autosomal dominant 21 (MRD21) [MIM:615502]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Additional MRD21 features include short stature, microcephaly, and developmental delay. {ECO:0000269|PubMed:23746550}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.78428	0.25142	-0.293801652	32.93819297	9.66001	0.35497	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	101	116	chr16	67670520	chr16:67670520	A	G	101	PASS	AN=2;DP=116	GT	0/1
chr16	70714811	70714811	-	GG	intronic	MTSS1L	.	.	.	0.86986055	0.130124337	1.51E-05	.	.	0.1222	-1.548724932	3.273177636	236.86198	3.32283	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	30	chr16	70714811	chr16:70714811	C	CGG	60	PASS	AN=2;DP=30	GT	0/1
chr16	71895793	71895793	C	T	exonic	ZNF821	.	nonsynonymous SNV	ZNF821:NM_017530:exon5:c.G344A:p.R115Q,ZNF821:NM_001201553:exon6:c.G470A:p.R157Q,ZNF821:NM_001201554:exon6:c.G344A:p.R115Q,ZNF821:NM_001318239:exon6:c.G20A:p.R7Q,ZNF821:NM_001201552:exon7:c.G470A:p.R157Q,ZNF821:NM_001318238:exon7:c.G20A:p.R7Q	0.158430833	0.838272719	0.003296448	.	0.16787	0.10783	-0.183570861	39.95046001	15.0966	0.54233	0.003	0.682	D	0.998	0.715	D	0.992	0.790	D	0.000	0.843	D	1	0.810	D	1.04	0.263	L	2.4	0.544	T	-1.28	0.346	N	0.843	0.831	-1.123	0.022	T	0.093	0.353	T	0.065	0.695	D	7.782	0.955	35	1.000	1.000	0.983	0.817	D	c	0.759	0.807	1.000	0.747	0.707	0.730	0	6.08	0.990	7.568	0.814	0.892	0.403	1.000	0.715	1.000	0.888	20.672	0.997	Zinc finger C2H2-type/integrase DNA-binding domain|Zinc finger, C2H2|Zinc finger, C2H2-like	.	.	0.5	.	26	chr16	71895793	chr16:71895793	C	T	.	PASS	AN=0;DP=26	GT	0/1
chr16	86565882	86565882	G	C	exonic	MTHFSD	.	nonsynonymous SNV	MTHFSD:NM_001159377:exon8:c.C887G:p.S296C,MTHFSD:NM_001159378:exon8:c.C887G:p.S296C,MTHFSD:NM_001159379:exon8:c.C884G:p.S295C,MTHFSD:NM_001159380:exon8:c.C827G:p.S276C,MTHFSD:NM_022764:exon8:c.C884G:p.S295C	3.76E-09	0.098530815	0.901469182	.	0.09755	0.09128	1.309952855	94.01981599	2917.56396	10.24622	0.06	0.375	T	0.002	0.090	B	0.002	0.063	B	0.037	0.018	U	1	0.090	P	1.7	0.440	L	2.42	0.192	T	-1.18	0.362	N	0.037	0.025	-0.934	0.436	T	0.000	0.000	T	.	.	.	0.535	0.145	7.696	0.798	0.125	0.326	0.244	N	c	-0.763	-0.750	0.027	0.138	0.646	0.450	0	2.07	0.259	2.850	0.477	0.936	0.528	0.207	0.242	0.045	0.161	8.401	0.316	Nucleotide-binding alpha-beta plait domain	.	.	0.5	61	14	chr16	86565882	chr16:86565882	G	C	61	PASS	AN=2;DP=14	GT	0/1
chr16	87723838	87723838	T	C	exonic	JPH3	.	synonymous SNV	JPH3:NM_020655:exon4:c.T1872C:p.H624H	0.986177997	0.013815541	6.46E-06	DISEASE: Huntington disease-like 2 (HDL2) [MIM:606438]: Huntington disease (HD) is a neurodegenerative disorder resulting primarily from the loss of medium spiny projection neurons in the striatum, especially in the caudate nucleus, and, to a lesser extent, atrophy of mesencephalic and cortical structures. The typical clinical picture of HD combines familial adult onset chorea and subcortical dementia that usually begin during the fourth decade of life. {ECO:0000269|PubMed:11914418, ECO:0000269|PubMed:14557581}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.13441	0.26404	-1.230963997	5.543760321	231.25612	3.28718	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	27	chr16	87723838	chr16:87723838	T	C	54	PASS	AN=2;DP=27	GT	0/1
chr16	88593209	88593211	CCT	-	intronic	ZFPM1	.	.	.	0.031491837	0.959089121	0.009419042	.	0.18944	.	.	.	1660.90603	7.52751	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	9	chr16	88593208	chr16:88593208	CCCT	C	43	PASS	AN=2;DP=9	GT	0/1
chr16	89715671	89715671	T	C	intronic	CHMP1A	.	.	.	0.252036809	0.719472862	0.028490329	DISEASE: Pontocerebellar hypoplasia 8 (PCH8) [MIM:614961]: An autosomal recessive neurodevelopmental disorder characterized by severe psychomotor retardation, abnormal movements, hypotonia, spasticity, and variable visual defects. Brain MRI shows pontocerebellar hypoplasia, decreased cerebral white matter, and a thin corpus callosum. {ECO:0000269|PubMed:23023333}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.08801	.	0.150760231	64.51403633	463.07131	4.4604	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	74	32	chr16	89715671	chr16:89715671	T	C	74	PASS	AN=2;DP=32	GT	0/1
chr16	89715916	89715916	C	G	intronic	CHMP1A	.	.	.	0.252036809	0.719472862	0.028490329	DISEASE: Pontocerebellar hypoplasia 8 (PCH8) [MIM:614961]: An autosomal recessive neurodevelopmental disorder characterized by severe psychomotor retardation, abnormal movements, hypotonia, spasticity, and variable visual defects. Brain MRI shows pontocerebellar hypoplasia, decreased cerebral white matter, and a thin corpus callosum. {ECO:0000269|PubMed:23023333}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.08801	.	0.150760231	64.51403633	463.07131	4.4604	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	14	chr16	89715916	chr16:89715916	C	G	53	PASS	AN=2;DP=14	GT	0/1
chr16	89858417	89858417	C	A	exonic	FANCA	.	synonymous SNV	FANCA:NM_000135:exon13:c.G1143T:p.T381T,FANCA:NM_001286167:exon13:c.G1143T:p.T381T	2.08E-34	0.000122619	0.999877381	DISEASE: Fanconi anemia, complementation group A (FANCA) [MIM:227650]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. {ECO:0000269|PubMed:10094191, ECO:0000269|PubMed:10210316, ECO:0000269|PubMed:10521298, ECO:0000269|PubMed:10807541, ECO:0000269|PubMed:11091222, ECO:0000269|PubMed:17924555, ECO:0000269|PubMed:9371798, ECO:0000269|PubMed:9399890, ECO:0000269|PubMed:9929978}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.23385	0.24341	-0.101294944	45.66525124	1788.01434	7.80511	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	18	chr16	89858417	chr16:89858417	C	A	58	PASS	AN=2;DP=18	GT	0/1
chr17	1953325	1953325	G	A	upstream;downstream	MIR132;MIR212	dist=23;dist=240	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	40	chr17	1953325	chr17:1953325	G	A	.	PASS	AN=0;DP=40	GT	0/1
chr17	3628362	3628362	T	C	exonic	HASPIN	.	nonsynonymous SNV	HASPIN:NM_031965:exon1:c.T1133C:p.V378A	.	.	.	.	.	.	.	.	.	.	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.470	0.049	N	1	0.090	P	-1.24	0.008	N	3.47	0.052	T	0.92	0.016	N	0.006	0.000	-0.977	0.356	T	0.000	0.000	T	.	.	.	-1.165	0.026	0.008	0.764	0.111	0.007	0.029	N	c	-1.314	-1.277	1.000	0.462	0.543	0.218	0	0.989	0.188	-0.138	0.103	-1.107	0.018	0.000	0.063	0.001	0.043	4.249	0.101	.	.	.	0.5	45	9	chr17	3628362	chr17:3628362	T	C	45	PASS	AN=2;DP=9	GT	0/1
chr17	5389505	5389505	C	-	UTR5	DERL2	NM_016041:c.-24delG;NM_001304779:c.-24delG;NM_001304777:c.-24delG	.	.	0.932959932	0.066973865	6.62E-05	.	0.60196	0.13588	-0.141298762	42.87567823	650.6157	5.11656	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	81	29	chr17	5389504	chr17:5389504	AC	A	81	PASS	AN=2;DP=29	GT	0/1
chr17	7578263	7578263	G	A	exonic	TP53	.	stopgain	TP53:NM_001126115:exon2:c.C190T:p.R64X,TP53:NM_001126116:exon2:c.C190T:p.R64X,TP53:NM_001126117:exon2:c.C190T:p.R64X,TP53:NM_001276697:exon2:c.C109T:p.R37X,TP53:NM_001276698:exon2:c.C109T:p.R37X,TP53:NM_001276699:exon2:c.C109T:p.R37X,TP53:NM_001126118:exon5:c.C469T:p.R157X,TP53:NM_000546:exon6:c.C586T:p.R196X,TP53:NM_001126112:exon6:c.C586T:p.R196X,TP53:NM_001126113:exon6:c.C586T:p.R196X,TP53:NM_001126114:exon6:c.C586T:p.R196X,TP53:NM_001276695:exon6:c.C469T:p.R157X,TP53:NM_001276696:exon6:c.C469T:p.R157X,TP53:NM_001276760:exon6:c.C469T:p.R157X,TP53:NM_001276761:exon6:c.C469T:p.R157X	0.912222953	0.087750328	2.67E-05	DISEASE: Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.; DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: Autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor of neuroectodermal origin that generally occurs in childhood, but has also been reported in adults. Although generally found within the ventricular system, choroid plexus papillomas can arise ectopically in the brain parenchyma or disseminate throughout the neuraxis. Patients present with signs and symptoms of increased intracranial pressure including headache, hydrocephalus, papilledema, nausea, vomiting, cranial nerve deficits, gait impairment, and seizures. {ECO:0000269|PubMed:12085209}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant neoplasm of the adrenal cortex and a rare childhood tumor. It occurs with increased frequency in patients with Beckwith- Wiedemann syndrome and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant skin neoplasm that typically appears on hair-bearing skin, most commonly on sun-exposed areas. It is slow growing and rarely metastasizes, but has potentialities for local invasion and destruction. It usually develops as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the area may bleed following minor injury. Tumor size can vary from a few millimeters to several centimeters in diameter. {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.99999	0.9998	-0.247889024	35.98726115	15.3263	0.55115	.	.	.	.	.	.	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.697	0.964	36	0.995	0.682	0.959	0.662	D	c	0.403	0.225	0.406	0.202	0.722	0.854	0	4.44	0.530	2.230	0.424	0.953	0.551	1.000	0.715	0.999	0.750	12.305	0.540	p53, DNA-binding domain|p53-like transcription factor, DNA-binding|p53/RUNT-type transcription factor, DNA-binding domain	.	.	0.5	.	46	chr17	7578263	chr17:7578263	G	A	.	PASS	AN=0;DP=46	GT	0/1
chr17	7804735	7804735	C	-	intronic	CHD3	.	.	.	0.999999996	4.48E-09	1.38E-26	.	0.81281	0.12928	-2.475079584	0.973106865	670.89222	5.17831	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	72	chr17	7804734	chr17:7804734	TC	T	58	PASS	AN=2;DP=72	GT	0/1
chr17	8063659	8063659	A	T	UTR3	VAMP2	NM_001330125:c.*514T>A;NM_014232:c.*514T>A	.	.	0.837117601	0.159707638	0.003174761	.	0.42512	0.11262	-0.053113545	49.38664779	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	33	chr17	8063659	chr17:8063659	A	T	.	PASS	AN=0;DP=33	GT	0/1
chr17	15215660	15215660	T	C	exonic	TEKT3	.	synonymous SNV	TEKT3:NM_031898:exon7:c.A1017G:p.Q339Q	3.20E-14	0.010360828	0.989639172	.	0.04933	0.09715	0.911261639	89.50813871	3686.69181	11.82421	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	11	chr17	15215660	chr17:15215660	T	C	44	PASS	AN=2;DP=11	GT	0/1
chr17	15878110	15878112	CAA	-	exonic	ADORA2B	.	nonframeshift deletion	ADORA2B:NM_000676:exon2:c.453_455del:p.N153del	2.01E-05	0.276665266	0.723314659	.	0.08265	0.18465	0.639420866	83.8995046	449.84282	4.40801	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	45	16	chr17	15878109	chr17:15878109	CCAA	C	45	PASS	AN=2;DP=16	GT	0/1
chr17	18326023	18326023	T	C	ncRNA_exonic	KRT17P5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	29	chr17	18326023	chr17:18326023	T	C	64	PASS	AN=2;DP=29	GT	0/1
chr17	18918505	18918505	G	A	exonic	SLC5A10	.	nonsynonymous SNV	SLC5A10:NM_001270648:exon10:c.G1153A:p.V385M,SLC5A10:NM_001270649:exon10:c.G1126A:p.V376M,SLC5A10:NM_001282417:exon10:c.G1033A:p.V345M,SLC5A10:NM_001042450:exon11:c.G1234A:p.V412M,SLC5A10:NM_152351:exon11:c.G1282A:p.V428M	3.66E-12	0.158427678	0.841572322	.	0.13415	0.12866	-0.817464788	11.97806086	259.29549	3.46053	0.001	0.784	D	1.0	0.899	D	0.991	0.782	D	0.021	0.269	N	1.000	0.588	D	2.92	0.846	M	-2.47	0.895	D	-2.71	0.577	D	0.859	0.846	0.902	0.957	D	0.846	0.949	D	0.279	0.902	D	4.973	0.669	25.1	0.998	0.885	0.973	0.735	D	c	0.583	0.452	1.000	0.747	0.581	0.326	0	4.31	0.505	6.737	0.744	0.951	0.538	1.000	0.715	0.886	0.372	14.027	0.640	.	.	.	0.5	58	86	chr17	18918505	chr17:18918505	G	A	58	PASS	AN=2;DP=86	GT	0/1
chr17	30714694	30714694	A	G	intergenic	ZNF207;PSMD11	dist=17226;dist=56787	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	77	89	chr17	30714694	chr17:30714694	A	G	77	PASS	AN=2;DP=89	GT	0/1
chr17	35297622	35297622	G	A	exonic	LHX1	.	nonsynonymous SNV	LHX1:NM_005568:exon2:c.G206A:p.G69D	0.289265566	0.689648123	0.021086311	.	0.86552	0.33462	0.150760231	64.51403633	193.33354	3.01652	.	.	.	1.0	0.899	D	0.991	0.782	D	0.000	0.843	D	1	0.810	D	1.76	0.459	L	.	.	.	.	.	.	0.933	0.926	0.664	0.927	D	0.760	0.918	D	0.109	0.786	D	6.235	0.861	28.8	0.999	0.939	0.982	0.805	D	c	0.799	0.746	1.000	0.747	0.598	0.340	0	4.05	0.462	10.003	0.997	1.048	0.713	1.000	0.715	1.000	0.888	17.516	0.876	Zinc finger, LIM-type	.	.	0.5	.	49	chr17	35297622	chr17:35297622	G	A	.	PASS	AN=0;DP=49	GT	0/1
chr17	35896123	35896123	T	C	exonic	SYNRG	.	synonymous SNV	SYNRG:NM_001163547:exon17:c.A3006G:p.V1002V,SYNRG:NM_001163544:exon18:c.A3390G:p.V1130V,SYNRG:NM_001163545:exon18:c.A3387G:p.V1129V,SYNRG:NM_001163546:exon18:c.A3255G:p.V1085V,SYNRG:NM_080550:exon18:c.A3390G:p.V1130V,SYNRG:NM_198882:exon18:c.A3390G:p.V1130V,SYNRG:NM_007247:exon19:c.A3624G:p.V1208V	0.972748212	0.027251786	2.37E-09	.	0.05386	0.09802	-0.699966832	14.82071243	2722.3113	9.83401	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	16	chr17	35896123	chr17:35896123	T	C	43	PASS	AN=2;DP=16	GT	0/1
chr17	37366900	37366900	G	-	UTR3	STAC2	NM_001351360:c.*1645delC;NM_198993:c.*1645delC	.	.	1.66E-05	0.871297263	0.128686133	.	0.2536	0.10406	-0.977252525	8.799245105	52.09893	1.4266	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	31	chr17	37366899	chr17:37366899	TG	T	54	PASS	AN=2;DP=31	GT	0/1
chr17	37873563	37873563	C	-	intronic	ERBB2	.	.	.	0.998894657	0.001105343	1.88E-13	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Note=Chromosomal aberrations involving ERBB2 may be a cause gastric cancer. Deletions within 17q12 region producing fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to truncated CDK12 protein not in-frame with ERBB2.; 	0.99949	0.89401	-0.5879134	18.28261382	5901.30986	15.94968	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	56	45	chr17	37873562	chr17:37873562	GC	G	56	PASS	AN=2;DP=45	GT	0/1
chr17	38975328	38975328	G	A	exonic	KRT10	.	nonsynonymous SNV	KRT10:NM_000421:exon7:c.C1459T:p.H487Y	0.020062694	0.976136429	0.003800877	DISEASE: Epidermolytic hyperkeratosis (EHK) [MIM:113800]: An autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop. {ECO:0000269|PubMed:10201536, ECO:0000269|PubMed:1380725, ECO:0000269|PubMed:1381287, ECO:0000269|PubMed:21271994, ECO:0000269|PubMed:7507150, ECO:0000269|PubMed:7507152, ECO:0000269|PubMed:7508181, ECO:0000269|PubMed:7512983, ECO:0000269|Ref.7}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis annular epidermolytic (AEI) [MIM:607602]: A skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months. {ECO:0000269|PubMed:9036939, ECO:0000269|PubMed:9856845}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Erythroderma, ichthyosiform, congenital reticular (CRIE) [MIM:609165]: A rare skin condition characterized by slowly enlarging islands of normal skin surrounded by erythematous ichthyotic patches in a reticulated pattern. The condition starts in infancy as a lamellar ichthyosis, with small islands of normal skin resembling confetti appearing in late childhood and at puberty. Histopathologic findings include band-like parakeratosis, psoriasiform acanthosis, and vacuolization of keratinocytes with binucleated cells in the upper epidermis, sometimes associated with amyloid deposition in the dermis. Ultrastructural abnormalities include perinuclear shells formed from a network of fine filaments in the upper epidermis. {ECO:0000269|PubMed:20798280}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.54103	0.54019	0.220536484	68.38287332	1152.47941	6.46886	0.27	0.160	T	0.0	0.026	B	0.0	0.013	B	0.913	0.074	N	1	0.090	P	-2.005	0.002	N	-2.39	0.884	D	-0.62	0.183	N	0.115	0.126	-0.955	0.402	T	0.000	0.000	T	.	.	.	1.579	0.251	13.74	0.944	0.241	0.012	0.043	N	c	-1.289	-1.313	1.000	0.747	0.623	0.393	0	-1.49	0.082	-0.352	0.077	-0.849	0.029	0.000	0.063	0.000	0.016	2.944	0.054	.	ENSG00000167920.4|ENSG00000186395.6|ENSG00000167920.4|ENSG00000167920.4|ENSG00000167920.4|ENSG00000167920.4|ENSG00000167920.4|ENSG00000167920.4|ENSG00000167920.4|ENSG00000167920.4	Adipose_Subcutaneous|Cells_Transformed_fibroblasts|Cells_Transformed_fibroblasts|Esophagus_Mucosa|Lung|Nerve_Tibial|Pancreas|Pituitary|Stomach|Thyroid	0.5	51	43	chr17	38975328	chr17:38975328	G	A	51	PASS	AN=2;DP=43	GT	0/1
chr17	39411615	39411615	A	G	intronic	KRTAP9-9	.	.	.	0.007298706	0.536562679	0.456138614	.	.	0.10345	.	.	5752.9952	15.75321	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	86	93	chr17	39411615	chr17:39411615	A	G	86	PASS	AN=2;DP=93	GT	0/1
chr17	39633317	39633317	A	G	exonic	KRT35	.	synonymous SNV	KRT35:NM_002280:exon7:c.T1359C:p.G453G	0.017032338	0.960141959	0.022825703	.	0.11567	0.11898	0.604424343	82.90280727	1949.21087	8.12325	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	34	chr17	39633317	chr17:39633317	A	G	54	PASS	AN=2;DP=34	GT	0/1
chr17	39634625	39634625	A	G	exonic	KRT35	.	synonymous SNV	KRT35:NM_002280:exon5:c.T987C:p.A329A	0.017032338	0.960141959	0.022825703	.	0.11567	0.11898	0.604424343	82.90280727	1949.21087	8.12325	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	27	chr17	39634625	chr17:39634625	A	G	64	PASS	AN=2;DP=27	GT	0/1
chr17	40283682	40283682	G	A	UTR5	RAB5C	NM_001252039:c.-47C>T	.	.	0.826569532	0.172639649	0.000790818	.	0.57797	0.12971	0.215080721	67.91696155	28.22907	0.90529	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	21	chr17	40283682	chr17:40283682	G	A	.	PASS	AN=0;DP=21	GT	0/1
chr17	40461067	40461067	A	G	exonic	STAT5A	.	nonsynonymous SNV	STAT5A:NM_001288719:exon16:c.A1975G:p.K659E,STAT5A:NM_001288720:exon16:c.A1972G:p.K658E,STAT5A:NM_001288718:exon17:c.A2065G:p.K689E,STAT5A:NM_003152:exon18:c.A2065G:p.K689E	0.999866029	0.000133971	1.60E-11	.	0.68233	0.58998	-0.644723694	16.52512385	205.21053	3.09506	0.291	0.215	T	0.063	0.219	B	0.023	0.262	B	0.587	0.111	N	1.000	0.588	D	2.645	0.776	M	-3.96	0.962	D	-1.24	0.314	N	0.668	0.678	0.455	0.899	D	0.831	0.944	D	0.084	0.744	D	1.099	0.200	11.21	0.949	0.252	0.991	0.912	D	c	-0.155	-0.073	1.000	0.747	0.672	0.522	0	4.91	0.638	9.161	0.938	1.140	0.893	1.000	0.715	0.212	0.220	14.570	0.677	SH2 domain	.	.	0.5	82	63	chr17	40461067	chr17:40461067	A	G	82	PASS	AN=2;DP=63	GT	0/1
chr17	41362009	41362009	G	A	exonic	NBR1	.	synonymous SNV	NBR1:NM_005899:exon21:c.G2817A:p.L939L,NBR1:NM_031862:exon21:c.G2817A:p.L939L	0.000436707	0.999230855	0.000332438	.	.	.	0.867166666	88.81811748	3800.47731	12.10337	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	29	chr17	41362009	chr17:41362009	G	A	.	PASS	AN=0;DP=29	GT	0/1
chr17	47076450	47076450	T	-	intronic	IGF2BP1	.	.	.	0.998573997	0.001426002	1.03E-09	.	0.92265	0.48799	-0.381986487	27.68931352	33.32025	1.02987	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	49	chr17	47076449	chr17:47076449	AT	A	39	PASS	AN=2;DP=49	GT	0/1
chr17	47210429	47210429	A	G	exonic	B4GALNT2	.	synonymous SNV	B4GALNT2:NM_153446:exon1:c.A42G:p.E14E	9.64E-07	0.768740676	0.23125836	.	0.05778	0.28364	0.802845857	87.69167256	3125.19031	10.63438	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	68	84	chr17	47210429	chr17:47210429	A	G	68	PASS	AN=2;DP=84	GT	0/1
chr17	47241481	47241541	TACCAAGACTTTCCTCCGCCCCCACAAGCTCATGATCATGCTCCGGAGTATTCGAGAGTAT	-	exonic	B4GALNT2	.	frameshift deletion	B4GALNT2:NM_001159387:exon8:c.798_858del:p.K268Qfs*2,B4GALNT2:NM_001159388:exon8:c.720_780del:p.K242Qfs*2,B4GALNT2:NM_153446:exon8:c.978_1038del:p.K328Qfs*2	9.64E-07	0.768740676	0.23125836	.	0.05778	0.28364	0.802845857	87.69167256	3125.19031	10.63438	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	8	chr17	47241480	chr17:47241480	CTACCAAGACTTTCCTCCGCCCCCACAAGCTCATGATCATGCTCCGGAGTATTCGAGAGTAT	C	39	PASS	AN=2;DP=8	GT	0/1
chr17	60757562	60757564	ACG	-	exonic	MRC2	.	nonframeshift deletion	MRC2:NM_006039:exon15:c.2330_2332del:p.D781del	0.985888158	0.014111842	3.87E-12	.	0.68336	0.13319	-1.163005113	6.086341118	972.4639	6.02816	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	46	chr17	60757561	chr17:60757561	CACG	C	44	PASS	AN=2;DP=46	GT	0/1
chr17	60827660	60827660	A	G	intronic	MARCH10	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1.000	0.090	P	.	.	.	.	.	.	.	.	.	0.045	0.025	.	.	.	.	.	.	.	.	.	0.449	0.137	7.030	0.418	0.030	0.002	0.011	N	n	0.337	-0.089	0.040	0.144	0.487	0.133	0	4.37	0.517	1.484	0.349	-0.945	0.024	0.007	0.175	0.000	0.016	7.680	0.275	.	ENSG00000173838.7|ENSG00000265702.1|ENSG00000265702.1	Artery_Tibial|Cells_Transformed_fibroblasts|Testis	0.5	51	24	chr17	60827660	chr17:60827660	A	G	51	PASS	AN=2;DP=24	GT	0/1
chr17	74722899	74722899	C	T	upstream	JMJD6;METTL23	dist=13	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	87	chr17	74722899	chr17:74722899	C	T	59	PASS	AN=2;DP=87	GT	0/1
chr17	77043574	77043574	T	C	intronic	C1QTNF1	.	.	.	7.24E-05	0.504506997	0.495420602	.	0.34557	0.12013	-0.358119787	29.16371786	33.51466	1.03494	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	63	45	chr17	77043574	chr17:77043574	T	C	63	PASS	AN=2;DP=45	GT	0/1
chr17	79916149	79916172	TCCCTGCCCTGCCATCCGGCCCCG	-	intronic	NOTUM	.	.	.	0.0008604	0.984521789	0.014617811	.	0.24251	0.12435	-0.468351206	23.42533616	393.9962	4.17307	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	60	chr17	79916148	chr17:79916148	CTCCCTGCCCTGCCATCCGGCCCCG	C	53	PASS	AN=2;DP=60	GT	0/1
chr18	658064	658064	G	C	exonic	TYMSOS	.	nonsynonymous SNV	TYMSOS:NM_001012716:exon1:c.C184G:p.R62G	.	.	.	.	0.06401	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	63	47	chr18	658064	chr18:658064	G	C	63	PASS	AN=2;DP=47	GT	0/1
chr18	722366	722366	-	G	UTR3	YES1	NM_005433:c.*2057_*2058insC	.	.	0.046391622	0.953390447	0.000217931	.	0.92686	0.51349	-0.203796826	38.81811748	69.86384	1.73424	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	8	chr18	722366	chr18:722366	T	TG	40	PASS	AN=2;DP=8	GT	0/1
chr18	14225787	14225787	C	-	ncRNA_exonic	ANKRD20A5P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	78	124	chr18	14225786	chr18:14225786	GC	G	78	PASS	AN=2;DP=124	GT	0/1
chr18	18531365	18531365	A	-	intronic	ROCK1	.	.	.	0.999996548	3.45E-06	1.48E-19	.	.	0.55483	-0.574945567	18.90186365	77.81309	1.85951	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	35	chr18	18531364	chr18:18531364	GA	G	44	PASS	AN=2;DP=35	GT	0/1
chr18	29480910	29480910	G	A	exonic	TRAPPC8	.	stopgain	TRAPPC8:NM_014939:exon10:c.C1468T:p.Q490X	0.999999744	2.56E-07	1.56E-19	.	0.1499	0.09632	0.721954055	85.86341118	3775.56161	12.03543	.	.	.	.	.	.	.	.	.	0.000	0.537	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.924	0.987	40	0.999	0.931	0.998	0.993	D	c	1.128	1.008	1.000	0.747	0.732	0.924	0	5.5	0.813	9.454	0.968	0.953	0.551	1.000	0.715	1.000	0.888	19.819	0.966	Tetratricopeptide-like helical domain	.	.	0.5	.	38	chr18	29480910	chr18:29480910	G	A	.	PASS	AN=0;DP=38	GT	0/1
chr18	42643480	42643480	A	G	exonic	SETBP1	.	synonymous SNV	SETBP1:NM_015559:exon6:c.A4608G:p.P1536P	0.999002929	0.00099707	4.30E-10	DISEASE: Note=SETBP1 somatic mutations are frequently found in myeloid malignancies. They cause gain of function associated with myeloid leukemic transformation (PubMed:23832012). Myeloid malignancies are separated into three main categories: myeloproliferative neoplasms (MPN) characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, myelodysplastic syndromes (MDS) and MDS/MPN. The MDS/MPN category shows overlapping characteristics of both MDS and MPN and includes chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia (ACML) and unclassified MDS/MPN (PubMed:23628959). {ECO:0000269|PubMed:23628959, ECO:0000269|PubMed:23832012}.; DISEASE: Myelodysplastic syndrome (MDS) [MIM:614286]: A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS); chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. MDS is considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). {ECO:0000269|PubMed:23648668, ECO:0000269|PubMed:23889083}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Mental retardation, autosomal dominant 29 (MRD29) [MIM:616078]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD29 patients manifest severe intellectual disability, behavioral difficulties, speech and motor delays, and dysmorphic facial features. {ECO:0000269|PubMed:25217958}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. {ECO:0000269|PubMed:23648668, ECO:0000269|PubMed:23889083}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Leukemia, chronic myeloid, atypical (ACML) [MIM:608232]: A myeloproliferative disorder that shares clinical and laboratory features with chronic myeloid leukemia but lacks the pathognomonic Philadelphia chromosome and the corresponding BCR/ABL1 fusion transcript. Features include myeloid predominance in the bone marrow, myeloid proliferation and low leukocyte alkaline phosphatase value, splenomegaly, hepatomegaly, elevated white blood cell count. Enlarged spleen may also be associated with a hypermetabolic state, fever, weight loss, and chronic fatigue. The enlarged liver may contribute to the patient's weight loss. {ECO:0000269|PubMed:23222956}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:23832011}. Note=The gene represented in this entry is involved in disease pathogenesis.; 	0.7551	0.29962	-1.118903529	6.611229063	3394.47384	11.15813	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	28	chr18	42643480	chr18:42643480	A	G	61	PASS	AN=2;DP=28	GT	0/1
chr18	44424035	44424035	C	T	exonic	PIAS2	.	synonymous SNV	PIAS2:NM_001324058:exon8:c.G1023A:p.R341R,PIAS2:NM_001324060:exon8:c.G1035A:p.R345R,PIAS2:NM_004671:exon8:c.G1023A:p.R341R,PIAS2:NM_173206:exon8:c.G1023A:p.R341R,PIAS2:NM_001324047:exon9:c.G996A:p.R332R,PIAS2:NM_001324051:exon9:c.G996A:p.R332R,PIAS2:NM_001324054:exon9:c.G996A:p.R332R,PIAS2:NM_001324046:exon10:c.G996A:p.R332R,PIAS2:NM_001324048:exon10:c.G996A:p.R332R,PIAS2:NM_001324055:exon10:c.G996A:p.R332R,PIAS2:NM_001324059:exon10:c.G996A:p.R332R,PIAS2:NM_001324049:exon11:c.G996A:p.R332R,PIAS2:NM_001324052:exon11:c.G996A:p.R332R,PIAS2:NM_001324053:exon11:c.G996A:p.R332R,PIAS2:NM_001324057:exon11:c.G996A:p.R332R	0.997942261	0.002057727	1.24E-08	.	0.98247	0.28737	-0.426079032	25.36565228	52.72409	1.43865	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	47	chr18	44424035	chr18:44424035	C	T	.	PASS	AN=0;DP=47	GT	0/1
chr18	47014912	47014920	GTTTCTTCA	-	exonic	RPL17	.	nonframeshift deletion	RPL17:NM_001199345:exon6:c.410_418del:p.L137_K139del,RPL17:NM_000985:exon7:c.524_532del:p.L175_K177del,RPL17:NM_001035006:exon7:c.524_532del:p.L175_K177del,RPL17:NM_001199341:exon7:c.524_532del:p.L175_K177del,RPL17:NM_001199344:exon7:c.524_532del:p.L175_K177del,RPL17:NM_001199340:exon8:c.524_532del:p.L175_K177del,RPL17:NM_001199342:exon8:c.524_532del:p.L175_K177del,RPL17:NM_001199343:exon8:c.524_532del:p.L175_K177del	0.494059426	0.501442148	0.004498425	.	0.33905	0.0819	-0.09720619	46.20193442	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	14	chr18	47014911	chr18:47014911	TGTTTCTTCA	T	41	PASS	AN=2;DP=14	GT	0/1
chr18	56204489	56204489	C	G	exonic	ALPK2	.	nonsynonymous SNV	ALPK2:NM_052947:exon5:c.G2930C:p.S977T	3.56E-13	0.89022526	0.10977474	.	0.03572	0.07481	4.926038688	99.79948101	17557.68576	27.86174	0.03	0.453	D	0.013	0.163	B	0.021	0.181	B	0.004	0.010	N	1	0.090	P	1.795	0.474	L	0.74	0.505	T	-1.32	0.330	N	0.029	0.010	-1.084	0.066	T	0.002	0.006	T	.	.	.	2.119	0.316	16.98	0.901	0.188	0.039	0.092	N	c	-0.903	-0.946	1.000	0.747	0.628	0.401	0	0.184	0.143	-0.352	0.077	-0.384	0.065	0.000	0.063	0.000	0.016	2.033	0.033	.	.	.	0.5	60	51	chr18	56204489	chr18:56204489	C	G	60	PASS	AN=2;DP=51	GT	0/1
chr18	59878413	59878413	A	G	exonic	KIAA1468	.	nonsynonymous SNV	KIAA1468:NM_001346229:exon2:c.A554G:p.D185G,KIAA1468:NM_001346230:exon2:c.A554G:p.D185G,KIAA1468:NM_001346231:exon2:c.A554G:p.D185G,KIAA1468:NM_001346232:exon2:c.A554G:p.D185G,KIAA1468:NM_001346233:exon2:c.A554G:p.D185G,KIAA1468:NM_001346234:exon2:c.A554G:p.D185G,KIAA1468:NM_020854:exon2:c.A554G:p.D185G	0.99999956	4.40E-07	2.89E-18	.	0.18204	0.12098	-1.285933373	5.083746167	74.67048	1.80768	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.843	D	1	0.810	D	2.41	0.699	M	0.86	0.468	T	-5.46	0.855	D	0.91	0.900	-0.408	0.718	T	0.316	0.686	T	0.148	0.831	D	6.326	0.874	29.3	0.999	0.940	0.987	0.851	D	c	0.778	0.744	1.000	0.747	0.706	0.609	0	5.21	0.719	8.718	0.911	1.199	0.960	1.000	0.715	0.999	0.750	15.078	0.716	.	.	.	0.5	.	40	chr18	59878413	chr18:59878413	A	G	.	PASS	AN=0;DP=40	GT	0/1
chr18	60015409	60015409	G	A	exonic	TNFRSF11A	.	synonymous SNV	TNFRSF11A:NM_001270949:exon2:c.G84A:p.L28L,TNFRSF11A:NM_001270950:exon2:c.G84A:p.L28L,TNFRSF11A:NM_001270951:exon2:c.G84A:p.L28L,TNFRSF11A:NM_001278268:exon2:c.G84A:p.L28L,TNFRSF11A:NM_003839:exon2:c.G84A:p.L28L	0.879917354	0.120022306	6.03E-05	DISEASE: Paget disease of bone 2, early-onset (PDB2) [MIM:602080]: A form of Paget disease, a disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone. {ECO:0000269|PubMed:10615125}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Osteopetrosis, autosomal recessive 7 (OPTB7) [MIM:612301]: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia. {ECO:0000269|PubMed:18606301}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.0838	.	0.665103516	84.6131163	577.42674	4.87253	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	42	chr18	60015409	chr18:60015409	G	A	.	PASS	AN=0;DP=42	GT	0/1
chr18	60017126	60017126	G	A	exonic	TNFRSF11A	.	stopgain	TNFRSF11A:NM_001270949:exon3:c.G239A:p.W80X,TNFRSF11A:NM_001270950:exon3:c.G239A:p.W80X,TNFRSF11A:NM_001270951:exon3:c.G239A:p.W80X,TNFRSF11A:NM_001278268:exon3:c.G239A:p.W80X,TNFRSF11A:NM_003839:exon3:c.G239A:p.W80X	0.879917354	0.120022306	6.03E-05	DISEASE: Paget disease of bone 2, early-onset (PDB2) [MIM:602080]: A form of Paget disease, a disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone. {ECO:0000269|PubMed:10615125}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Osteopetrosis, autosomal recessive 7 (OPTB7) [MIM:612301]: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia. {ECO:0000269|PubMed:18606301}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.0838	.	0.665103516	84.6131163	577.42674	4.87253	.	.	.	.	.	.	.	.	.	0.000	0.481	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.200	0.973	37	0.995	0.693	0.935	0.580	D	c	1.079	0.924	1.000	0.747	0.706	0.609	0	5.33	0.756	6.345	0.728	0.953	0.551	1.000	0.715	0.999	0.750	16.290	0.825	TNFR/NGFR cysteine-rich region	.	.	0.5	50	41	chr18	60017126	chr18:60017126	G	A	50	PASS	AN=2;DP=41	GT	0/1
chr18	74637067	74637067	T	C	intronic	ZNF236	.	.	.	0.999998364	1.64E-06	5.86E-19	.	0.17316	0.10239	-1.532514394	3.349846662	617.34905	5.01532	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	15	chr18	74637067	chr18:74637067	T	C	44	PASS	AN=2;DP=15	GT	0/1
chr19	464129	464129	C	G	exonic	ODF3L2	.	synonymous SNV	ODF3L2:NM_182577:exon4:c.G585C:p.P195P	0.003142588	0.596423811	0.400433601	.	0.10249	0.1069	.	.	1099.14153	6.3446	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	45	20	chr19	464129	chr19:464129	C	G	45	PASS	AN=2;DP=20	GT	0/1
chr19	811918	811920	CTC	-	UTR3	PTBP1	NM_031990:c.*1092_*1094delCTC;NM_031991:c.*1092_*1094delCTC;NM_002819:c.*1092_*1094delCTC	.	.	0.9987392	0.001260782	1.86E-08	.	0.88766	0.24759	-1.217968826	5.638122199	29.53361	0.94402	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	27	chr19	811917	chr19:811917	GCTC	G	44	PASS	AN=2;DP=27	GT	0/1
chr19	811931	811933	CTC	-	UTR3	PTBP1	NM_031990:c.*1105_*1107delCTC;NM_031991:c.*1105_*1107delCTC;NM_002819:c.*1105_*1107delCTC	.	.	0.9987392	0.001260782	1.86E-08	.	0.88766	0.24759	-1.217968826	5.638122199	29.53361	0.94402	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	25	chr19	811930	chr19:811930	TCTC	T	39	PASS	AN=2;DP=25	GT	0/1
chr19	900809	900809	C	T	intronic	R3HDM4	.	.	.	0.019345311	0.900324136	0.080330553	.	0.14605	0.10939	0.262810045	70.43524416	922.19623	5.89756	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	104	chr19	900809	chr19:900809	C	T	.	PASS	AN=0;DP=104	GT	0/1
chr19	984533	984533	T	C	exonic	WDR18	.	synonymous SNV	WDR18:NM_024100:exon1:c.T180C:p.N60N	0.90160756	0.09821575	0.00017669	.	0.10939	0.1084	-0.001743238	53.85114414	2052.48581	8.34958	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	24	chr19	984533	chr19:984533	T	C	55	PASS	AN=2;DP=24	GT	0/1
chr19	984554	984554	C	G	exonic	WDR18	.	synonymous SNV	WDR18:NM_024100:exon1:c.C201G:p.L67L	0.90160756	0.09821575	0.00017669	.	0.10939	0.1084	-0.001743238	53.85114414	2052.48581	8.34958	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	11	chr19	984554	chr19:984554	C	G	41	PASS	AN=2;DP=11	GT	0/1
chr19	1036468	1036468	A	G	exonic	CNN2	.	synonymous SNV	CNN2:NM_201277:exon5:c.A444G:p.R148R,CNN2:NM_001303499:exon6:c.A528G:p.R176R,CNN2:NM_001303501:exon6:c.A624G:p.R208R,CNN2:NM_004368:exon6:c.A561G:p.R187R	0.212309401	0.778747265	0.008943334	.	0.15623	0.1447	-0.780646273	12.77423921	27.26201	0.87829	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	49	chr19	1036468	chr19:1036468	A	G	54	PASS	AN=2;DP=49	GT	0/1
chr19	1041352	1041352	A	G	UTR5	ABCA7	NM_019112:c.-9A>G	.	.	1.89E-36	0.000203957	0.999796043	.	0.05554	0.15483	-2.151227095	1.462609106	5319.06822	15.08136	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	50	chr19	1041352	chr19:1041352	A	G	53	PASS	AN=2;DP=50	GT	0/1
chr19	1496263	1496263	A	G	intronic	REEP6	.	.	.	0.000463082	0.66517966	0.334357258	.	0.06456	0.03846	-0.427900189	25.14744043	125.42377	2.43777	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	29	chr19	1496263	chr19:1496263	A	G	55	PASS	AN=2;DP=29	GT	0/1
chr19	1611803	1611803	T	C	exonic	TCF3	.	nonsynonymous SNV	TCF3:NM_001136139:exon18:c.A1859G:p.E620G,TCF3:NM_003200:exon19:c.A1868G:p.E623G	0.185647144	0.813858528	0.000494328	DISEASE: Note=Chromosomal aberrations involving TCF3 are cause of forms of pre-B-cell acute lymphoblastic leukemia (B-ALL). Translocation t(1;19)(q23;p13.3) with PBX1. TCF3-PBX1 transforms cells by constitutively activating transcription of genes regulated by PBX1 or by other members of the PBX protein family (PubMed:1967983, PubMed:1671560). Translocation t(17;19)(q22;p13.3) with HLF (PubMed:1386162). Inversion inv(19)(p13;q13) with TFPT (PubMed:10086727). {ECO:0000269|PubMed:10086727, ECO:0000269|PubMed:1386162, ECO:0000269|PubMed:1671560, ECO:0000269|PubMed:1967983}.; 	0.8525	0.49369	-0.075375604	47.26350554	1035.94021	6.18027	0.0	0.912	D	1.0	0.899	D	0.999	0.916	D	0.000	0.843	D	1	0.810	D	2.72	0.798	M	1.75	0.571	T	-6.23	0.905	D	0.631	0.794	-0.251	0.763	T	0.351	0.715	T	0.112	0.791	D	5.419	0.735	26.0	0.999	0.976	0.963	0.681	D	c	0.626	0.524	1.000	0.517	0.707	0.730	0	4.69	0.584	7.862	0.853	0.888	0.391	1.000	0.715	0.699	0.309	13.637	0.615	.	.	.	0.5	81	134	chr19	1611803	chr19:1611803	T	C	81	PASS	AN=2;DP=134	GT	0/1
chr19	1827080	1827080	G	A	exonic	REXO1	.	nonsynonymous SNV	REXO1:NM_020695:exon2:c.C1708T:p.L570F	0.567927564	0.432051209	2.12E-05	.	0.22306	0.10566	-1.357871407	4.535267752	6405.25153	16.73276	0.01	0.564	D	0.995	0.657	D	0.854	0.591	P	0.994	0.080	N	1	0.090	N	2.125	0.592	M	1.7	0.269	T	-1.59	0.383	N	0.197	0.241	-1.038	0.181	T	0.083	0.327	T	0.044	0.614	D	4.867	0.654	24.9	0.997	0.833	0.439	0.270	N	c	0.274	0.246	1.000	0.747	0.646	0.450	0	3.93	0.445	1.853	0.388	0.877	0.384	0.884	0.308	0.907	0.385	6.698	0.223	.	.	.	0.5	.	23	chr19	1827080	chr19:1827080	G	A	.	PASS	AN=0;DP=23	GT	0/1
chr19	2344338	2344338	C	G	intronic	SPPL2B	.	.	.	.	.	.	.	0.13874	0.12165	-0.135838822	43.77211607	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	76	127	chr19	2344338	chr19:2344338	C	G	76	PASS	AN=2;DP=127	GT	0/1
chr19	2939331	2939331	C	T	exonic	ZNF77	.	synonymous SNV	ZNF77:NM_021217:exon2:c.G78A:p.R26R	4.31E-13	0.012914198	0.987085802	.	0.1856	0.18198	1.537740199	95.57088936	321.29502	3.807	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	59	chr19	2939331	chr19:2939331	C	T	.	PASS	AN=0;DP=59	GT	0/1
chr19	6731560	6731560	C	A	intronic	GPR108	.	.	.	1.69E-08	0.840489879	0.159510104	.	0.1498	0.10366	0.268267497	70.64166077	318.67096	3.79102	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	65	chr19	6731560	chr19:6731560	C	A	.	PASS	AN=0;DP=65	GT	0/1
chr19	7912579	7912579	G	A	intronic	EVI5L	.	.	.	0.989107013	0.01089284	1.48E-07	.	0.53412	0.10843	-0.824740496	11.67728238	14.85019	0.53429	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chr19	7912579	chr19:7912579	G	A	.	PASS	AN=0;DP=44	GT	0/1
chr19	8027207	8027207	C	A	UTR3	ELAVL1	NM_001419:c.*1160G>T	.	.	0.959986604	0.039924327	8.91E-05	.	0.41503	0.49283	-0.317668748	31.45789101	12.81067	0.46627	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	55	chr19	8027207	chr19:8027207	C	A	70	PASS	AN=2;DP=55	GT	0/1
chr19	10078107	10078107	C	G	intronic	COL5A3	.	.	.	7.12E-07	0.999999288	2.65E-11	.	0.45391	.	0.135796279	63.57631517	15615.64674	27.11541	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	55	chr19	10078107	chr19:10078107	C	G	53	PASS	AN=2;DP=55	GT	0/1
chr19	10662733	10662734	TG	-	exonic	ATG4D	.	frameshift deletion	ATG4D:NM_001281504:exon8:c.869_870del:p.Y291Pfs*51,ATG4D:NM_032885:exon8:c.1058_1059del:p.Y354Pfs*51	0.000323904	0.945773923	0.053902174	.	0.15091	0.10598	-0.578583623	18.71903751	85.56652	1.97238	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	82	237	chr19	10662732	chr19:10662732	CTG	C	82	PASS	AN=2;DP=237	GT	0/1
chr19	11234008	11234008	A	G	exonic	LDLR	.	nonsynonymous SNV	LDLR:NM_001195800:exon13:c.A1795G:p.M599V,LDLR:NM_001195803:exon13:c.A1765G:p.M589V,LDLR:NM_001195799:exon14:c.A2176G:p.M726V,LDLR:NM_000527:exon15:c.A2299G:p.M767V,LDLR:NM_001195798:exon15:c.A2299G:p.M767V	2.59E-16	0.058594457	0.941405543	DISEASE: Familial hypercholesterolemia (FH) [MIM:143890]: Common autosomal semi-dominant disease that affects about 1 in 500 individuals. The receptor defect impairs the catabolism of LDL, and the resultant elevation in plasma LDL-cholesterol promotes deposition of cholesterol in the skin (xanthelasma), tendons (xanthomas), and coronary arteries (atherosclerosis). {ECO:0000269|PubMed:10090484, ECO:0000269|PubMed:10206683, ECO:0000269|PubMed:10422803, ECO:0000269|PubMed:10447263, ECO:0000269|PubMed:10532689, ECO:0000269|PubMed:10660340, ECO:0000269|PubMed:10882754, ECO:0000269|PubMed:10978268, ECO:0000269|PubMed:10980548, ECO:0000269|PubMed:11298688, ECO:0000269|PubMed:11462246, ECO:0000269|PubMed:1446662, ECO:0000269|PubMed:1464748, ECO:0000269|PubMed:17142622, ECO:0000269|PubMed:17347910, ECO:0000269|PubMed:1867200, ECO:0000269|PubMed:19318025, ECO:0000269|PubMed:19319977, ECO:0000269|PubMed:22160468, ECO:0000269|PubMed:2318961, ECO:0000269|PubMed:24529145, ECO:0000269|PubMed:2569482, ECO:0000269|PubMed:2726768, ECO:0000269|PubMed:3263645, ECO:0000269|PubMed:3955657, ECO:0000269|PubMed:7550239, ECO:0000269|PubMed:7573037, ECO:0000269|PubMed:7583548, ECO:0000269|PubMed:7635461, ECO:0000269|PubMed:7635482, ECO:0000269|PubMed:7649546, ECO:0000269|PubMed:7649549, ECO:0000269|PubMed:8168830, ECO:0000269|PubMed:8347689, ECO:0000269|PubMed:8462973, ECO:0000269|PubMed:8664907, ECO:0000269|PubMed:8740918, ECO:0000269|PubMed:9026534, ECO:0000269|PubMed:9104431, ECO:0000269|PubMed:9143924, ECO:0000269|PubMed:9254862, ECO:0000269|PubMed:9259195, ECO:0000269|PubMed:9452094, ECO:0000269|PubMed:9452095, ECO:0000269|PubMed:9452118, ECO:0000269|PubMed:9654205, ECO:0000269|PubMed:9678702, ECO:0000269|PubMed:9852677, ECO:0000269|Ref.70}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.42568	0.94311	-1.853858183	2.028780373	654.09994	5.13173	0.982	0.132	T	0.0	0.026	B	0.0	0.013	B	0.090	0.024	N	1	0.090	N	1.055	0.270	L	-2.49	0.894	D	-0.17	0.096	N	0.176	0.469	-0.493	0.689	T	0.455	0.788	T	0.407	0.935	D	-1.779	0.011	0.002	0.334	0.020	0.146	0.183	N	c	-1.541	-1.601	0.431	0.204	0.672	0.522	0	-3.53	0.043	-0.261	0.086	-0.698	0.038	0.000	0.063	0.001	0.043	8.513	0.322	Six-bladed beta-propeller, TolB-like	.	.	0.5	97	125	chr19	11234008	chr19:11234008	A	G	97	PASS	AN=2;DP=125	GT	0/1
chr19	11363664	11363664	A	G	intronic	DOCK6	.	.	.	2.83E-19	0.984497718	0.015502282	DISEASE: Adams-Oliver syndrome 2 (AOS2) [MIM:614219]: A disorder characterized by the congenital absence of skin (aplasia cutis congenita) in combination with transverse limb defects. Aplasia cutis congenita can be located anywhere on the body, but in the vast majority of the cases, it is present on the posterior parietal region where it is often associated with an underlying defect of the parietal bones. Limb abnormalities are typically limb truncation defects affecting the distal phalanges or entire digits (true ectrodactyly). Only rarely, metatarsals/metacarpals or more proximal limb structures are also affected. Apart from transverse limb defects, syndactyly, most commonly of second and third toes, can also be observed. The clinical features are highly variable and can also include cardiovascular malformations, brain abnormalities and vascular defects such as cutis marmorata and dilated scalp veins. {ECO:0000269|PubMed:21820096}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.15719	0.10035	-0.941152229	9.418494928	1944.2298	8.11461	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	25	chr19	11363664	chr19:11363664	A	G	61	PASS	AN=2;DP=25	GT	0/1
chr19	12639557	12639557	G	A	intronic	ZNF564	.	.	.	8.59E-05	0.929602645	0.070311445	.	0.18832	.	-0.47017169	23.25430526	61.90992	1.60412	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	35	chr19	12639557	chr19:12639557	G	A	.	PASS	AN=0;DP=35	GT	0/1
chr19	14952262	14952262	A	C	exonic	OR7A10	.	nonsynonymous SNV	OR7A10:NM_001005190:exon1:c.T428G:p.L143R	0.007992982	0.555798032	0.436208986	.	0.06006	.	1.241986644	93.38877094	2606.77431	9.55666	0.002	0.721	D	0.985	0.592	D	0.937	0.655	D	0.008	0.311	U	1	0.090	N	1.885	0.502	L	8.62	0.002	T	-4.62	0.791	D	0.459	0.511	-0.890	0.490	T	0.001	0.003	T	0.001	0.003	T	2.801	0.398	21.4	0.993	0.576	0.044	0.098	N	c	-0.424	-0.705	0.000	0.029	0.487	0.133	0	0.373	0.153	-1.952	0.016	-0.001	0.135	0.000	0.063	0.006	0.095	6.265	0.200	GPCR, rhodopsin-like, 7TM	.	.	0.5	.	39	chr19	14952262	chr19:14952262	A	C	.	PASS	AN=0;DP=39	GT	0/1
chr19	15376233	15376233	G	A	exonic	BRD4	.	nonsynonymous SNV	BRD4:NM_001330384:exon5:c.C781T:p.P261S,BRD4:NM_014299:exon5:c.C781T:p.P261S,BRD4:NM_058243:exon5:c.C781T:p.P261S	0.999993446	6.55E-06	1.03E-14	DISEASE: Note=A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUT which produces a BRD4-NUT fusion protein. {ECO:0000269|PubMed:11733348, ECO:0000269|PubMed:12543779}.; 	0.42814	0.18694	-1.480759435	3.686010852	185.92351	2.96128	0.116	0.284	T	0.19	0.397	B	0.081	0.314	B	0.002	0.374	N	0.994	0.420	D	1.79	0.469	L	1.4	0.336	T	-1.95	0.456	N	0.473	0.523	-1.093	0.051	T	0.059	0.248	T	0.013	0.317	T	0.809	0.171	9.517	0.998	0.904	0.952	0.635	D	c	-0.333	-0.292	1.000	0.454	0.672	0.522	0	3.54	0.395	4.223	0.581	1.048	0.713	1.000	0.715	0.516	0.274	11.923	0.519	.	.	.	0.5	.	22	chr19	15376233	chr19:15376233	G	A	.	PASS	AN=0;DP=22	GT	0/1
chr19	15511150	15511150	C	T	exonic	AKAP8L	.	nonsynonymous SNV	AKAP8L:NM_001291478:exon8:c.G821A:p.G274E,AKAP8L:NM_014371:exon8:c.G1004A:p.G335E	0.542386261	0.457587658	2.61E-05	.	0.09475	.	-0.336073593	30.55555556	45.99788	1.30586	0.256	0.168	T	0.917	0.488	P	0.446	0.481	B	0.283	0.149	N	0.999	0.220	N	1.5	0.380	L	0.93	0.441	T	-1.71	0.406	N	0.419	0.476	-1.073	0.088	T	0.058	0.244	T	0.007	0.173	T	2.544	0.367	19.75	0.990	0.487	0.945	0.611	D	c	-0.044	0.057	0.779	0.238	0.707	0.730	0	3.48	0.388	2.702	0.465	0.935	0.490	0.972	0.342	1.000	0.888	9.941	0.406	.	.	.	0.5	.	68	chr19	15511150	chr19:15511150	C	T	.	PASS	AN=0;DP=68	GT	0/1
chr19	15543290	15543290	C	T	UTR5	WIZ	NM_001330395:c.-1320G>A	.	.	0.998940437	0.00105955	1.22E-08	.	0.34714	.	-0.799052816	12.45576787	321.62309	3.8086	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	16	chr19	15543290	chr19:15543290	C	T	.	PASS	AN=0;DP=16	GT	0/1
chr19	17370190	17370190	T	G	exonic	USHBP1	.	synonymous SNV	USHBP1:NM_001297703:exon6:c.A762C:p.L254L,USHBP1:NM_001321417:exon7:c.A954C:p.L318L,USHBP1:NM_031941:exon7:c.A954C:p.L318L	3.28E-13	0.259438278	0.740561722	.	0.05039	0.10302	-0.391302095	27.06416608	2829.1436	10.03299	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	11	chr19	17370190	chr19:17370190	T	G	43	PASS	AN=2;DP=11	GT	0/1
chr19	17395055	17395055	C	G	exonic	ANKLE1	.	synonymous SNV	ANKLE1:NM_001278443:exon6:c.C1407G:p.T469T,ANKLE1:NM_001278444:exon6:c.C1440G:p.T480T,ANKLE1:NM_001278445:exon6:c.C1344G:p.T448T,ANKLE1:NM_152363:exon6:c.C1518G:p.T506T	8.12E-14	0.004843148	0.995156852	.	0.06468	0.09439	2.804006769	99.0504836	7647.36009	18.79705	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	43	chr19	17395055	chr19:17395055	C	G	65	PASS	AN=2;DP=43	GT	0/1
chr19	17531872	17531933	TCCTCTTCTGGGCCCACAACCCTAGTGCAGCCCTCCCAGCCCCACCTGAACTTTCCCACCCT	-	intronic	MVB12A	.	.	.	0.000679169	0.914542667	0.084778163	.	0.09158	.	0.350995466	74.37485256	188.19304	2.97888	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	57	chr19	17531871	chr19:17531871	CTCCTCTTCTGGGCCCACAACCCTAGTGCAGCCCTCCCAGCCCCACCTGAACTTTCCCACCCT	C	43	PASS	AN=2;DP=57	GT	0/1
chr19	38164602	38164602	C	G	intronic	ZNF781	.	.	.	7.22E-06	0.160947174	0.839045605	.	0.19433	.	0.084621747	60.31493277	330.24448	3.86285	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	15	chr19	38164602	chr19:38164602	C	G	52	PASS	AN=2;DP=15	GT	0/1
chr19	38385614	38385616	GGA	-	exonic	WDR87	.	nonframeshift deletion	WDR87:NM_001291088:exon4:c.727_729del:p.S243del,WDR87:NM_031951:exon4:c.610_612del:p.S204del	.	.	.	.	0.06224	.	4.142836195	99.6933239	2359.54264	9.01627	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	16	chr19	38385613	chr19:38385613	TGGA	T	53	PASS	AN=2;DP=16	GT	0/1
chr19	39019153	39019153	A	G	intronic	RYR1	.	.	.	1.61E-07	0.999999839	2.45E-26	DISEASE: Malignant hyperthermia 1 (MHS1) [MIM:145600]: Autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the 'in vitro' contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively). {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10484775, ECO:0000269|PubMed:10612851, ECO:0000269|PubMed:10823104, ECO:0000269|PubMed:10888602, ECO:0000269|PubMed:11241852, ECO:0000269|PubMed:11389482, ECO:0000269|PubMed:11525881, ECO:0000269|PubMed:11575529, ECO:0000269|PubMed:11928716, ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12066726, ECO:0000269|PubMed:12123492, ECO:0000269|PubMed:12208234, ECO:0000269|PubMed:12411788, ECO:0000269|PubMed:12709367, ECO:0000269|PubMed:12883402, ECO:0000269|PubMed:1354642, ECO:0000269|PubMed:14732627, ECO:0000269|PubMed:14985404, ECO:0000269|PubMed:15221887, ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:1774074, ECO:0000269|PubMed:19191329, ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:20681998, ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24013571, ECO:0000269|PubMed:7751854, ECO:0000269|PubMed:7849712, ECO:0000269|PubMed:7881417, ECO:0000269|PubMed:8012359, ECO:0000269|PubMed:9066328, ECO:0000269|PubMed:9138151, ECO:0000269|PubMed:9389851, ECO:0000269|PubMed:9450902, ECO:0000269|PubMed:9497245}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Central core disease of muscle (CCD) [MIM:117000]: Autosomal dominant congenital myopathy, but a severe autosomal recessive form also exists. Both clinical and histological variability is observed. Affected individuals typically display hypotonia and proximal muscle weakness in infancy, leading to the delay of motor milestones. The clinical course of the disorder is usually slow or nonprogressive in adulthood, and the severity of the symptoms may vary from normal to significant muscle weakness. Microscopic examination of CCD-affected skeletal muscle reveals a predominance of type I fibers containing amorphous-looking areas (cores) that do not stain with oxidative and phosphorylase histochemical techniques. {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10097181, ECO:0000269|PubMed:11113224, ECO:0000269|PubMed:11709545, ECO:0000269|PubMed:11741831, ECO:0000269|PubMed:12112081, ECO:0000269|PubMed:12136074, ECO:0000269|PubMed:12565913, ECO:0000269|PubMed:12566385, ECO:0000269|PubMed:12937085, ECO:0000269|PubMed:14670767, ECO:0000269|PubMed:14985404, ECO:0000269|PubMed:17204054, ECO:0000269|PubMed:17226826, ECO:0000269|PubMed:18253926, ECO:0000269|PubMed:18312400, ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:21674524, ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24561095, ECO:0000269|PubMed:7829078, ECO:0000269|PubMed:8220422, ECO:0000269|PubMed:8220423, ECO:0000269|PubMed:9497245}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Multiminicore disease with external ophthalmoplegia (MMDO) [MIM:255320]: Clinically heterogeneous neuromuscular disorder. General features include neonatal hypotonia, delayed motor development, and generalized muscle weakness and amyotrophy, which may progress slowly or remain stable. Muscle biopsy shows multiple, poorly circumscribed, short areas of sarcomere disorganization and mitochondria depletion (areas termed minicores) in most muscle fibers. Typically, no dystrophic signs, such as muscle fiber necrosis or regeneration or significant endomysial fibrosis, are present in multiminicore disease. {ECO:0000269|PubMed:12719381, ECO:0000269|PubMed:16380615}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, congenital, with fiber-type disproportion (CFTD) [MIM:255310]: A genetically heterogeneous disorder in which there is relative hypotrophy of type 1 muscle fibers compared to type 2 fibers on skeletal muscle biopsy. However, these findings are not specific and can be found in many different myopathic and neuropathic conditions. {ECO:0000269|PubMed:20583297}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in RYR1 may be a cause of Samaritan myopathy, a congenital myopathy with benign course. Patients display severe hypotonia and respiratory distress at birth. Unlike other congenital myopathies, the health status constantly improves and patients are minimally affected at adulthood.; 	0.22212	.	-8.291678111	0.005897617	2142.38985	8.51518	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	77	40	chr19	39019153	chr19:39019153	A	G	77	PASS	AN=2;DP=40	GT	0/1
chr19	39025341	39025341	T	G	intronic	RYR1	.	.	.	1.61E-07	0.999999839	2.45E-26	DISEASE: Malignant hyperthermia 1 (MHS1) [MIM:145600]: Autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the 'in vitro' contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively). {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10484775, ECO:0000269|PubMed:10612851, ECO:0000269|PubMed:10823104, ECO:0000269|PubMed:10888602, ECO:0000269|PubMed:11241852, ECO:0000269|PubMed:11389482, ECO:0000269|PubMed:11525881, ECO:0000269|PubMed:11575529, ECO:0000269|PubMed:11928716, ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12066726, ECO:0000269|PubMed:12123492, ECO:0000269|PubMed:12208234, ECO:0000269|PubMed:12411788, ECO:0000269|PubMed:12709367, ECO:0000269|PubMed:12883402, ECO:0000269|PubMed:1354642, ECO:0000269|PubMed:14732627, ECO:0000269|PubMed:14985404, ECO:0000269|PubMed:15221887, ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:1774074, ECO:0000269|PubMed:19191329, ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:20681998, ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24013571, ECO:0000269|PubMed:7751854, ECO:0000269|PubMed:7849712, ECO:0000269|PubMed:7881417, ECO:0000269|PubMed:8012359, ECO:0000269|PubMed:9066328, ECO:0000269|PubMed:9138151, ECO:0000269|PubMed:9389851, ECO:0000269|PubMed:9450902, ECO:0000269|PubMed:9497245}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Central core disease of muscle (CCD) [MIM:117000]: Autosomal dominant congenital myopathy, but a severe autosomal recessive form also exists. Both clinical and histological variability is observed. Affected individuals typically display hypotonia and proximal muscle weakness in infancy, leading to the delay of motor milestones. The clinical course of the disorder is usually slow or nonprogressive in adulthood, and the severity of the symptoms may vary from normal to significant muscle weakness. Microscopic examination of CCD-affected skeletal muscle reveals a predominance of type I fibers containing amorphous-looking areas (cores) that do not stain with oxidative and phosphorylase histochemical techniques. {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10097181, ECO:0000269|PubMed:11113224, ECO:0000269|PubMed:11709545, ECO:0000269|PubMed:11741831, ECO:0000269|PubMed:12112081, ECO:0000269|PubMed:12136074, ECO:0000269|PubMed:12565913, ECO:0000269|PubMed:12566385, ECO:0000269|PubMed:12937085, ECO:0000269|PubMed:14670767, ECO:0000269|PubMed:14985404, ECO:0000269|PubMed:17204054, ECO:0000269|PubMed:17226826, ECO:0000269|PubMed:18253926, ECO:0000269|PubMed:18312400, ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:21674524, ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24561095, ECO:0000269|PubMed:7829078, ECO:0000269|PubMed:8220422, ECO:0000269|PubMed:8220423, ECO:0000269|PubMed:9497245}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Multiminicore disease with external ophthalmoplegia (MMDO) [MIM:255320]: Clinically heterogeneous neuromuscular disorder. General features include neonatal hypotonia, delayed motor development, and generalized muscle weakness and amyotrophy, which may progress slowly or remain stable. Muscle biopsy shows multiple, poorly circumscribed, short areas of sarcomere disorganization and mitochondria depletion (areas termed minicores) in most muscle fibers. Typically, no dystrophic signs, such as muscle fiber necrosis or regeneration or significant endomysial fibrosis, are present in multiminicore disease. {ECO:0000269|PubMed:12719381, ECO:0000269|PubMed:16380615}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, congenital, with fiber-type disproportion (CFTD) [MIM:255310]: A genetically heterogeneous disorder in which there is relative hypotrophy of type 1 muscle fibers compared to type 2 fibers on skeletal muscle biopsy. However, these findings are not specific and can be found in many different myopathic and neuropathic conditions. {ECO:0000269|PubMed:20583297}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in RYR1 may be a cause of Samaritan myopathy, a congenital myopathy with benign course. Patients display severe hypotonia and respiratory distress at birth. Unlike other congenital myopathies, the health status constantly improves and patients are minimally affected at adulthood.; 	0.22212	.	-8.291678111	0.005897617	2142.38985	8.51518	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	16	chr19	39025341	chr19:39025341	T	G	55	PASS	AN=2;DP=16	GT	0/1
chr19	39025366	39025366	C	G	exonic	RYR1	.	nonsynonymous SNV	RYR1:NM_001042723:exon78:c.C11251G:p.Q3751E,RYR1:NM_000540:exon79:c.C11266G:p.Q3756E	1.61E-07	0.999999839	2.45E-26	DISEASE: Malignant hyperthermia 1 (MHS1) [MIM:145600]: Autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the 'in vitro' contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively). {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10484775, ECO:0000269|PubMed:10612851, ECO:0000269|PubMed:10823104, ECO:0000269|PubMed:10888602, ECO:0000269|PubMed:11241852, ECO:0000269|PubMed:11389482, ECO:0000269|PubMed:11525881, ECO:0000269|PubMed:11575529, ECO:0000269|PubMed:11928716, ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12066726, ECO:0000269|PubMed:12123492, ECO:0000269|PubMed:12208234, ECO:0000269|PubMed:12411788, ECO:0000269|PubMed:12709367, ECO:0000269|PubMed:12883402, ECO:0000269|PubMed:1354642, ECO:0000269|PubMed:14732627, ECO:0000269|PubMed:14985404, ECO:0000269|PubMed:15221887, ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:1774074, ECO:0000269|PubMed:19191329, ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:20681998, ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24013571, ECO:0000269|PubMed:7751854, ECO:0000269|PubMed:7849712, ECO:0000269|PubMed:7881417, ECO:0000269|PubMed:8012359, ECO:0000269|PubMed:9066328, ECO:0000269|PubMed:9138151, ECO:0000269|PubMed:9389851, ECO:0000269|PubMed:9450902, ECO:0000269|PubMed:9497245}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Central core disease of muscle (CCD) [MIM:117000]: Autosomal dominant congenital myopathy, but a severe autosomal recessive form also exists. Both clinical and histological variability is observed. Affected individuals typically display hypotonia and proximal muscle weakness in infancy, leading to the delay of motor milestones. The clinical course of the disorder is usually slow or nonprogressive in adulthood, and the severity of the symptoms may vary from normal to significant muscle weakness. Microscopic examination of CCD-affected skeletal muscle reveals a predominance of type I fibers containing amorphous-looking areas (cores) that do not stain with oxidative and phosphorylase histochemical techniques. {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10097181, ECO:0000269|PubMed:11113224, ECO:0000269|PubMed:11709545, ECO:0000269|PubMed:11741831, ECO:0000269|PubMed:12112081, ECO:0000269|PubMed:12136074, ECO:0000269|PubMed:12565913, ECO:0000269|PubMed:12566385, ECO:0000269|PubMed:12937085, ECO:0000269|PubMed:14670767, ECO:0000269|PubMed:14985404, ECO:0000269|PubMed:17204054, ECO:0000269|PubMed:17226826, ECO:0000269|PubMed:18253926, ECO:0000269|PubMed:18312400, ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:21674524, ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24561095, ECO:0000269|PubMed:7829078, ECO:0000269|PubMed:8220422, ECO:0000269|PubMed:8220423, ECO:0000269|PubMed:9497245}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Multiminicore disease with external ophthalmoplegia (MMDO) [MIM:255320]: Clinically heterogeneous neuromuscular disorder. General features include neonatal hypotonia, delayed motor development, and generalized muscle weakness and amyotrophy, which may progress slowly or remain stable. Muscle biopsy shows multiple, poorly circumscribed, short areas of sarcomere disorganization and mitochondria depletion (areas termed minicores) in most muscle fibers. Typically, no dystrophic signs, such as muscle fiber necrosis or regeneration or significant endomysial fibrosis, are present in multiminicore disease. {ECO:0000269|PubMed:12719381, ECO:0000269|PubMed:16380615}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, congenital, with fiber-type disproportion (CFTD) [MIM:255310]: A genetically heterogeneous disorder in which there is relative hypotrophy of type 1 muscle fibers compared to type 2 fibers on skeletal muscle biopsy. However, these findings are not specific and can be found in many different myopathic and neuropathic conditions. {ECO:0000269|PubMed:20583297}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in RYR1 may be a cause of Samaritan myopathy, a congenital myopathy with benign course. Patients display severe hypotonia and respiratory distress at birth. Unlike other congenital myopathies, the health status constantly improves and patients are minimally affected at adulthood.; 	0.22212	.	-8.291678111	0.005897617	2142.38985	8.51518	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.000	0.629	N	0.999	0.218	N	-2.49	0.001	N	-1.58	0.820	D	2.36	0.003	N	0.016	0.003	-0.980	0.351	T	0.011	0.043	T	.	.	.	1.140	0.204	11.43	0.963	0.286	0.062	0.121	N	c	-0.821	-0.476	1.000	0.473	0.707	0.730	0	4.82	0.615	8.161	0.895	0.073	0.181	1.000	0.715	0.984	0.507	14.259	0.655	.	.	.	0.5	56	23	chr19	39025366	chr19:39025366	C	G	56	PASS	AN=2;DP=23	GT	0/1
chr19	39227901	39227901	G	C	exonic	CAPN12	.	synonymous SNV	CAPN12:NM_144691:exon10:c.C1257G:p.G419G	7.48E-20	0.000491944	0.999508056	.	0.38998	0.11824	-0.523584927	20.93654164	2537.68423	9.40302	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	123	716	chr19	39227901	chr19:39227901	G	C	123	PASS	AN=2;DP=716	GT	0/1
chr19	39978801	39978801	C	G	exonic	TIMM50	.	nonsynonymous SNV	TIMM50:NM_001329559:exon8:c.C458G:p.P153R,TIMM50:NM_001001563:exon9:c.C1106G:p.P369R	0.442656937	0.557064432	0.000278631	.	0.15447	0.10784	-0.045835247	50.34206181	685.25632	5.2276	0.236	0.179	T	0.002	0.156	B	0.005	0.121	B	0.001	0.409	D	0.795	0.344	D	0.015	0.080	N	2.23	0.181	T	3.42	0.001	N	0.227	0.278	-1.018	0.242	T	0.024	0.101	T	0.005	0.137	T	2.418	0.352	18.94	0.225	0.009	0.912	0.527	D	c	-0.128	0.081	0.857	0.251	0.707	0.730	0	4.96	0.650	2.818	0.475	0.852	0.362	0.999	0.424	0.997	0.653	10.696	0.449	FCP1 homology domain|HAD-like domain	.	.	0.5	62	76	chr19	39978801	chr19:39978801	C	G	62	PASS	AN=2;DP=76	GT	0/1
chr19	40392585	40392585	T	G	exonic	FCGBP	.	nonsynonymous SNV	FCGBP:NM_003890:exon16:c.A7919C:p.E2640A	.	.	.	.	0.54275	.	.	.	18359.5916	28.93384	.	.	.	0.057	0.214	B	0.074	0.267	B	0.524	0.052	U	1	0.090	P	1.33	0.334	L	.	.	.	.	.	.	0.217	0.266	-0.964	0.383	T	0.038	0.164	T	.	.	.	-1.631	0.014	0.002	0.275	0.014	0.008	0.032	N	c	-1.238	-1.359	0.001	0.078	0.554	0.246	0	-1.62	0.079	0.274	0.183	1.058	0.762	0.001	0.137	0.001	0.043	7.861	0.285	von Willebrand factor, type D domain	.	.	0.5	60	47	chr19	40392585	chr19:40392585	T	G	60	PASS	AN=2;DP=47	GT	0/1
chr19	43763019	43763019	T	C	exonic	PSG9	.	synonymous SNV	PSG9:NM_001301707:exon3:c.A699G:p.L233L,PSG9:NM_002784:exon4:c.A978G:p.L326L	2.75E-14	0.004925661	0.995074339	.	0.24972	.	1.607548084	95.91884879	1896.34765	8.00804	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	10	chr19	43763019	chr19:43763019	T	C	55	PASS	AN=2;DP=10	GT	0/1
chr19	45033485	45033485	A	G	exonic	CEACAM20	.	synonymous SNV	CEACAM20:NM_001102597:exon1:c.T48C:p.L16L,CEACAM20:NM_001102598:exon1:c.T48C:p.L16L,CEACAM20:NM_001102599:exon1:c.T48C:p.L16L,CEACAM20:NM_001102600:exon1:c.T48C:p.L16L	.	.	.	.	0.0885	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	79	49	chr19	45033485	chr19:45033485	A	G	79	PASS	AN=2;DP=49	GT	0/1
chr19	46025606	46025606	C	T	exonic	VASP	.	nonsynonymous SNV	VASP:NM_003370:exon6:c.C487T:p.P163S	0.583670616	0.415875146	0.000454238	.	0.493	0.35835	-0.137658575	43.57159707	79.23731	1.88068	0.058	0.377	T	0.018	0.165	B	0.016	0.166	B	0.006	0.327	N	0.953	0.264	N	2.895	0.841	M	-0.7	0.728	T	-2.46	0.537	N	0.18	0.219	-0.928	0.444	T	0.225	0.590	T	0.043	0.608	D	2.278	0.335	18.02	0.947	0.248	0.218	0.213	N	c	-0.551	-0.502	1.000	0.416	0.707	0.730	0	0.954	0.186	0.530	0.226	0.930	0.439	0.018	0.193	0.998	0.697	8.921	0.346	.	.	.	0.5	58	68	chr19	46025606	chr19:46025606	C	T	58	PASS	AN=2;DP=68	GT	0/1
chr19	46029812	46029812	A	-	UTR3	VASP	NM_003370:c.*377delA	.	.	0.583670616	0.415875146	0.000454238	.	0.493	0.35835	-0.137658575	43.57159707	79.23731	1.88068	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	25	chr19	46029811	chr19:46029811	GA	G	42	PASS	AN=2;DP=25	GT	0/1
chr19	49184178	49184178	C	G	ncRNA_exonic	SEC1P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	32	chr19	49184178	chr19:49184178	C	G	50	PASS	AN=2;DP=32	GT	0/1
chr19	49384368	49384368	A	T	exonic	TULP2	.	nonsynonymous SNV	TULP2:NM_003323:exon13:c.T1463A:p.L488H	1.83E-07	0.963783935	0.036215882	.	0.07447	.	1.646168225	96.17834395	1047.80804	6.21357	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.629	D	0.995	0.425	D	3.565	0.936	H	-2.83	0.913	D	-5.41	0.902	D	0.807	0.806	0.964	0.966	D	0.875	0.959	D	0.142	0.825	D	5.621	0.765	26.6	0.979	0.363	0.955	0.648	D	c	0.767	0.629	1.000	0.747	0.615	0.372	0	4.67	0.579	8.984	0.930	1.113	0.880	1.000	0.715	0.924	0.398	12.382	0.545	Tubby C-terminal-like domain|Tubby, C-terminal	.	.	0.5	.	63	chr19	49384368	chr19:49384368	A	T	.	PASS	AN=0;DP=63	GT	0/1
chr19	49863041	49863041	C	G	intronic	TEAD2	.	.	.	0.002047317	0.993646682	0.004306002	.	0.60613	0.38068	0.020302773	55.60863411	147.32359	2.64505	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	13	chr19	49863041	chr19:49863041	C	G	42	PASS	AN=2;DP=13	GT	0/1
chr19	49865065	49865065	-	G	intronic	TEAD2	.	.	.	0.002047317	0.993646682	0.004306002	.	0.60613	0.38068	0.020302773	55.60863411	147.32359	2.64505	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	94	chr19	49865065	chr19:49865065	A	AG	55	PASS	AN=2;DP=94	GT	0/1
chr19	54972918	54972918	T	C	UTR3	LENG8	NM_052925:c.*810T>C	.	.	0.998395296	0.001604704	5.62E-11	.	0.14592	0.10396	-1.080231599	7.277659825	678.50553	5.2062	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	44	chr19	54972918	chr19:54972918	T	C	71	PASS	AN=2;DP=44	GT	0/1
chr19	55009497	55009497	A	C	intergenic	CDC42EP5;LAIR2	dist=25060;dist=4516	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	29	chr19	55009497	chr19:55009497	A	C	65	PASS	AN=2;DP=29	GT	0/1
chr19	55494881	55494881	C	G	exonic	NLRP2	.	synonymous SNV	NLRP2:NM_001174082:exon5:c.C1749G:p.L583L,NLRP2:NM_001174081:exon6:c.C1815G:p.L605L,NLRP2:NM_001348003:exon6:c.C1806G:p.L602L,NLRP2:NM_017852:exon6:c.C1815G:p.L605L,NLRP2:NM_001174083:exon7:c.C1746G:p.L582L	1.88E-20	0.002997681	0.997002319	.	0.84299	0.12808	1.199631139	92.95824487	1690.10482	7.58061	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	11	chr19	55494881	chr19:55494881	C	G	42	PASS	AN=2;DP=11	GT	0/1
chr19	55715319	55715319	C	G	exonic	PTPRH	.	synonymous SNV	PTPRH:NM_002842:exon5:c.G717C:p.S239S	5.10E-29	7.03E-05	0.999929729	.	0.0771	.	1.111434312	92.06770465	5182.51875	14.81765	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	31	chr19	55715319	chr19:55715319	C	G	62	PASS	AN=2;DP=31	GT	0/1
chr19	55742053	55742053	C	T	splicing	PPP6R1	NM_014931:exon23:c.2571-1G>A	.	.	0.997854506	0.002145492	2.79E-09	.	0.16523	0.11824	0.121225147	62.22576079	190.13458	2.99301	.	.	.	.	.	.	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.463	0.474	23.0	0.983	0.391	0.777	0.380	D	c	0.755	0.502	0.988	0.313	0.257	0.036	0	3.6	0.402	1.627	0.364	0.852	0.362	0.998	0.411	0.762	0.325	11.021	0.467	.	.	.	0.5	58	23	chr19	55742053	chr19:55742053	C	T	58	PASS	AN=2;DP=23	GT	0/1
chr19	57950046	57950047	CA	-	intronic	ZNF749	.	.	.	1.63E-06	0.413190579	0.586807793	.	0.27413	0.1155	0.20394914	67.45694739	989.24767	6.06389	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	74	45	chr19	57950045	chr19:57950045	CCA	C	74	PASS	AN=2;DP=45	GT	0/1
chr19	58118572	58118572	A	G	exonic	ZNF530	.	nonsynonymous SNV	ZNF530:NM_020880:exon3:c.A1679G:p.N560S,ZNF530:NM_001321981:exon4:c.A1580G:p.N527S	1.74E-10	0.114407016	0.885592984	.	0.08489	.	1.820761234	97.009908	298.54254	3.68443	1.0	0.010	T	0.006	0.126	B	0.002	0.063	B	.	.	.	1	0.090	N	-1.34	0.007	N	3.21	0.071	T	2.18	0.003	N	0.01	0.001	-0.935	0.434	T	0.004	0.013	T	0.001	0.011	T	-2.277	0.005	0.001	0.157	0.004	0.041	0.094	N	c	-1.774	-1.775	0.003	0.100	0.563	0.310	0	-2.9	0.053	-2.862	0.008	-1.267	0.014	0.000	0.063	0.000	0.016	2.216	0.037	Zinc finger C2H2-type/integrase DNA-binding domain|Zinc finger, C2H2|Zinc finger, C2H2-like	.	.	0.5	79	36	chr19	58118572	chr19:58118572	A	G	79	PASS	AN=2;DP=36	GT	0/1
chr19	59093550	59093550	G	C	ncRNA_exonic	CENPBD1P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	71	chr19	59093550	chr19:59093550	G	C	70	PASS	AN=2;DP=71	GT	0/1
chr20	271135	271135	-	C	intronic	C20orf96	.	.	.	7.45E-13	0.017792517	0.982207483	.	0.02739	.	-0.314027422	31.9297004	25.57746	0.83421	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	81	166	chr20	271135	chr20:271135	G	GC	81	PASS	AN=2;DP=166	GT	0/1
chr20	13936733	13936733	C	A	exonic	SEL1L2	.	nonsynonymous SNV	SEL1L2:NM_001271539:exon2:c.G103T:p.V35F	2.69E-11	0.43582028	0.56417972	.	0.14689	0.0744	0.42259095	77.22929936	615.74121	5.0111	0.105	0.443	T	0.622	0.381	P	0.157	0.329	B	0.027	0.258	N	0.958	0.262	N	.	.	.	2.0	0.280	T	-1.29	0.328	N	0.363	0.458	-1.064	0.108	T	0.038	0.164	T	0.005	0.125	T	4.003	0.538	23.6	0.989	0.483	0.635	0.319	D	c	-0.217	-0.126	0.000	0.012	0.487	0.133	0	2.54	0.295	0.345	0.196	0.069	0.176	0.999	0.424	0.996	0.625	6.196	0.196	.	.	.	0.5	.	34	chr20	13936733	chr20:13936733	C	A	.	PASS	AN=0;DP=34	GT	0/1
chr20	24930259	24930259	A	G	intronic	CST7	.	.	.	9.92E-07	0.099089026	0.900909982	.	0.09739	0.21451	-0.007201372	53.19061099	163.63628	2.79416	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	20	chr20	24930259	chr20:24930259	A	G	42	PASS	AN=2;DP=20	GT	0/1
chr20	32972827	32972827	T	-	intronic	ITCH	.	.	.	0.999990177	9.82E-06	5.57E-15	DISEASE: Autoimmune disease, multisystem, with facial dysmorphism (ADMFD) [MIM:613385]: A disorder characterized by organomegaly, failure to thrive, developmental delay, dysmorphic features and autoimmune inflammatory cell infiltration of the lungs, liver and gut. {ECO:0000269|PubMed:20170897}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.59377	0.08471	-1.089312628	7.047652748	40.17092	1.18051	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	57	chr20	32972826	chr20:32972826	AT	A	50	PASS	AN=2;DP=57	GT	0/1
chr20	34295072	34295072	A	G	exonic	RBM39	.	nonsynonymous SNV	RBM39:NM_001242599:exon13:c.T1211C:p.F404S,RBM39:NM_001242600:exon13:c.T1193C:p.F398S,RBM39:NM_001323422:exon13:c.T1181C:p.F394S,RBM39:NM_001323424:exon14:c.T1274C:p.F425S,RBM39:NM_004902:exon14:c.T1259C:p.F420S,RBM39:NM_184234:exon14:c.T1277C:p.F426S,RBM39:NM_001323423:exon16:c.T806C:p.F269S	0.999996915	3.08E-06	8.09E-15	.	0.85822	0.14229	-0.207437529	38.2814343	7.60928	0.28162	0.0	0.912	D	1.0	0.899	D	0.98	0.749	D	0.000	0.843	D	1	0.810	D	2.315	0.665	M	0.66	0.524	T	-7.48	0.954	D	0.711	0.732	-0.316	0.746	T	0.316	0.686	T	0.150	0.833	D	5.973	0.821	27.7	0.999	0.944	0.995	0.973	D	c	0.620	0.546	1.000	0.747	0.672	0.522	0	4.65	0.575	8.297	0.898	1.140	0.893	1.000	0.715	0.967	0.454	14.228	0.653	Nucleotide-binding alpha-beta plait domain|RNA recognition motif domain|Splicing factor RBM39, linker;Splicing factor RBM39, linker	.	.	0.5	58	60	chr20	34295072	chr20:34295072	A	G	58	PASS	AN=2;DP=60	GT	0/1
chr20	37146163	37146163	C	T	exonic	RALGAPB	.	stopgain	RALGAPB:NM_001282917:exon8:c.C1066T:p.R356X,RALGAPB:NM_001282918:exon8:c.C1066T:p.R356X,RALGAPB:NM_020336:exon8:c.C1066T:p.R356X	0.999999956	4.44E-08	5.33E-20	.	0.64391	0.10552	-0.949752638	9.32413305	208.99718	3.12049	.	.	.	.	.	.	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.749	0.970	36	0.995	0.696	0.897	0.500	D	c	0.495	0.308	0.078	0.158	0.732	0.924	0	0.856	0.181	0.335	0.194	0.935	0.490	0.929	0.320	1.000	0.888	14.989	0.709	.	.	.	0.5	.	20	chr20	37146163	chr20:37146163	C	T	.	PASS	AN=0;DP=20	GT	0/1
chr20	43530234	43530234	A	C	exonic	YWHAB	.	synonymous SNV	YWHAB:NM_139323:exon2:c.A60C:p.R20R,YWHAB:NM_003404:exon3:c.A60C:p.R20R	0.938360894	0.061376766	0.00026234	.	0.98107	0.70722	0.103030231	61.2762444	18.29907	0.63541	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	10	chr20	43530234	chr20:43530234	A	C	44	PASS	AN=2;DP=10	GT	0/1
chr20	44756862	44756862	C	T	exonic	CD40	.	stopgain	CD40:NM_152854:exon6:c.C583T:p.Q195X,CD40:NM_001302753:exon7:c.C685T:p.Q229X	0.658237504	0.340601066	0.001161431	.	0.16893	0.72844	0.327131069	73.27199811	32.77151	1.0175	.	.	.	.	.	.	.	.	.	.	.	.	0.913	0.364	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.934	0.183	10.28	0.972	0.323	0.130	0.174	N	c	0.305	0.012	0.996	0.342	0.744	0.983	0	1.48	0.218	1.222	0.319	0.892	0.403	0.283	0.249	0.497	0.270	2.712	0.048	.	.	.	0.5	.	27	chr20	44756862	chr20:44756862	C	T	.	PASS	AN=0;DP=27	GT	0/1
chr20	46264671	46264671	G	A	exonic	NCOA3	.	nonsynonymous SNV	NCOA3:NM_001174087:exon12:c.G1541A:p.G514E,NCOA3:NM_001174088:exon12:c.G1571A:p.G524E,NCOA3:NM_006534:exon12:c.G1541A:p.G514E,NCOA3:NM_181659:exon12:c.G1541A:p.G514E	0.999916718	8.33E-05	1.70E-15	.	0.74944	0.1263	-1.232771118	5.537862703	2649.41599	9.66014	0.004	0.654	D	0.716	0.528	P	0.493	0.535	P	0.000	0.445	D	0.988	0.407	D	2.54	0.743	M	2.3	0.170	T	-4.57	0.787	D	0.317	0.378	-1.013	0.260	T	0.088	0.340	T	0.018	0.403	T	3.905	0.526	23.5	0.995	0.687	0.981	0.791	D	c	0.256	0.241	0.927	0.268	0.707	0.730	0	4.42	0.526	4.118	0.574	1.048	0.713	1.000	0.715	0.983	0.502	15.432	0.747	.	.	.	0.5	40	34	chr20	46264671	chr20:46264671	G	A	40	PASS	AN=2;DP=34	GT	0/1
chr20	49225796	49225796	A	G	intronic	RIPOR3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	56	46	chr20	49225796	chr20:49225796	A	G	56	PASS	AN=2;DP=46	GT	0/1
chr20	57276230	57276230	G	A	ncRNA_intronic	STX16-NPEPL1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	99	chr20	57276230	chr20:57276230	G	A	70	PASS	AN=2;DP=99	GT	0/1
chr21	15311637	15311637	G	T	intergenic	LOC110091776;ANKRD20A11P	dist=5437;dist=4459	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	48	chr21	15311637	chr21:15311637	G	T	.	PASS	AN=0;DP=48	GT	0/1
chr21	15311638	15311638	C	T	intergenic	LOC110091776;ANKRD20A11P	dist=5438;dist=4458	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	49	chr21	15311638	chr21:15311638	C	T	.	PASS	AN=0;DP=49	GT	0/1
chr21	15352253	15352253	A	C	ncRNA_exonic	ANKRD20A11P	.	.	.	.	.	.	.	0.00688	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	53	chr21	15352253	chr21:15352253	A	C	71	PASS	AN=2;DP=53	GT	0/1
chr21	33867280	33867280	A	G	intronic	EVA1C	.	.	.	0.325814898	0.670822939	0.003362163	.	0.15987	.	0.174625237	65.9648502	244.83382	3.37468	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	6	chr21	33867280	chr21:33867280	A	G	41	PASS	AN=2;DP=6	GT	1/0
chr21	34017906	34017906	T	C	intronic	SYNJ1	.	.	.	0.214295146	0.785704854	2.10E-10	DISEASE: Parkinson disease 20, early-onset (PARK20) [MIM:615530]: An early-onset form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK20 is characterized by young adult-onset of parkinsonism. Additional features may include seizures, cognitive decline, abnormal eye movements, and dystonia. {ECO:0000269|PubMed:23804563, ECO:0000269|PubMed:23804577}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.72364	0.1212	0.499660491	79.67091295	3892.53157	12.30627	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	38	chr21	34017906	chr21:34017906	T	C	69	PASS	AN=2;DP=38	GT	0/1
chr21	38459601	38459601	C	T	exonic	TTC3	.	nonsynonymous SNV	TTC3:NM_001001894:exon2:c.C44T:p.A15V,TTC3:NM_001320703:exon2:c.C110T:p.A37V,TTC3:NM_001320704:exon2:c.C44T:p.A15V,TTC3:NM_001330683:exon2:c.C44T:p.A15V,TTC3:NM_003316:exon2:c.C44T:p.A15V	5.39E-20	0.999708412	0.000291588	.	0.33574	0.08857	-0.972178525	8.911299835	2405.24665	9.10751	0.077	0.437	T	0.595	0.373	P	0.123	0.309	B	0.216	0.163	N	1	0.810	D	1.845	0.488	L	2.69	0.460	T	-0.81	0.245	N	0.273	0.455	-1.095	0.048	T	0.073	0.297	T	0.011	0.280	T	2.851	0.403	21.6	0.995	0.664	0.241	0.221	N	c	-0.344	-0.364	1.0	0.983	0.744	0.983	0	2.96	0.332	0.099	0.149	0.024	0.147	0.010	0.182	0.616	0.292	7.207	0.249	.	.	.	0.5	39	30	chr21	38459601	chr21:38459601	C	T	39	PASS	AN=2;DP=30	GT	0/1
chr21	45094558	45094558	G	A	exonic	RRP1B	.	synonymous SNV	RRP1B:NM_015056:exon5:c.G399A:p.K133K	0.036818435	0.963118575	6.30E-05	.	0.43897	0.12441	-0.354480518	29.42911064	196.09453	3.03033	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	58	chr21	45094558	chr21:45094558	G	A	.	PASS	AN=0;DP=58	GT	0/1
chr22	18910451	18910451	A	-	intronic	PRODH	.	.	.	4.75E-06	0.851614667	0.14838058	DISEASE: Hyperprolinemia 1 (HYRPRO1) [MIM:239500]: An inborn error of proline metabolism resulting in elevated levels of proline in the plasma and urine. The disorder is generally benign and most affected individuals are clinically asymptomatic. Some patients, however, have neurologic manifestations, including epilepsy and mental retardation. Association with certain forms of schizophrenia have been reported. {ECO:0000269|PubMed:12217952, ECO:0000269|PubMed:15662599, ECO:0000269|PubMed:17135275}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Schizophrenia 4 (SCZD4) [MIM:600850]: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder. {ECO:0000269|PubMed:11891283, ECO:0000269|PubMed:15662599}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.66122	.	1.73619725	96.62656287	2500.61703	9.31868	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	82	47	chr22	18910450	chr22:18910450	CA	C	82	PASS	AN=2;DP=47	GT	0/1
chr22	20132980	20132980	C	-	UTR3	ZDHHC8	NM_013373:c.*57delC	.	.	0.988991096	0.011008753	1.52E-07	.	0.15989	.	-1.168429872	6.062750649	606.91004	4.98443	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	12	chr22	20132979	chr22:20132979	AC	A	55	PASS	AN=2;DP=12	GT	0/1
chr22	20457177	20457247	GAAGTCAGATGCATACTGTTGGCTGGCGCCCAGCTGGGGAGGTGTGAACCCTTGGGCATCTTGCTTTTGCC	-	exonic	RIMBP3	.	frameshift deletion	RIMBP3:NM_015672:exon1:c.4055_4125del:p.R1352Pfs*1	.	.	.	.	.	0.08391	.	.	1804.88297	7.84008	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	61	chr22	20457176	chr22:20457176	GGAAGTCAGATGCATACTGTTGGCTGGCGCCCAGCTGGGGAGGTGTGAACCCTTGGGCATCTTGCTTTTGCC	G	41	PASS	AN=2;DP=61	GT	0/1
chr22	21057025	21057025	G	A	ncRNA_intronic	TMEM191A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	193	chr22	21057025	chr22:21057025	G	A	.	PASS	AN=0;DP=193	GT	0/1
chr22	26897791	26897794	AAAA	-	intronic	TFIP11	.	.	.	1.97E-06	0.993647861	0.006350171	.	0.17486	0.11762	-1.524862616	3.42061807	160.57464	2.76594	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	56	40	chr22	26897790	chr22:26897790	CAAAA	C	56	PASS	AN=2;DP=40	GT	0/1
chr22	29683091	29683091	A	G	exonic	EWSR1	.	nonsynonymous SNV	EWSR1:NM_001163286:exon6:c.A593G:p.Y198C,EWSR1:NM_001163285:exon7:c.A761G:p.Y254C,EWSR1:NM_001163287:exon7:c.A761G:p.Y254C,EWSR1:NM_005243:exon7:c.A761G:p.Y254C,EWSR1:NM_013986:exon8:c.A779G:p.Y260C	0.998559249	0.00144075	2.13E-10	DISEASE: Ewing sarcoma (ES) [MIM:612219]: A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors. {ECO:0000269|PubMed:15044653, ECO:0000269|PubMed:1522903, ECO:0000269|PubMed:7700648, ECO:0000269|PubMed:9121764}. Note=The protein represented in this entry is involved in disease pathogenesis. Chromosomal aberrations involving EWSR1 are found in patients with Ewing sarcoma. Translocation t(11;22)(q24;q12) with FLI1 (PubMed:1522903, PubMed:15044653). Translocation t(7;22)(p22;q12) with ETV1 (PubMed:7700648). Translocation t(21;22)(q22;q21) with ERG (PubMed:15044653). Translocation t(2;21;22)(q23;q22;q12) that forms a EWSR1-FEV fusion protein with potential oncogenic activity (PubMed:9121764). {ECO:0000269|PubMed:15044653, ECO:0000269|PubMed:1522903, ECO:0000269|PubMed:7700648, ECO:0000269|PubMed:9121764}.; DISEASE: Note=A chromosomal aberration involving EWSR1 has been found in extraskeletal myxoid chondrosarcoma. Translocation t(9;22)(q22-31;q11-12) with NR4A3. {ECO:0000269|PubMed:7539287}.; DISEASE: Note=A chromosomal aberration involving EWSR1 is associated with desmoplastic small round cell tumor (DSRCT). Translocation t(11;22)(p13;q12) with WT1. {ECO:0000269|PubMed:7862627}.; DISEASE: Note=A chromosomal aberration involving EWSR1 is associated with malignant melanoma of soft parts (MMSP). Translocation t(12;22)(q13;q12) with ATF1. Malignant melanoma of soft parts, also known as soft tissue clear cell sarcoma, is a rare tumor developing in tendons and aponeuroses. {ECO:0000269|PubMed:8401579}.; DISEASE: Note=A chromosomal aberration involving EWSR1 is associated with small round cell sarcoma. Translocation t(11;22)(p36.1;q12) with PATZ1. {ECO:0000269|PubMed:10949935}.; DISEASE: Angiomatoid fibrous histiocytoma (AFH) [MIM:612160]: A distinct variant of malignant fibrous histiocytoma that typically occurs in children and adolescents and is manifest by nodular subcutaneous growth. Characteristic microscopic features include lobulated sheets of histiocyte-like cells intimately associated with areas of hemorrhage and cystic pseudovascular spaces, as well as a striking cuffing of inflammatory cells, mimicking a lymph node metastasis. {ECO:0000269|PubMed:15884099, ECO:0000269|PubMed:17724745}. Note=The gene represented in this entry is involved in disease pathogenesis. Chromosomal aberrations involving EWSR1 are found in patients with angiomatoid fibrous histiocytoma. Translocation t(12;22)(q13;q12) with ATF1 generates a chimeric EWSR1/ATF1 protein (PubMed:15884099). Translocation t(2;22)(q33;q12) with CREB1 generates a EWSR1/CREB1 fusion gene that is most common genetic abnormality in this tumor type (PubMed:17724745). {ECO:0000269|PubMed:15884099, ECO:0000269|PubMed:17724745}.; DISEASE: Note=EFPS arise due to chromosomal translocations in which EWSR1 is fused to a variety of cellular transcription factors. EFPS are very potent transcriptional activators dependent on the EAD and a C-terminal DNA-binding domain contributed by the fusion partner. The spectrum of malignancies associated with EFPS are thought to arise via EFP-induced transcriptional deregulation, with the tumor phenotype specified by the EWSR1 fusion partner and cell type. Transcriptional repression of the transforming growth factor beta type II receptor (TGF beta RII) is an important target of the EWS-FLI1, EWS-ERG, or EWS-ETV1 oncogene. {ECO:0000305}.; 	0.95588	0.43129	-0.778825328	12.88039632	40.05548	1.1773	0.023	0.912	D	0.999	0.764	D	0.867	0.671	P	0.000	0.629	U	1.000	0.810	D	2.88	0.837	M	1.48	0.317	T	-4.85	0.965	D	0.757	0.872	-0.916	0.461	T	0.168	0.508	T	0.022	0.455	T	2.856	0.404	21.7	0.990	0.494	0.967	0.704	D	c	0.721	0.731	1.000	0.517	0.672	0.522	0	5.7	0.886	6.451	0.732	1.194	0.916	1.000	0.715	1.000	0.888	15.966	0.797	.	.	.	0.5	65	71	chr22	29683091	chr22:29683091	A	G	65	PASS	AN=2;DP=71	GT	0/1
chr22	35742925	35742925	T	G	exonic	TOM1	.	synonymous SNV	TOM1:NM_001135730:exon13:c.T1152G:p.G384G,TOM1:NM_001135729:exon14:c.T1188G:p.G396G,TOM1:NM_001135732:exon14:c.T1287G:p.G429G,TOM1:NM_005488:exon14:c.T1287G:p.G429G	6.78E-06	0.974913137	0.025080085	.	0.25337	0.13124	-0.554717505	19.79830149	1589.92055	7.37684	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	50	chr22	35742925	chr22:35742925	T	G	71	PASS	AN=2;DP=50	GT	0/1
chr22	38880098	38880098	A	-	UTR3	DDX17	NM_006386:c.*1842delT;NM_001098504:c.*1842delT	.	.	.	.	.	.	0.95209	0.27727	-0.516085732	21.20193442	42.19846	1.22768	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	16	chr22	38880097	chr22:38880097	GA	G	44	PASS	AN=2;DP=16	GT	0/1
chr22	39421059	39421059	C	T	intronic	APOBEC3D	.	.	.	2.36E-05	0.912736699	0.087239749	.	.	0.04922	-0.157884861	42.05590941	49.3236	1.37327	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	86	122	chr22	39421059	chr22:39421059	C	T	86	PASS	AN=2;DP=122	GT	0/1
chr22	43267336	43267336	-	C	UTR3	PACSIN2	NM_001184971:c.*26_*27insG;NM_007229:c.*26_*27insG;NM_001184970:c.*26_*27insG;NM_001349968:c.*26_*27insG;NM_001349969:c.*26_*27insG;NM_001349970:c.*26_*27insG;NM_001349971:c.*26_*27insG;NM_001349974:c.*26_*27insG;NM_001349973:c.*26_*27insG;NM_001349972:c.*26_*27insG	.	.	0.270395757	0.729383646	0.000220597	.	0.24823	0.20703	0.044168103	57.40740741	250.49463	3.41008	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	41	chr22	43267336	chr22:43267336	T	TC	59	PASS	AN=2;DP=41	GT	0/1
chr22	44276728	44276728	G	A	exonic	PNPLA5	.	stopgain	PNPLA5:NM_001177675:exon7:c.C895T:p.Q299X,PNPLA5:NM_138814:exon9:c.C1237T:p.Q413X	9.38E-07	0.317699047	0.682300015	.	0.17953	0.09445	0.576916344	82.25406936	1541.98025	7.28556	.	.	.	.	.	.	.	.	.	.	.	.	0.810	0.346	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.992	0.961	35	0.967	0.301	0.113	0.163	N	c	0.037	-0.331	0.035	0.142	0.615	0.352	0	2.1	0.261	1.248	0.322	1.048	0.713	0.057	0.215	0.008	0.104	8.910	0.345	.	.	.	0.5	.	51	chr22	44276728	chr22:44276728	G	A	.	PASS	AN=0;DP=51	GT	0/1
chr22	44287062	44287062	A	G	exonic	PNPLA5	.	synonymous SNV	PNPLA5:NM_138814:exon2:c.T306C:p.D102D	9.38E-07	0.317699047	0.682300015	.	0.17953	0.09445	0.576916344	82.25406936	1541.98025	7.28556	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	34	chr22	44287062	chr22:44287062	A	G	60	PASS	AN=2;DP=34	GT	0/1
chr22	50552226	50552226	G	C	intronic	MOV10L1	.	.	.	5.75E-10	0.999564705	0.000435294	.	0.0863	0.12601	-0.694532205	14.83840528	7325.51336	18.41075	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	57	48	chr22	50552226	chr22:50552226	G	C	57	PASS	AN=2;DP=48	GT	0/1
chr22	50552242	50552242	C	T	intronic	MOV10L1	.	.	.	5.75E-10	0.999564705	0.000435294	.	0.0863	0.12601	-0.694532205	14.83840528	7325.51336	18.41075	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	29	chr22	50552242	chr22:50552242	C	T	.	PASS	AN=0;DP=29	GT	0/1
chr22	50646919	50646919	G	T	intronic	SELENOO	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	72	chr22	50646919	chr22:50646919	G	T	58	PASS	AN=2;DP=72	GT	0/1
chrX	31200833	31200833	T	-	intronic	DMD	.	.	.	1	1.96E-10	2.29E-33	DISEASE: Duchenne muscular dystrophy (DMD) [MIM:310200]: Most common form of muscular dystrophy; a sex-linked recessive disorder. It typically presents in boys aged 3 to 7 year as proximal muscle weakness causing waddling gait, toe-walking, lordosis, frequent falls, and difficulty in standing up and climbing up stairs. The pelvic girdle is affected first, then the shoulder girdle. Progression is steady and most patients are confined to a wheelchair by age of 10 or 12. Flexion contractures and scoliosis ultimately occur. About 50% of patients have a lower IQ than their genetic expectations would suggest. There is no treatment. {ECO:0000269|PubMed:12632325, ECO:0000269|PubMed:7981690, ECO:0000269|PubMed:8401582, ECO:0000269|PubMed:8817332, ECO:0000269|PubMed:9851445}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Becker muscular dystrophy (BMD) [MIM:300376]: A neuromuscular disorder characterized by dystrophin deficiency. It appears between the age of 5 and 15 years with a proximal motor deficiency of variable progression. Heart involvement can be the initial sign. Becker muscular dystrophy has a more benign course than Duchenne muscular dystrophy. {ECO:0000269|PubMed:10573008}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated, X-linked 3B (CMD3B) [MIM:302045]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:12354438, ECO:0000269|PubMed:12359139, ECO:0000269|PubMed:25340340, ECO:0000269|PubMed:9170407}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.3401	0.7637	-0.842180844	11.28214201	7684.36218	18.86491	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	36	chrX	31200832	chrX:31200832	AT	A	39	PASS	AN=2;DP=36	GT	0/1
chrX	31432049	31432049	G	A	intronic	DMD	.	.	.	1	1.96E-10	2.29E-33	DISEASE: Duchenne muscular dystrophy (DMD) [MIM:310200]: Most common form of muscular dystrophy; a sex-linked recessive disorder. It typically presents in boys aged 3 to 7 year as proximal muscle weakness causing waddling gait, toe-walking, lordosis, frequent falls, and difficulty in standing up and climbing up stairs. The pelvic girdle is affected first, then the shoulder girdle. Progression is steady and most patients are confined to a wheelchair by age of 10 or 12. Flexion contractures and scoliosis ultimately occur. About 50% of patients have a lower IQ than their genetic expectations would suggest. There is no treatment. {ECO:0000269|PubMed:12632325, ECO:0000269|PubMed:7981690, ECO:0000269|PubMed:8401582, ECO:0000269|PubMed:8817332, ECO:0000269|PubMed:9851445}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Becker muscular dystrophy (BMD) [MIM:300376]: A neuromuscular disorder characterized by dystrophin deficiency. It appears between the age of 5 and 15 years with a proximal motor deficiency of variable progression. Heart involvement can be the initial sign. Becker muscular dystrophy has a more benign course than Duchenne muscular dystrophy. {ECO:0000269|PubMed:10573008}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated, X-linked 3B (CMD3B) [MIM:302045]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:12354438, ECO:0000269|PubMed:12359139, ECO:0000269|PubMed:25340340, ECO:0000269|PubMed:9170407}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.3401	0.7637	-0.842180844	11.28214201	7684.36218	18.86491	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chrX	31432049	chrX:31432049	G	A	.	PASS	AN=0;DP=44	GT	0/1
chrX	47969530	47969530	C	G	ncRNA_intronic	SSX6	.	.	.	.	.	.	.	0.01464	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	22	chrX	47969530	chrX:47969530	C	G	61	PASS	AN=2;DP=22	GT	0/1
chrX	53246267	53246267	G	A	intronic	KDM5C	.	.	.	0.997842569	0.002157431	1.16E-10	DISEASE: Mental retardation, X-linked, syndromic, Claes-Jensen type (MRXSCJ) [MIM:300534]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRXSCJ patients manifest mental retardation associated with variable features such as slowly progressive spastic paraplegia, seizures, facial dysmorphism. {ECO:0000269|PubMed:15586325, ECO:0000269|PubMed:16538222, ECO:0000269|PubMed:16541399, ECO:0000269|PubMed:23356856, ECO:0000269|PubMed:25666439}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.23488	0.19342	-1.50825116	3.503184713	16.80604	0.59116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	35	chrX	53246267	chrX:53246267	G	A	39	PASS	AN=2;DP=35	GT	0/1
chrX	63409495	63409495	G	A	UTR3	AMER1	NM_152424:c.*264C>T	.	.	0.953441253	0.046553393	5.35E-06	.	.	0.08523	-0.394936437	27.02878037	88.95926	2.02444	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	61	chrX	63409495	chrX:63409495	G	A	58	PASS	AN=2;DP=61	GT	0/1
chrX	70586333	70586333	G	A	exonic	TAF1	.	nonsynonymous SNV	TAF1:NM_001286074:exon1:c.G169A:p.V57I,TAF1:NM_004606:exon1:c.G169A:p.V57I,TAF1:NM_138923:exon1:c.G169A:p.V57I	0.999999756	2.44E-07	6.88E-19	DISEASE: Dystonia 3, torsion, X-linked (DYT3) [MIM:314250]: A X- linked dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT3 is characterized by severe progressive torsion dystonia followed by parkinsonism. It has a well-defined pathology of extensive neuronal loss and mosaic gliosis in the striatum (caudate nucleus and putamen) which appears to resemble that in Huntington disease. {ECO:0000269|PubMed:12928496, ECO:0000269|PubMed:17273961}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.65141	0.18046	-0.420619508	25.72540694	384.74802	4.1332	0.709	0.040	T	0.004	0.131	B	0.005	0.121	B	0.000	0.629	D	0.932	0.370	D	1.345	0.336	L	3.13	0.092	T	0.31	0.042	N	0.139	0.163	-1.075	0.084	T	0.020	0.085	T	0.014	0.335	T	2.240	0.330	17.77	0.967	0.301	0.840	0.428	D	.	.	.	1.000	0.747	.	.	.	4.99	0.658	3.993	0.565	1.035	0.655	1.000	0.715	1.000	0.888	12.257	0.538	TAFII-230 TBP-binding	.	.	0.5	.	94	chrX	70586333	chrX:70586333	G	A	.	PASS	AN=0;DP=94	GT	0/1
chrX	107433688	107433688	A	G	exonic	COL4A6	.	nonsynonymous SNV	COL4A6:NM_001287758:exon20:c.T1360C:p.S454P,COL4A6:NM_001287759:exon20:c.T1360C:p.S454P,COL4A6:NM_001287760:exon20:c.T1360C:p.S454P,COL4A6:NM_001847:exon20:c.T1363C:p.S455P,COL4A6:NM_033641:exon20:c.T1360C:p.S454P	0.990988266	0.009011734	6.37E-12	DISEASE: Note=Deletions covering the N-terminal regions of COL4A5 and COL4A6, which are localized in a head-to-head manner, are found in the chromosome Xq22.3 centromeric deletion syndrome. This results in a phenotype with features of diffuse leiomyomatosis and Alport syndrome (DL-ATS).; DISEASE: Deafness, X-linked, 6 (DFNX6) [MIM:300914]: A non- syndromic form of sensorineural hearing loss with prelingual onset. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:23714752}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.14684	0.07461	0.36555769	74.7287096	361.2174	4.02247	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.031	0.252	N	1.000	0.090	P	-2.35	0.001	N	-3.28	0.937	D	2.56	0.002	N	0.016	0.069	-0.958	0.395	T	0.000	0.000	T	.	.	.	1.193	0.209	11.71	0.838	0.144	0.002	0.013	N	.	.	.	0.989	0.316	.	.	.	0.71	0.172	0.077	0.145	-0.282	0.084	0.133	0.232	0.643	0.297	3.877	0.085	.	.	.	0.5	43	12	chrX	107433688	chrX:107433688	A	G	43	PASS	AN=2;DP=12	GT	0/1
chrX	107917970	107917970	C	T	intronic	COL4A5	.	.	.	0.999918348	8.17E-05	8.02E-15	DISEASE: Alport syndrome, X-linked (APSX) [MIM:301050]: A syndrome that is characterized by progressive glomerulonephritis, renal failure, sensorineural deafness, specific eye abnormalities (lenticonous and macular flecks), and glomerular basement membrane defects. The disorder shows considerable heterogeneity in that families differ in the age of end-stage renal disease and the occurrence of deafness. {ECO:0000269|PubMed:10094548, ECO:0000269|PubMed:10561141, ECO:0000269|PubMed:10563487, ECO:0000269|PubMed:10684360, ECO:0000269|PubMed:10862091, ECO:0000269|PubMed:11004279, ECO:0000269|PubMed:11223851, ECO:0000269|PubMed:1352287, ECO:0000269|PubMed:1363780, ECO:0000269|PubMed:1376965, ECO:0000269|PubMed:1672282, ECO:0000269|PubMed:24522658, ECO:0000269|PubMed:7599631, ECO:0000269|PubMed:7853788, ECO:0000269|PubMed:8406498, ECO:0000269|PubMed:8651292, ECO:0000269|PubMed:8651296, ECO:0000269|PubMed:8829632, ECO:0000269|PubMed:8940267, ECO:0000269|PubMed:9150741, ECO:0000269|PubMed:9452056, ECO:0000269|PubMed:9848783}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Deletions covering the N-terminal regions of COL4A5 and COL4A6, which are localized in a head-to-head manner, are found in the chromosome Xq22.3 centromeric deletion syndrome. This results in a phenotype with features of diffuse leiomyomatosis and Alport syndrome (DL-ATS).; 	0.87803	.	-1.148192153	6.316348195	776.06095	5.51594	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	68	chrX	107917970	chrX:107917970	C	T	50	PASS	AN=2;DP=68	GT	0/1
chrX	118758031	118758031	A	T	intronic	SEPT6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	42	chrX	118758031	chrX:118758031	A	T	.	PASS	AN=0;DP=42	GT	0/1
chrX	128650420	128650420	C	T	exonic	SMARCA1	.	nonsynonymous SNV	SMARCA1:NM_001282874:exon3:c.G316A:p.A106T,SMARCA1:NM_001282875:exon3:c.G316A:p.A106T,SMARCA1:NM_003069:exon3:c.G316A:p.A106T	0.999946646	5.34E-05	3.43E-13	.	0.99248	0.11262	-0.380166007	27.88393489	111.24798	2.29759	0.208	0.214	T	0.08	0.230	B	0.074	0.267	B	0.000	0.629	D	1	0.810	D	1.31	0.329	L	-2.84	0.914	D	-0.94	0.251	N	0.716	0.722	-0.075	0.807	T	0.585	0.851	D	0.763	0.981	D	3.836	0.518	23.4	0.997	0.781	0.983	0.813	D	.	.	.	1.000	0.747	.	.	.	5.37	0.769	7.905	0.864	0.935	0.490	1.000	0.715	1.000	0.888	18.167	0.896	DBINO domain	.	.	0.5	.	29	chrX	128650420	chrX:128650420	C	T	.	PASS	AN=0;DP=29	GT	0/1
chrX	152935352	152935352	-	G	UTR3	PNCK	NM_001135740:c.*240_*241insC;NM_001039582:c.*240_*241insC	.	.	0.00047919	0.874195492	0.125325319	.	0.13631	0.11128	-0.494039303	22.09247464	30.66195	0.9756	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	57	chrX	152935352	chrX:152935352	C	CG	53	PASS	AN=2;DP=57	GT	0/1
chrX	153049525	153049525	C	-	exonic	SRPK3	.	frameshift deletion	SRPK3:NM_001170760:exon10:c.1001delC:p.A336Pfs*55,SRPK3:NM_014370:exon10:c.1004delC:p.A337Pfs*55	0.179643538	0.817765333	0.002591129	.	0.22866	0.11172	-0.33061537	30.82094834	46.03612	1.30706	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	63	chrX	153049524	chrX:153049524	TC	T	43	PASS	AN=2;DP=63	GT	0/1
chrY	27535800	27535800	G	A	intergenic	TTTY17A;GOLGA2P3Y	dist=204880;dist=65658	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	51	chrY	27535800	chrY:27535800	G	A	.	PASS	AN=0;DP=51	GT	0/1
